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ZUSAMMENFASSUNG 
Plasmazytoide Dendritische Zellen (PDCs) repräsentieren eine Subpopulation Dendritischer 
Zellen und sind die Hauptproduzenten von Typ I Interferonen nach viraler oder mikrobieller 
Stimulation. Dadurch beeinflussen und verbinden sie die angeborene und adaptive 
Immunabwehr. Obwohl es immer mehr Anzeichen einer Beteiligung von PDCs an der 
Entstehung und Aufrechterhaltung von Autoimmunerkrankungen oder Krebs gibt, und ihnen 
auch eine Rolle bei der Induktion von Toleranz zugeschrieben wird, ist wenig über ihre exakte 
immunologische Funktion bekannt. Besonders ihre Rolle als Antigen-präsentierende Zellen bei 
der Induktion einer T-Zell-Antwort wird kontrovers diskutiert. Die funktionelle Charakterisierung 
von murinen PDCs wurde durch das Fehlen eines spezifischen Oberflächenrezeptors 
erschwert. PDCs wurden identifiziert anhand der Co-Expression von B220, Ly-6C, und CD11c. 
 
In dieser Arbeit wurden verschiedene monoklonale Antikörper generiert, die alle ein 
Oberflächenantigen erkannten, das spezifisch auf PDCs in naïven Mäusen exprimiert war und 
das als „murines PDC Antigen 1“ (mPDCA-1) bezeichnet wurde. Mithilfe differentieller 
Genexpressionsanalyse konnte gezeigt werden, daß die anti-mPDCA-1 Antikörper das „Bone 
marrow stromal antigen 2“ (BST2) erkennen.  
Weitere Experimente zeigten, daß Ligation des mPDCA-1 Rezeptors eine Toll-like Rezeptor-
induzierte Produktion von Typ I Interferonen in PDCs inhibierte. Die Kreuzvernetzung des 
Rezeptors mit anti-mPDCA-1 Antikörpern resultierte in einer intrazellulären Kalzium-
Mobilisierung sowie in einer allgemeinen Phosphorylierung von Proteintyrosinresten. Des 
Weiteren führte die Kreuzvernetzung sowohl in vitro als auch in vivo zu einer schnellen und 
effizienten Internalisierung des Rezeptor-Antikörperkomplexes.  
 
Als nächstes wurde die potentielle Funktion des mPDCA-1 Moleküls als PDC-spezifischer 
Antigen-Aufnahmerezeptor untersucht. Da die Applikation des vollständigen anti-mPDCA-1 
Antikörpers in vivo in Fc-vermittelter oder ADCC-abhängiger Depletion der PDCs resultierte, 
wurde Ovalbuminprotein kovalent an ein nichtdepletierendes F(ab’)2-Fragment des anti-PDCA-1 
Antikörpers konjugiert. Somit konnten PDCs spezifisch in vitro und in vivo angefärbt werden. 
Über mPDCA-1 aufgenommenes Antigen wurde prozessierte und auf Klasse I und II MHC-
Molekülen präsentiert. Dabei waren PDCs in der Lage, naïve CD4+ and CD8+ T-Lymphozyten in 
vitro effizient zu primen. Sowohl das Priming als auch das cross-priming antigenspezifischer    
T-Zellen war abhängig von einer Aktivierung der PDCs, die mit einer verstärkten Expression 
costimulatorischer und MHC-Moleküle einherging. Dieser zusätzliche Stimulus schien auch die 
Antigenprozessierungs- und präsentationsmaschinerie zu aktivieren.   
 
Letztlich wurde eine heterogene Expression des „Stem cell antigen 1“ (Sca-1) auf PDCs 
beobachtet, die organabhängig variierte. Sca-1- PDCs erschienen früher in der Entwicklung der 
Zellen und produzierten mehr IFNα nach Stimulation. Aktivierte PDCs regulierten die 
Expression von Sca-1 hoch.  
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Zusammengefasst ist mPDCA-1 ein spezifischer Marker für die Identifizierung von PDCs. Die 
direkte Interaktion mit naïven T-Zellen unterstreicht die Rolle der PDCs in der Koordination von 
angeborener und adaptiver Immunantwort. Die Ergebnisse dieser Arbeit zeigen, daß PDCs ein 
viel versprechendes Ziel für die Entwicklung neuartiger Therapiemöglichkeiten und deren 
Untersuchung im Mausmodel sind, vor allem für die Behandlung von Tumor- oder 
Autoimmunerkrankungen, z.B. von SLE. 
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ABSTRACT 
Plasmacytoid dendritic cells (PDCs) represent a distinct subset of dendritic cells in humans and 
mice. In the murine system PDCs were characterized by the co-expression of B220, Ly-6C, and 
CD11c. Due to their ability to produce large amounts of interferon (IFN)-alpha upon microbial 
challenge and due to their stimulatory capacity they are believed to link innate and adaptive 
immune responses. Although there is growing evidence of their contribution in the induction of 
anti-viral immune responses, autoimmune disorders and tolerance, less is known about their 
exact function. In particular their role as antigen-presenting cells in the induction of T cell 
responses is still controversially discussed.  
In the present study, a panel of monoclonal antibodies (mAb) was generated, all recognizing a 
cell surface antigen specifically expressed on PDCs in naïve mice. The antigen was termed 
mPDCA-1. Differential gene expression analysis revealed that mPDCA-1 is identical to the bone 
marrow stromal antigen 2 (BST2). Triggering of mPDCA-1/BST2 with the mAb resulted in 
calcium mobilization and overall protein-tyrosine phosphorylation, which inhibited TLR-induced 
IFN-alpha production in PDCs. Cross-linking of mPDCA-1 also resulted in rapid internalization 
of the antibody-receptor complex in vitro and in vivo. Since the administration of the complete 
anti-mPDCA-1 mAb resulted in Fc-mediated or ADCC-dependent depletion of PDCs in vivo, 
Ovalbumin protein was covalently conjugated to a non-depleting anti-mPDCA-1-F(ab’)2 
fragment. When targeted via mPDCA-1, antigens entered the MHC class I and II processing 
and presentation pathway and PDCs were shown to efficiently prime naïve CD4+ and CD8+ T 
cells in vitro. Interestingly, this process was dependent on stimulation of PDCs leading to the 
activation of their antigen processing and presentation machinery. In contrast, without activation 
PDCs failed to stimulate naïve T cells.  
In summary, mPDCA-1/BST2 is a novel specific marker for PDCs in mice, influencing their 
innate and adaptive functions. Further experiments including the identification of the natural 
ligand of mPDCA-1/BST2 in mice will be needed for better understanding its in vivo function. 
The effect of IFN-alpha abrogation after mPDCA-1 triggering could be investigated in murine 
models of autoimmune disease (e.g. SLE) or in viral infections. Furthermore, targeting antigen 
via mPDCA-1 would be a promising system to study the role of PDCs in adaptive immunity 
including the initiation of cytotoxic T cell responses in vivo. 
In the second part of the work, two subpopulations of PDC characterized by the differential 
expression of the stem cell antigen 1 (Sca-1) could be identified. Sca-1- PDCs produced large 
amounts of IFN-alpha after stimulation with TLR9 ligands, appeared earlier in the development 
and were predominantly present in the bone marrow. In contrast, Sca-1+ PDCs were poor IFN-
alpha producers, represented the majority of PDCs in the lymph nodes and seemed to develop 
from Sca-1- PDCs upon in vitro activation or adoptive transfer. Further work will be necessary to 
elucidate whether Sca-1 expression characterizes developmental/activation stages or two 
different subpopulations of PDCs. 
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aa   Amino acid 
Ab   antibody 
ADCC  Antibody-dependent cell-mediated cytotoxicity   
Ag   Antigen 
APC    Antigen-presenting cell  
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BM Bone marrow 
bp Base pair 
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BSA Bovine serum albumin 
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1. INTRODUCTION 
1.1 The immune system 
The invasion of pathogens (bacteria, viruses, parasites) influences the organism, often leading 
to the development of diseases and, finally, to its death. To counter and neutralize the multitude 
of pathogens the organism is confronted with constantly, the immune system developed 
different strategies. In vertebrates, and in particular in mammals, the immune system can be 
divided into the innate and the adaptive arm. The innate response works as the first line 
defense against various pathogens. The adaptive or acquired immune response is acting slower 
but builds up a specific response that clears the infection and offers the advantage of an 
immunological memory. This principle of a dual immune system in vertebrates has been 
evolutionary established and strengthens the immunological protection [Lo D, Immunol Rev 
1999; Medzhitov R, Nature 2007]. 
 
The innate immune system comprises both cells and mechanisms that defend the host from 
pathogenic infections. Components of this system are physiological barriers, such as the skin, 
mucosa and the epithelium, that prevent the encounter, or the low gastric pH that inactivates 
invading microbes as well as the complement system. On the other cellular level a multitude of 
specialized cells recognize and respond to invading pathogens before they are able to replicate 
and cause serious damage to the host [Reis e Sousa C, Immunity 2001; Medzhitov R, Nat Rev 
Immunol 2000]. These inflammatory reactions include the activation of the complement 
cascade, which leads to the clearance of opsonized cells as well as the recruitment of immune 
cells to sites of infection, through the production of mediators, such as cytokines and 
chemokines secreted by mast cells and other cells of the innate immune system. Upon 
pathogen encounter the granulocyte family and NK cells produce toxic proteins (such as 
perforins or granzymes) that kill target cells (i.e. infected or tumor cells) by induction of 
apoptosis [Grundy MA, Cancer Immunol Immunother. 2007; Veugelers K, Mol Biol Cell. 2005]. 
So-called phagocytes, mainly macrophages, can ingest and thus remove foreign or 
degenerated cells [Ljunggren HG, Immunol Today 1990; Smyth MJ, Nat Rev Cancer 2002; 
Medzhitov R, Immunol Rev 2000/Semin Immunol. 2000].  
Whereas the innate immune system becomes activated upon recognition of few, highly 
conserved pathogen structures, adaptive immunity is able to detect an almost unlimited number 
of structures. This diversity is based on the recombination of antigen receptor gene segments, 
generating a large number of lymphocytes each equipped with a unique antigen recognition 
receptor. The major effector cells of the adaptive immune system are T and B lymphocytes, 
initiating cellular (cytotoxic T cells) and/or humoral (B cells/plasma cells) responses in an 
antigen-specific manner [Medzhitov R, Seminar Immunol 1998].  
B cells can take up antigens directly via cell-surface bound immunoglobulin molecules (the B 
cell receptor). After uptake, B cells also process and present antigens on MHC-II molecules. 
MHC-II-peptide complexes presented by B cells can be recognized by antigen specific T helper 
cells, which in turn provide a co-stimulatory signal to B cells via CD40-CD40L interaction. This T 
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cell feedback is necessary for the efficient activation of naïve B cells leading to clonal 
proliferation and further differentiation into effector plasma cells or long-lived memory B cells. A 
characteristic B cell response results in the production of antibodies by plasma cells recognizing 
specifically the pathogen-derived structures. Binding of the antigen by an antibody may result in 
opsonization and neutralization of toxins and pathogens or in the activation of the complement 
cascade. Remaining memory B cells as well as persisting antibodies in the serum are part of the 
immunological memory. These factors provide an immediate and strong response against the 
same antigen upon new encounter and due to somatic mutation usually demonstrate higher 
affinities after repeated infections.  
Whereas B cells are able to sense native antigen via the B cell receptor, T cells can recognize 
only short peptides in the context of MHC molecules on specialized antigen-presenting cells 
(APC) [Romani N, Res Immunol 1989; Germain RN, Cell 1994; Brown MG, JI 1993; Carbone 
FR, Cold. Spring Harb. Symp. Quant Biol 1989]. APCs comprise of macrophages, monocytes, B 
cells and Dendritic Cells (DCs). These cell types and in particular the DCs are characterized by 
a continuous uptake and processing of antigens from the environment. Peptides originating 
from endogenous proteins (e.g after virus infection) are loaded onto MHC class I molecules and 
presented to CD8+ T cells. Endocytosed antigens are primarily loaded onto MHC II molecules to 
be presented to CD4+ T cells [Janeway C, Cold Spring Harb Symp Quant Biol 1989; Wang RF, 
Trends Immunol 2001]. 
The activation of T lymphocytes is a complex process. The T cell receptor (TCR) recognizes a 
distinct antigenic peptide in the context of MHC molecules on the surface of an APC. For 
sufficient activation, naïve T cells further need an additional activation signal, provided by co-
stimulatory molecules (e.g. CD80, CD86) highly upregulated on activated DCs. When activated, 
CD8+ T cells differentiate into cytotoxic T cells (CTLs) that lyse tumor or virus-infected target 
cells [Barry M and Bleackley RC, Nat Rev Immunol 2002]. On the other hand, differentiated 
CD4+ TH cells support and influence the development of other lymphocytes (such as B cells and 
CD8+ T cells) towards effector cells through the secretion of certain sets of cytokines. Beside the 
presentation of immunogenic peptides and T cell activation, DCs are important to mediate a 
“third signal”. Depending on the stimulus provided by the pathogen, DCs secrete distinct 
cytokines, which in turn influence the type of T cell response, the so-called “T helper cell 
polarization” [O'Garra A, Curr Opin Immunol 1994; Kalinski P, Immunol Today 1999a]. In 
analogy to B cells, also T cells develop a memory compartment.  
 
The benefit of adaptive immunity lies in the large diversity of antigen-specific responses. By 
combinatory diversity and junctional recombination processes the B cell receptor repertoire can 
generate theoretically up to 1011 different immunoglobulins and this number is further expanded 
by somatic hypermutation [Weigert M, Nature 1980]. The variability of the TCR repertoire is also 
created by gene rearrangements and different combinatory recombination whereas no somatic 
hypermutation occurred [Zheng B, Nature 1994]. Another advantage is based on the generation 
of an immunological memory, which provides a faster and more effective response in case of a 
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secondary exposure to the pathogen. For the optimal induction of adaptive immune response, 
APCs, and in particular DCs, have an important function. These cells not only sense, take up, 
and process microbial structures, but also activate T cells and induce the differentiation of naïve 
lymphocytes to effector cells [Guermonprez P, Annu Rev Immunol 2002; Banchereau J and 
Steinman RM, Nature 1998]. Finally, they recruit other cells of both the innate and adaptive 
immune system to the site of infection and thus are crucial for the induction of immunity. 
Depending on the origin and status of the cells as well as on the type of pathogen either cellular 
or humoral immunity but also anergy (tolerance) can be initiated. 
 
1.2 Dendritic Cells 
Dendritic cells have been first described in the early 1970s by Ralph Steinman and Zanvil Cohn. 
These BM-derived immune cells showed a dendritic morphology characterized by protrusions of 
the plasma membrane, and were able to activate naïve T cells [Steinman RM + Cohn ZA, JEM 
1973]. DCs represent not a homogeneous population but rather consist of different subsets, 
which develop continuously from CD34+ hematopoietic stem cells and migrate through the 
circulation into peripheral tissues. DC subpopulations differ in phenotype, life span, tissue 
localization, and immunological function [Shortman K and Liu YJ, Nat Rev Immunol 2002; Naik 
SH, Nat Immunol 2007; Shortman K, Nat Rev Immunol 2007].  
 
Resident DCs from peripheral tissues typically demonstrate an immature phenotype, 
characterized by low expression of MHC and co-stimulatory molecules. In this immature stage 
DCs show a high endocytotic activity, and constantly scan their environment by taking up 
antigens via different mechanisms, including macropinocytosis and phagocytosis (nonspecific 
uptake of extracellular fluid and particles, respectively) or receptor-mediated endocytosis. DCs 
express a variety of receptors, which have been shown to be involved in antigen uptake, such 
as Calcium-dependent lectin receptors (CLRs)  [Brown GD, Nat Rev Immunol, 2006], Toll-like 
receptors (TLRs) or Fc receptors [Figdor CG, Nat. Rev. Immunol 2002]. CLRs and TLRs belong 
to the family of pathogen-recognition receptors (PRRs), which recognize highly conserved 
pathogenic structures on Gram-positive and negative bacteria, viruses, fungi or protozoan 
parasites that are naturally absent in the host [Akira S, Nat Rev Immunol 2004; Matzinger P, 
Science 2002; Janeway CA, Jr. Cold Spring Harb Symp Quant Biol. 1989; Galiana-Arnoux D, 
Tissue Antigens 2006]. These receptors enable DCs to identify Danger- and Pathogen 
associated molecular patterns (DAMPs and PAMPs). Ligation of PRRs not only leads to the 
uptake of the given antigen, but also can induce maturation processes. Once maturation has 
been initiated DCs stop the antigen uptake and migrate to secondary lymphoid organs (draining 
lymph nodes (LNs) or spleen) [Banchereau J and Steinman RM, Nature 1998; Janeway C and 
Travers P, Garland Publishing 2001]. During this passage, activated DCs undergo a number of 
phenotypical and functional changes including the loss of their endocytic/phagocytic capacity, 
the up-regulation of cell-adhesion and co-stimulatory molecules as well as an increase of the 
processing and presentation activity. The latter is mainly mediated by the recruitment of MHC 
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molecules to the antigen processing compartments (lysosomes) and a significant increase of 
the half-life of peptide-MHC complexes on the cell surface. [Banchereau J, Nature 1998]. Thus, 
upon activation, DCs are phenotypically characterized by high expression level of MHC, cell 
adhesion and co-stimulatory molecules (e.g. ICAM1, LFA3, CD40, and in particular the B7 
family). These molecules mediate the so-called immunological synapse between DCs and T 
cells, which is necessary for the efficient activation of the latter [Cella M, JEM 1996]. The 
activation of naïve T cells depends on - at least - two signals: a first signal is provided by the 
recognition of the specific MHC/peptide complex via the TCR, the second signal is mediated 
through the interaction of co-stimulatory receptors (CD80 and CD86) on the APC side with the 
appropriate ligand (CD28) on T cells. Without the co-stimulatory signal the response of naïve T 
cells results in anergy or apoptosis [Kuwana M, Hum Immunol 2002]. Since immature APCs 
continuously present autoantigens in the periphery, this mechanism prevents the activation of 
autoreactive T cells and the development of autoimmune responses. 
For loading of MHC-I and -II molecules different processing pathways are known. After uptake, 
exogenous proteins are transported to endosomes and later to lysosomes. Upon acidification, 
lysosomal proteases degrade the proteins to smaller peptides. MHC II molecules, which are 
exclusively present on APCs [Wang RF, Trends Immunol 2001], are produced in the 
Endoplasmatic reticulum (ER) and transported to MHC-II–rich compartments (MIIC), which fuse 
with lysosomes upon activation. Within this fusion compartment the loading of MHC-II molecules 
with appropriate, so-called immunocompetent peptides takes place [Wang RF, Trends Immunol 
2001].  
In contrast, endogenous proteins are ubiquitinated and degraded into peptides within the 
proteasome. Generated peptides are then transported to the ER via TAP proteins and loaded 
onto MHC-I molecules for transport to the cell surface via the Golgi apparatus [York IA, Annul 
Rev Immunol 1996; Tong JC, Protein Science 2004]. While immature dendritic cells and other 
APCs express the classical proteasome and also a special “immuno-proteasome”, mature 
dendritic cells express the latter one, which might be more competent for antigen presentation 
since its cleavage patterns yield in peptides that bind efficiently to MHC-I molecules [Macagno 
A, EJI 1999; Van den Eynde BJ, Curr Opin Immunol 2001].  
Beside the classical route describing, that peptides from exogenous proteins are presented on 
MHC class II molecules, several reports demonstrated that they could also be presented by 
MHC-I molecules [Brode S, Immunology 2004]. This mechanism is referred to as “cross-
presentation” [Amigorena S, Nat Immunol 2003; Roy CR, Nature 2003; Heath WR, Nat Rev 
Immunol 2001; Groothuis TA, JEM 2005] and may play an important role in the priming of virus- 
and tumor-specific CD8+ T cells. 
An overview of the processing pathway of both endogenous and antigens is given in Fig.1.1. 
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Fig.1.1 Professional antigen-presenting cells process intracellular and extracellular pathogens differently.  
Modified after Roy CR, Nature 2003.  
 
The mechanism of cross-presentation is poorly understood and can be explained by several 
models. By the “canonical model” exogenous proteins “escape” or are translocated from the 
endosome and are proteasomally degraded. Resulting peptides gain access to the 
endoplasmatic reticulum (ER) via the TAP complex and MHC molecules are loaded and 
transported to the cell surface [Lin ML, Immunol Cell Biol 2008]. In a revised model it has been 
demonstrated that phagosomes in particular in APCs fuse with the ER membrane. Here, 
specialized transporter proteins translocated the phagocytosed antigen into the cytosol for 
degradation. There the ubiquitination and degradation takes place, and in turn the peptides are 
transported to the lumen of the phagosome via TAP for MHC I loading. This mechanism differs 
from the first pathway described above since MHC loading occurs in the phagosome and not in 
the ER. A third mechanism proposed that proteins endocytosed by specific receptors (e.g. the 
Mannose receptor) are targeted to stable early endosomes for cross-presentation [Burgdorf S, 
Science 2007; Trombetta ES and Mellman I, Annu Rev Immunol 2005; Ramirez MC and Sigal 
LJ, Trends Microbiol 2004; reviewed in Kasturi SP, Nat Immmunol 2008].  
 
Based on their capacity to process and present exogenous antigens, DCs play a central role in 
the activation of antigen-specific responses. DCs contribute to the induction of adaptive 
immunity not only by their APC function but produce a variety of cytokines [Steinman RM Annu 
Rev Immunol 1991; Banchereau J, Annu Rev Immunol 2000]. Hereby the kind of pathogen or 
stimulus influences the DC and balances the cytokine production towards a cellular or humoral 
response. Pro-inflammatory cytokines such as IL-12, which induce a strong cellular (TH1) 
response, are mainly induced after contact with viruses or intracellular bacteria [Hochrein H, JI 
2001; Cella M, JEM 1996; Koch F, JEM 1996]. The absence of IL-12 as well as the presence of 
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anti-inflammatory molecules such as IL-10, TGF-β, PGE-2, corticosteroids and also IL-4 favorite 
a humoral (TH2) immune reaction [Liu Y-J, Cell 2001; Kapsenberg ML, Nat Rev Immunol 2003]. 
DCs seem to play also a role in the induction of regulatory T cells and so-called TH17 cells. TH17 
cells are critical for local inflammation and amplification of inflammatory responses and 
mediating autoimmune diseases in mice. The commitment of these TH subsets is induced by 
cytokines like TGFβ and IL-10 (Tregs), or Treg-derived TGFβ and DC-derived IL-6, whereas IL-
23 is important for the expansion and maintenance of TH17 cells [Reiner SL, Science 2007; 
reviewed by Afzali B, Clin Exp Immunol. 2007; Steinman L, Nat Med 2007]. Interestingly, naïve 
T cells develop into Tregs or TH17 cells in a mutually exclusive process. The relative flexibility of 
DC subpopulations in their cytokine production might be based on the differential expression of 
PRRs by different DC subsets [Backer R, EJI 2008; Iwasaki A, Nat Immunol 2004; Schnorrer P, 
PNAS 2006; Dudziak D, Science 2007; den Haan JM, JEM 2000]. DC-secreted cytokines 
influence not only the polarization of T helper cells, but also B cells, macrophages, and NK 
cells, thereby mainly determing the type of immune response.  
 
As mentioned before, DCs are not a homogeneous population and in the human and murine 
system several subsets are described that share the ability to process and present antigens to 
naïve T cells for the initiation of an adaptive immune response. Depending on their differential 
expression of several cell surface receptors (e.g. TLRs, CLRs) each DC subtype is specialized 
to respond to certain pathogens and induce distinct immune responses [Steinman RM, Annu 
Rev Immunol, 1991; Shortman K and YJ Liu, Nat Rev Immunol, 2002]. 
In the human system different types of DCs can be classified according to origin, function or 
anatomical localization. Most DC research in humans was focused on blood-derived DCs. 
These cells are characterized by the expression of MHC-II and the absence of linage markers 
such as CD3, CD14, CD19, and CD56. Phenotypical analysis has demonstrated that human 
DCs can be further divided into three subpopulations: CD11c+ CD1c+ CD123low myeloid DCs, a 
minor CD11cdim CD1c- CD123- CD141+ (BDCA-3+) myeloid population, and the lymphoid or 
Plasmacytoid DCs (PDCs). The latter are CD11c- CD1c- CD123+ (IL-3Rα) and specifically 
express CD303 (BDCA-2) and CD304 (BDCA-4/Neuropillin-1) [Dzionek A, JI 2000; Liu Y-J, Cell 
2001; Banchereau J, Annu Rev Immunol 2000].  
In mice, several DC subsets are described in the steady-state, which all have been identified by 
the expression of the CD11c antigen (integrin αx chain) [Shortman K, Nat Rev Immunol 2002]. 
Beside DCs localized in the periphery such as dermal DCs, the epidermis-resident Langerhans’ 
cells [Romani N, J Inv Dermatol 1989], or interstitial DCs of non-lymphoid organs, the main 
focus has been made on DC subsets in lymphoid organs. In spleen “conventional” dendritic 
cells (cDCs) [Henri S, JI 2001] and PDCs have been found. The conventional DCs are 
subdivided according to their expression pattern of the CD11b antigen (integrin αM,), the co-
receptors CD4 and CD8, as well as the C-type lectin receptor DEC205 (CD205). By doing so 
three cDC subpopulations can be identified: CD8α+ CD11b- DEC205+ DCs (25%) and CD8α- 
CD11b+ DEC205- (75%), with the latter further divided into a CD4- and CD4+ subset [Shortman 
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K, Immunol Cell Biol 2000]. Some reports demonstrated that the single DC subsets develop 
from both common lymphoid and myeloid progenitors [Wu L, Blood 2001; Karsunky H, Exp 
Hematol 2005; del Hoyo GM, Nature 2002]. Historically, the CD8α+ DCs were supposed to be of 
lymphoid origin, whereas the CD8α- subset was described to be of myeloid origin [Liu YJ, Cell 
2001]. Compared to conventional DCs, the phenotype of PDCs is clearly different as this cell 
type is characterized by high expression of B220 but only intermediate levels of CD11c and the 
absence of CD11b. Compared to human PDCs, the murine counterpart does not express the IL-
3Rα chain. A known functional difference to other DC subsets is the lower antigen uptake and 
presentation activity of PDCs. 
PDCs secrete less IL-12 compared to other DC subsets but produce extraordinary amounts of 
type I interferons (IFN-I). Based on this main characteristic, PDCs are also named Interferon 
producing cells (IPCs) and are supposed to play a central role in the induction of anti-viral or 
anti-microbial immune responses [Kadowaki N, JEM 2000; Krug A, EJI 2001a+b]. INF-Is can be 
produced by a multitude of cell types upon viral infection, for example monocytes, 
macrophages, NK cells, fibroblasts, dendritic cells, and in particular PDCs [De Maeyer E, Int 
Rev Immunol 1998; Siegal FP, Science 1999]. This specialized DC subset can produce up to 
1,000-fold more IFN-I [as much as 3-10 pg of IFNα per cell] upon viral or microbial stimulation 
[De Maeyer E, Int Rev Immunol 1998; Cella M, Nat Med 1999; Asselin-Paturel C, Nat Immunol 
2001; Siegal FP, Science 1999; Pestka S, Annu Rev Biochem 1987; Samuel CE, Clin Microbiol 
Rev 2001; Fitzgerald-Bocarsly P, Cytokine Growth Factor Rev]. Therefore, they are regarded as 
the major producers of these cytokines. By the secretion of IFN-Is, PDCs inhibit the virus 
replication and induce the apoptosis of virus-infected cells [Pestka S, Immunol Rev 2004] but 
can also initiate immune responses by orchestration of other leukocytes. IFN-I production by 
PDCs is typically induced in response to infectious agents, including viruses, bacteria, protozoa, 
or different mitogens. The response can be mimicked by synthetic TLR agonist, e.g. double-
stranded RNA (TLR7) or unmethylated, CpG-containing DNA motifs (TLR9) both in vitro and in 
vivo [De Maeyer E, Int Rev Immunol 1998].  
  
1.3 Plasmacytoid Dendritic Cells 
In lymphoid organs of mice or humans PDCs represent approximately 0.1% to 1.5% of 
mononuclear cells. PDCs were originally described as “T cell-associated plasma cells” or 
“plasmacytoid T cells” [Lennert K, Acta Haematol 1958; Lennert K, Lancet 1975], because of 
their close proximity to T cells and their plasma-cell like morphology. Their interferon production 
capacity has been reported later as well as their DC characteristic [Trinchieri G, JEM 1978a+b; 
Grouard G, JEM 1997]. In 1999, human PDCs have been phenotypically characterized as 
CD11c- CD123+ (IL-3Rα) CD4+ CD45RA+ ILT3+ cells with an immature phenotype [Siegal FP, 
Science 1999; Cella M, Nat Med 1999]. It was demonstrated that the maturation of PDCs and 
the formation of the classical dendrite-like morphology could be induced by CD40 triggering 
[Grouard G, JEM 1997; O’Doherty U, Immunology 1994]. BDCA-2 and BCDA-4 were identified 
as specific cell surface receptors for PDCs [Dzionek A, JI 2000]. Recently it has been 
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demonstrated that the Immunoglobulin-like transcript (ILT) 7 is also selectively expressed in 
human PDCs [Cao W, JEM 2006].  
The murine counterpart of PDCs has been searched for a long time; finally in 2001, three 
independent groups identified (natural) interferon-producing cells in several lymphoid organs of 
mice, which showed similar phenotype, function, and morphology [Nakano H, JEM 2001; 
Asselin-Paturel C, Nat Immunol 2001; Björck P, Blood 2001]. In contrast to human PDCs, 
murine PDCs are defined by the simultaneous expression of B220 (CD45R), Ly-6C, and 
CD11c, whereas BDCA-2 and -4 were not expressed. The intermediate expression level of 
CD11c and lack of CD11b further distinguishes them from cDCs. Also the expression level and 
recycling pattern of MHC-II is differentially regulated, as PDCs use a different promoter (C2ta 
pIII) for the transcription of the MHC class II transactivator (CIITA) compared to cDCs 
[LeibundGut-Landmann S, Nat Immunol 2004]. A different equipment of PRRs further reflects 
the functional differences to conventional DCs. Whereas cDCs express TLRs 2, 3, 4, 7, and 9, 
PDCs only express TLRs 7 and 9, underlining their strong responsiveness to viral or bacterial 
derived nucleic acids [Iwasaki A, Nat Immunol 2004; Takeda K, Annu Rev Immunol 2003; 
Edwards AD, EJI 2003; Krug A, Blood 2004; Heil F, Science 2004; Diebold SS Science 2004; 
Lund JM, PNAS 2004]. PDCs also lack characteristic CLRs, such as CD205 (DEC205), CD209 
(DC-SIGN/CIRE), or Dectin-1 and -2, which are expressed on conventional DCs [Figdor CG, 
Nat Rev Immunol 2002; Proietto AI, Immunobiology 2004; Meyer-Wentrup F, Blood 2008; 
Caminischi I, Mol. Immunol 2001].  
 
It has been shown that PDCs like other DCs develop from BM progenitors and continuously 
migrate to lymphoid organs via the blood stream [O’Keeffe M, JEM 2003] residing there at an 
immature stage. Several growth or transcription factors are crucial for the development of 
PDCs. FLT-3L, the Interferon α/β consensus sequence-binding protein (ICSBP) and IKAROS 
are involved in the regulation of PDC development [Chen W, Blood 2004; Gilliet M, JEM 2002; 
Brawand P, JI 2002; Schiavoni G, JEM 2002; Allman D, Blood 2006]. Although, it has been 
hypothesized that PDCs can originate from both common lymphoid and myeloid progenitors 
[Yang GX, JI 2005; D’Amico A, JEM 2003; Shigematsu H, Immunity 2004; Karsunky H, Exp. 
Hematol 2005; Naik SH, Immunol Cell Biol. 2005], the direct progenitor for mouse PDCs has 
been identified very recently. CD31high Ly6C- BM cells were found to develop into cells that show 
the typical plasmacytoid morphology, express a PDC-characteristic phenotype and produce 
high IFN-I amounts after TLR stimulation [Kreisel FH, Cell Immunol 2006].  
 
In steady state PDCs circulate in low numbers in the blood stream or in lymphoid tissues 
[Nakano H, JEM 2001; Asselin-Paturel C, JI 2003]. PDCs migrate constantly from the blood and 
entry LNs via High Endothelial Venules (HEV) in a CXCL9- and L-selectin-dependent 
mechanism [Yoneyama H, Int Immunol 2004; Nakano H, JEM 2001]. In secondary lymphoid 
organs, PDCs are found in the marginal zone (spleen) or paracortex (LNs) as well as the T cell 
area [Asselin-Paturel C, Nat Immunol 2003; Blasius A, Blood 2004; Nakano H, JEM 2001]. 
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Upon sensing pathogens peripheral PDCs upregulate co-stimulatory and MHC molecules. They 
accumulate in inflamed tissues and in particular in LNs draining the sites of inflammation where 
they orchestrate other leukocytes [Cella M, Nat Med 1999; Blasius AL, Blood 2004; Dicaovo 
TG, JEM 2005; Yoneyama H, Int Immunol 2004; Palamara F, JI 2004; Liu C, Journal Clin Inv 
2008]. 
 
The role of PDCs in viral or microbial infections and other diseases such as melanoma cancer 
has been excessively investigated. It has been demonstrated that PDCs are required for 
protection against lethal herpes-simplex virus (HSV) infection [Shen H, J Clin Invest. 2006] and 
enhances antiviral responses against respiratory-syncytial virus (RSV) [Smit JJ, PLoS ONE 
2008], mainly by IFN-I production. Although the PDC population expands after viral infections 
and they are the major producers of anti-replicative IFN-I, their numbers are often decreased in 
peripheral blood, e.g. in human immunodeficiency virus (HIV) and Hepatitis infection [Duan XZ, 
J Clin Immunol 2004; Soumelis V, Blood 2001; Ulsenheimer A, Hepatology 2005]. As this effect 
is accompanied with an increased viral load, these reduced PDCs frequencies correlate with a 
poor prognosis for the patients. An explanation for these decreased frequencies of PDCs in 
peripheral blood might be the extravasation into inflamed tissues such as lung e.g. during a 
respiratory infection. In case of AIDS/HIV, PDC numbers are reduced as these cells obviously 
reflect a target of the virus. Not only in viral infections but also in autoimmune diseases, such as 
systemic lupus erythematosus (SLE) or psoriasis, the decrease of blood PDCs is associated 
with the progression of the disease. The reduced PDC numbers in the blood of SLE or psoriasis 
patients correlate with the accumulation of these cells in inflamed tissues and the skin 
[Cederblad B, J. Autoimmun 1998; Farkas L, Am J Pathol 2001; Blomberg S, Lupus 2001]. 
PDCs are also linked with the outcome of further pathological situations and in particular with 
the outcome of tumors as PDCs and IFN-I have an important but ambiguous function [Dunn GP, 
Nat Rev Immunol 2006]. In the absence of an appropriate stimulus PDCs may promote 
regulatory T cells and contribute to an impaired T-cell-mediated immune response against 
tumors correlating with worse outcome of the disease [Hartmann E, Cancer Res 2003; Vermi W, 
J Pathol 2003]. In breast cancer and ovarian epithelial cell carcinoma, large numbers of 
infiltrating PDCs have been detected, but they rather induced regulatory T cells than immunity 
[Treilleux I, Clin Cancer Res. 2004; Zou W Nat Med 2001; Munn DH, J Clin Invest 2004]. Thus, 
the presence of these tolerogenic PDCs correlates with a negative prognosis. On the other 
hand, activated PDCs are promoting and supporting anti-tumor responses and are currently 
investigated in therapeutical approaches. It has been mentioned before that PDCs infiltrate 
inflamed tissues and tumors. Upon TLR7 activation, both human and mouse PDCs have been 
shown to massively infiltrate skin melanomas resulting in efficient tumor reduction [Palamara F, 
JI 2004; Stary G, JEM 2007]. TLR9-activated murine PDCs have been shown to have a 
beneficial impact for the treatment of cancer [Krieg AM, Oncogene 2008; Liu C, J Clin Inv 2008] 
as they synergistically act with other DCs or NK cells to induce anti-tumor responses as 
mentioned above. This and above studies suggest PDCs as an attractive target for cell-based 
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vaccination and immunotherapy against virus infections and tumor treatment.  
 
PDCs are also associated with the emergence of autoimmune diseases and tolerance. It has 
been shown that e.g. DNA immune-complexes can trigger PDCs resulting in highly elevated 
IFN-I levels in sera of SLE patients. High IFN-I levels lead to the establishment of a pro-
inflammatory environment and the differentiation and activation of cDCs or autoreactive B cells, 
which secrete auto-(dsDNA) antibodies [Rönnblom L, Arthritis Res Ther 2003]. Beside their role 
in SLE, PDC-mediated IFN-I production is also relevant for other autoimmune disorders 
including psoriasis, rheumatic arthritis (RA) or the Sjögren's syndrome [Nestle FO, JEM 2005; 
Banchereau J, Immunity 2006; Christensen SR, Immunity 2006; Farkas L, Am J Pathol 2001; 
Blanco P, Science 2001; Cavanagh LL, Arthritis Res Ther 2005; Lande R, J Immunol 2004]. 
The abrogation of PDC-produced IFN-I might result in the attenuation of autoimmune 
reactions/symptoms and is currently investigated as therapeutical target. 
On the other hand PDCs show a tolerogenic role, suggesting a beneficial impact of these cells 
in transplantations  [Ochando JC, Nat Immunol 2006; Abe M, Am J Transplant 2005]. PDCs 
also prevent inflammatory reactions against harmless antigens by suppression of effector T 
cells induced by cDCs. Their ablation could result in the development of other autoimmune 
diseases such as asthma [De Heer H, JEM 2004]. 
 
PDCs have an essential function in the interaction with several cell types from both the innate 
and adaptive immune system. Mainly by their production of IFN-I, but also of IL-12, they directly 
activate NK cells, shown by increased proliferation, IFNγ secretion, and cytotoxicity [Krug A, 
Immunity 2004; Biron CA, Annu Rev Immunol 1999; Dalod M, JEM 2003]. This IFN-I production 
also results in the activation and maturation of DCs and other APCs [Honda K, PNAS 2003]. In 
particular, IFN-I “licenses” APCs for the cross-presentation of exogenous antigens and the 
induction of antigen-specific CD8+ CTLs [Le Bon A, Nat Immunol 2003]. Furthermore, PDCs 
influence the differentiation and immuno-stimulatory functions of other DC subtypes by 
secretion of cytokines such as IL-6, -8, -12, and TNFα  [Poeck H, Blood 2004; Decalf J, JEM 
2007]. The secretion of IL-6 and IFN-I sequentially influences the development of CD40L-
activated B cells towards plasma cells, as IFN-I leads to the generation of plasma blasts and IL-
6 subsequently triggers the differentiation into Ig-secreting plasma cells [Poeck H, Blood 2004; 
Jego G, Immunity 2003]. For example in SLE, high levels of PDC-derived IFN-I promotes the 
differentiation and activation of cDCs that capture and present antigens (e.g. from apoptotic 
cells) to autoreactive B cells resulting in the generation of autoantibody-producing plasma cells 
[Vallin H, JI 1999]. PDCs have a eminent impact on T cells as PDC-derived IFN-I can induce the 
activation and survival but also the polarization of naïve T cells [Agnello D, J Clin Immunol 
2003]. The influence of PDCs on T cells is based mainly on their interaction with conventional 
DCs that subsequently activates the T cells, but PDCs also influence T cells directly by the 
secretion of pro-inflammatory cytokines: Virus-infected PDCs are found to promote a strong 
IFNγ production in CD4+ T cells, suggesting their pivotal role in the induction of TH1 responses 
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[Kadowaki N, JEM 2000], but there are other reports of a PDC-triggered TH2 polarization 
depending on the antigen dose and activation status of the cells (in case PDCs received not an 
appropriate TLR activation [Cella M, Nat Immunol 2000; Kadowaki N, JEM 2000; Boonstra A, 
JEM 2003; Ito T, JI 2004]. Recently, there is increasing evidence for a tolerogenic function of 
PDCs if PDCs are not triggered to respond in an anti-viral manner, e.g. in the absence of high 
IFN-I production. These inhibitory effects are either mediated via the PD-1:PD-1L pathway or 
induced by the tolerogenic enzyme Indoleamine 2,3-dioxygenase (IDO), which is expressed on 
PDCs under certain, inducible conditions. For example stimulation of PDCs with the tolerogenic 
ligands CTLA-4–immunoglobulin (CTLA-4–Ig), CD200-Ig or soluble GITR initiate the 
immunoregulatory pathway of tryptophan catabolism and the induction of IDO expression [Ito T, 
JEM 2007; Gilliet M, JEM 2002; Kuwana M, Hum Immunol 2002; Fallarino F, JI 2004; De Heer 
H, JEM 2004; Sharma MD J Clin Inv 2007; Abe M, Amerc J of Transplant 2005]. An illustration 
of the differential functions of PDCs and their role at the interface of innate and adaptive 
immunity is given in Fig 1.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.2. The role of PDCs bridging innate and adaptive immune responses.   
For a more detailed explanation please refer to the text. 
 
It remains elusive whether PDCs have only an accessory function by their cytokine secretion 
[Yoneyama H, JEM 2005] or are directly acting as antigen-presenting cells, e.g. to prime naïve 
T cells, is still controversially discussed. In vitro generated PDCs promote in vitro the expansion 
of naïve CD4+ and CD8+ T cells [Boonstra A, JEM 2003; Brawand P, JI 2002]. In vivo 
experiments with peptide-pulsed and CpG-matured PDCs show that PDCs can induce naive 
CD8+ T cell responses to endogenous, but not exogenous, antigens [Salio M, JEM 2004]. And it 
has been shown that virus-activated but not CpG-activated PDCs can differentiate into APCs 
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and induce an effector/memory CD8+ T cell response in vivo [Schlecht G, Blood 2004]. In 
contrast, PDCs are considered to be poor T cell stimulators, as immature and virus-activated 
PDCs failed to prime naïve CD4+ and CD8+ T cells [Krug A, JEM 2003]. Recently, it has been 
shown that only peptide-pulsed PDCs have the capacity to activate naïve CD8+ T cells [Lou Y, 
JI 2007], whereas their ability to process soluble antigens is questionable. In a different 
experiment only CD8+ cDCs but not PDCs activate naïve CD8+ T cells in vivo [Belz GT, JI 
2005]. The qualitatively different capacities between PDCs and cDCs to prime naïve CD8+ T 
cells were further underlined as BM-derived and peptide-pulsed PDCs only induced minor CD8+ 
T cell responses without significant memory CD8+ T cell differentiation in vivo [Angelov GS, JI 
2005]. Thus, PDCs might have only a synergistic but important effect on cDCs to induce an 
antigen-specific immune response [Kadowaki N, Hum Immunol 2002; Lou Y, JO 2007; Liu C, J 
Clin Inv 2008]. These conflicting results are likely caused by either the different source of 
antigens (peptide vs. protein), the kind of PDC preparation or their activation status as freshly 
isolated or TLR-activated PDCs have been used in the studies. Although some experiments 
show the APC-function of PDC, this reaction was less efficient as compared to cDCs. Based on 
these reports further investigations on the antigen-presenting and -processing capacity of PDCs 
were necessary. A receptor-based strategy might be a promising approach, as the nature of the 
antigen-uptake receptor often has a critical influence on the direction and sorting of the 
endocytosed antigen [Burgdorf S, Science 2007]. At the beginning of this study no marker was 
known that allowed a specific targeting of antigens to murine PDCs in opposite to other APCs. 
Conventional DCs express the lectin receptors DC-SIGN, DCIR2 and in particular DEC-205. 
Antigens targeted to these receptors were efficiently internalized and processed resulting in 
efficient priming of naïve CD4+ or CD8+ T cells in vivo [Engering A, JI 2002; Bonifaz L, JEM 
2002 and 2004; Dudziak D, Science 2007]. Thus, the identification of a novel PDC-expressed 
receptor might help to discover the APC function of these cells. 
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2. OBJECTIVES OF THE WORK 
The central function of dendritic cells (DCs) is the uptake and presentation of antigens for the 
induction of adaptive immune responses. Several DC subpopulations have been described, 
differing in phenotype, morphology, tissue localization, and function. Since all cells interact with 
their environment via cell surface receptors, the characteristic function of the particular 
subpopulation is often defined by its phenotype. Thus, further exploration of specifically 
expressed molecules is crucial to understand the immunological role and to disclose functional 
differences between different DC subsets. 
 
The aim of this work was the identification of a cell surface receptor specifically expressed on 
mouse PDCs. In the first part of this work a PDC-specific monoclonal antibody should be 
generated by contralateral footpad immunization procedure. Next, the antigen recognized by the 
generated mAb should be identified and functionally characterized. The results might provide 
further evidence for the role of PDCs in the immune system. In particular, the ability of PDCs to 
act as professional APCs in the induction of T cell responses is currently controversially 
discussed and further insights would be beneficial. 
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3. MATERIALS AND METHODS 
3.1 Mice 
In this work female wild-type Balb/c and C57BL/6 mice were used, all purchased from Harlan 
Winkelmann, Borchen, Germany.  
To detect strain-specific differences in the expression of mPDCA-1 and/or Sca-1, additionally, 
AKR/J, CD1, DBA/1, FVB, HM1, and SV129 mice were used (Harlan Winkelmann, Borchen, 
Germany, and Charles River Laboratories, Sulzfeld, Germany). 
For studies describing the interaction of PDCs and naïve T cells, the following mouse models 
were used:  
OT-I (C57BL/6) TCR transgenic mice harboring OVA-specific CD8+ T cells, carrying a Vα2/Vβ5 
TCR specific for the OVA257-264 peptide presented in the context of MHC class I H2-Kb [Hogquist 
KA, Cell 1994], and OT-II (C57BL/6) TCR transgenic mice harboring OVA-specific CD4+ T cells, 
carrying a TCR specific for the OVA323-329 peptide [Robertson JM, JI 2000] were a kind gift of 
Professor Stefan Grabbe, University of Mainz, Germany. 
DO11.10 (BALB/c) TCR transgenic mice harboring OVA-specific CD4+ T cells, carrying a TCR 
specific for the OVA323-329 peptide [Robertson JM, JI 2000], were purchased from Charles River 
Laboratories. 
All mice were used at the age of 6 to 15 weeks, maintained under pathogen-free conditions and 
handled in accordance to protocols approved by local authority guidelines. Experiments were 
partly performed in collaboration with the Weizmann Institute of Science, Rehovot, Israel (group 
of Dr. S. Jung), at the DRFZ Berlin (group of Dr. A. Scheffold), at the Albert-Ludwigs-Universität 
Freiburg (group of Professor C. Bogdan) or at the Washington University in St. Louis (group of 
Professor M. Colonna). 
 
3.2 Reagents  
3.2.1 Antibodies  
3.2.1.1 Antibodies for flow cytometry  
In this study the following Fluorescein Isothiocyanate (FITC), Allophycocyanin (APC), R-
Phycoerythrin (PE) or Biotin-coupled rat anti-mouse monoclonal antibodies (mAb) were used to 
analyse cell surface markers: 
CD3ε (clone 145-2C11), CD4 (clone GK1.5), CD8α (clone 53-6.7), CD11b (clone 
M1/70.15.11.5), hamster anti-mouse CD11c (clone N418), CD16/32 (clone 93), CD19 (clone 
6D5), CD40 (clone FGK45.5), CD45R (B220, clone RA3-6B2), CD49b (clone DX5), CD90 
(Clone 30-H12), CD154 (CD40-L, clone MR1), CD205 (DEC205, clone NLDC-145), MHC-II 
(clone M5/114.15.2), Gr-1 (Ly-6C/G, clone RB6-8C5), Ly-6C (clone 1G7.G10), mPDCA-1 
(unless indicated otherwise, clone JF-05-1C2.4.1 was used), Sca-1 (clones D7, CT-6A/6E, and 
E13-161.7), Ter-119 (clone Ter-119), and H-2kb:SIINFEKL (25-D1.16) were all obtained from 
Miltenyi Biotec. 4-1BBL (clone TKS-1), CD40 (clone3/23), CD80 (clone 16-1OA1), CD86 (clone 
GL1), CD138 (Syndecan), CD274 (B7-H1, PD-L1 (clone MIH5), and TCRvβ5.1 (clone MR9-4), 
B220 (clone RA3-6B2), and MHC-I (H-2kb; clone AF6-88.5) were all purchased from BD 
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Pharmingen. CD69 (Clone H1.2F3), CD209 (DC-SIGN, clone 5H10), TCRβ (clone H57-597), 
and KJ1-26 (DO11.10 clonotype) were purchased from Natutec (eBioscience), Frankfurt, 
Germany. Siglec-H (clones 440c or 551-3D3) was a kind gift of M. Colonna, St-Louis, USA. SA-
PE-conjugated H-2Kb-OVA (SIINFEKL) iTAg™ MHC Class I murine tetramer was purchased 
from Immunomics [Beckman Coulter] (San Diego, CA). Anti-rat MPG1 pAb was purchased from 
Cell Sciences, Canton, USA. HRP-conjugated polyclonal rabbit anti-rat Ig (H+L) (Jackson 
Immuno Research Laboratories) and HRP-labeled rabbit anti-Ovalbumin (hen egg white) 
antibody (Research Diagnostics Inc., Concord, USA) were used for immunoblotting and ELISA, 
respectively. 
The following mAbs were used to detect intracellular cytokines: mAbs against IFN-γ (clone 
AN18.17.24), IL-2 (clone JES6-5H4), IL-4 (clone BVD4-1D11), IL-10 (clone JES5-16E3), IL-17 
(clone TC11-18H10), TNFα (clone MP6-XT22) (all MB); IFNα (clone F18) (HyCult 
Biotechnologies b.V., Uden, The Netherlands); PE-conjugated IL-12p40/70 (clone C15.6) (BD 
Pharmingen). 
Secondary antibodies were anti-Biotin mAb (Bio3-18E7.2) obtained from Miltenyi as well as 
FITC/PE-conjugated mouse anti-rat Kappa (clone MRK-1), anti-rat IgG1 (clone RG11/39.4), anti-
rat IgG2a (clone B46-79, or anti-rat IgG2b (cloneRG7/11.1) that had been purchased from BD 
Pharmingen. 
 
3.2.1.2 Antibodies for ELISA 
Anti-IFNα mAb (clone F18) was purchased from HyCult Biotechnologies (HBT), Uden, The 
Netherlands. HRP-coupled anti-OVA mAb was obtained from Research Diagnostics Inc., 
Concord, USA. 
 
3.2.1.3 Antibodies for Immunoblotting 
HRP-conjugated anti-phosphotyrosine mAb (clone Py-20) was obtained from BD Pharmingen, 
whereas HRP-coupled anti-OVA mAb was purchased from Research Diagnostics Inc., Concord, 
USA. Rabbit anti-rat-IgG(H+L) was purchased from Jackson Immuno Research Laboratories 
Inc. (distributed via Dianova, Hamburg). 
 
3.2.2 Chemicals  
3.2.2.1 General reagents 
Carboxy-fluorescein diacetate succinimidyl ester (CFDA-SE/CFSE) was obtained from 
Molecular Probes [Invitrogen], Karlsruhe, Germany. 
Bio-Safe colloid Coomassie staining reagent was purchased from Bio-Rad Laboratories, 
München, Germany. 
 
3.2.2.2 Proteins and peptides  
Imject OVA® protein was obtained from Perbio, Bonn, Germany, whereas OVA peptides OVA323-
339 (ISQAVHAAHAEINEAGR) and OVA257-264 (SIINFEKL) were synthesized by O. Braun, 
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Apharesis 2 Unit, Miltenyi Biotec. 
 
3.2.2.3 Stimulatory sequences 
Phorbol-12-Myristate-13-Acetate (PMA), Ionomycin Calcium salt from streptomyces 
conglobatus (min. 98% TLC), and the TLR7 agonist Loxoribine (7-allyl-7,8-dihydro-8-guanosine) 
were purchased from Sigma. CpG ODNs 1668, 1826, 2006, and 2216 were all synthesized by 
Metabion, München, Germany. 
Heat-inactivated Influenza virus (A/FPV/H7N7; Bratislava strain 79) was a kind gift of Dr. I. 
Johnston (Miltenyi). 
 
3.2.3 Buffers 
Staining and separation buffer: 
Antibody stainings for subsequent FACS analysis as well as MACS-based cell isolations were 
standardly performed in staining buffer based on phosphate-buffered saline containing 2 mM 
EDTA and 0.5% BSA. For stability reasons, optionally 0.05% NaN3 was added. 
 
Red blood cell lysis buffer:   
15.5 mM NH4CL, 1 mM KHCO3, 0.01 mM EDTA 
 
Cell lysis buffer for immunoprecipitation or western blot:  
100 mM Tris-HCl, 150 mM NaCl, 5 mM EDTA, supplemented with detergents (1% NP-40, 
Triton-X100 or other) and complete EDTA-free protease inhibitor cocktail (Roche). Low salt 
buffer used for washing before SDS-PAGE or elution contained 10 mM Tris HCl and 15 mM 
NaCl. 
 
5x sample (Laemmli) buffer:  
According to the protocol of Laemmli et al. 1970, 63 mM Tris-HCl (pH 6.8), 2% SDS, 0.025% 
3',3",5',5"-tetrabromophenolsulfonphthalein, and 10% glycerol were mixed and scaled up with 
distilled water to 10 ml volume. Optionally, DTT or β-mercapto ethanol was added for reducing 
conditions [Laemmli UK, Nature 1970]. 
 
10x SDS running buffer:   
25 mM Tris-Base, 192 mM Glycine, 0.1 % SDS 
 
Transfer buffer:   
48 mM Tris-Base, 39 mM Glycin, 1.3 mM SDS, 10% methanol 
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3.2.4 Instruments and miscellaneous 
NanoDrop  NanoDrop Technologies/Thermo 
Scientific, Wilmington, USA 
Agilent 2100 Bioanalyzer     Agilent Technologies, Böblingen 
Trans-Blot SD SemiDry Transfer Cell   BioRad, München 
Gene Pulser II      BioRad 
Flow cytometers FACScalibur and FACSvantageSE BD Biosciences, Heidelberg 
MACS-Separators and Stand    Miltenyi Biotec, Bergisch Gladbach 
Cell culture hood Hera Safe     Heraeus Instruments, Osterode 
Incubator Hera Cell      Heraeus 
Waterbath       Julabo, Seelbach 
Centrifuge Eppendorf 5415D     Eppendorf, Hamburg  
Centrifuge Megafuge 1.0     Heraeus 
Thermocycler: PTC-225     MJ Research, Ramsey, USA 
Multiplate reader Genios     Tecan, Crailsheim 
Cryostat CM3050      Leica, Wetzlar 
 
Chemicals were purchased at Merck Chemicals KGaA (Darmstadt) or Sigma-Aldrich Chemie 
GmbH (Munich; also: Fluka and Riedel-de-Haën), unless otherwise specified in the text.  
 
10-20% Tris/Glycine-gels  Anamed, Groß-Bieberau 
1 kb-PLUS-DNA-Ladder     Invitrogen 
PAGE-Ruler Prestained Protein Ladder   MBI Fermentas, St. Leon-Rot 
Blot Paper (Mini Blot size)     BioRad 
Cell strainer (40, 70, 100 µ)     Falcon (BD Biosciences) 
Conical and Round Bottom Tubes    Falcon (BD Biosciences) 
Cy3/5-dCTP        GE Healthcare, Munich 
Hybond-P PVDF and Hybond-XL Nylon Membranes  GE Healthcares 
Electroporation Cuvette (Type 165-2107)    BioRad 
NAP-5 and -10 columns     GE Healthcare 
PD-10 column       GE Healthcare 
Superdex 200 16/60 column     GE Helathcare 
Neubauer chamber      Brand, Wertheim 
MACS Separation columns (µ, MS, LS, LD)   Miltenyi Biotec 
Pre-Separation filter      Miltenyi Biotec 
Syringe needle 26G ½“, short    Braun, Melsungen 
CpG ODNs       Metabion, Munich 
PHA-Lectin       Sigma 
Azaserine       Sigma 
Polyethylenglycol      Roche, Mannheim 
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3.3 Cell culture 
3.3.1 Standard cell culture methods 
All cell types were cultured in a humidified incubator with a 5-9% CO2 atmosphere at 37°C. 
Murine primary cells were isolated directly from indicated tissues (as described below in the 
FACS section). RPMI 1640 (Miltenyi Biotec, Bergisch Gladbach, Germany; Invitrogen, 
Karlsruhe, Germany), supplemented with 10% FCS (PAA Laboratories, Pasching, Austria), 15 
mM HEPES buffer, 1 mM Sodium pyruvate, 50 µM β-mercaptoethanol, 2 mM L-Glutamine, 100 
U/ml Penicillin and 10 µg/ml Streptomycin (all medium supplements were obtained from 
Invitrogen) was used as culture medium for all in vitro experiments with primary cells. 
Human HEK 293T cells, murine 1881, EL-4, SP2/0, and Raw 264 cells as well as rat RBL-1 
cells were purchased from ATCC/LGC Promochem GmbH, Wesel, Germany. Cell lines were 
either cultured in RPMI or in Dulbeccos modified Eagles medium (DMEM; Miltenyi Biotec and 
Invitrogen), supplemented in analogy to RPMI. 
 
3.3.2 Generation of FLT-3L-derived BM-PDCs 
It has been shown that treatment of mice with FLT-3L resulted in increased numbers of DCs in 
different lymphoid organs including the bone marrow [Maraskovsky E, JEM 1996] leading to the 
development of several protocols to generate DCs and PDCs in vitro. 
Total BM cells were prepared by rinsing femurs and tibiae of one mouse. Red blood cells were 
lysed for 10 min at room temperature in lysis buffer. After sterile washing, cells were seeded at 
a final cell concentration of 2x106 cells/ml in complete medium, additionally containing 15% FCS 
(Biochrome) and 1% non-essential amino acids. Recombinant murine growth factors were 
added for the generation of PDCs: 100 ng/ml Flt-3 Ligand (R&D Systems) and 10 µg/ml 
Thrombopoietin (TPO; Biosource [Invitrogen]). At days 4 and 7, 50% of the medium was 
replaced by fresh medium supplemented with 50 ng/ml Flt-3L. In vitro generated PDCs were 
standardly harvested between days 7 and 10. 
 
3.4 Generation of monoclonal antibodies 
3.4.1 Contralateral (footpad) immunization and fusion 
For all immunization approaches PDCs were isolated from spleen of wild type (wt) BALB/c mice 
and subcutaneously (s.c.) immunized into the hind footpad of Lewis and LOU rats, respectively. 
In different immunization attempts, murine Sp2/0 myeloma or freshly isolated murine NK cells 
were used as decoy and subjected to the corresponding, contralateral foot pad [as described 
before by Brooks PC, Journal of Cell Biology, 1993; Yin AH, Blood 1997]. After several rounds 
of immunization, cells from the popliteal LNs of the one hind footpad were used for the fusion 
with a murine myeloma partner (Sp2/0 cells) based on the HAT system originally described by 
Köhler and Milstein [Köhler G & Milstein C: “Continuous cultures of fused cells secreting 
antibody of predetermined specificity”, Nature 256, 495–497 (1975); Cotton RGH & Milstein C: 
“Fusion of two immunoglobulin-producing myeloma cells” Nature 244, 42–43 (1973)]. 
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3.4.2 Screening of hybridoma clones 
To assess the specificity of the generated hybridoma clones and to select only PDC-specific 
clones, the following screening strategy was performed. Spleen single cell suspensions were 
incubated with hybridoma supernatant for 10-15 min at room temperature. After washing, the 
cell suspension was incubated via PE-conjugated marκ mAb (10 min at 4°C) followed by a 
second washing step. PDCs were subsequently identified by staining with APC-conjugated 
hamster anti-mouse CD11c or rat anti-mouse B220 or Gr-1 mAbs (10 min at 4°C). In case rat 
anti-mouse mAbs were used to detect PDCs, an intermediate blocking step (30 min at room 
temperature) with irrelevant rat IgG mAb was applied (100 µg/ml) before anti-B220 and Gr-1 
mAbs were added directly into the staining suspension. In all these stainings blocking of Fc 
receptors was omitted, as the anti-CD16/32 mAb would be detected by the marκ mAb.  
 
3.4.3 Isotype determination of generated mAbs 
The isotype of the generated PDC-specific antibodies was assessed either by flow cytometric 
analysis (intracellular staining with secondary mouse anti-rat Kappa, IgG1, IgG2a, or IgG2b) or 
was determined using the anti-rat monoclonal antibody isotyping test kit (RMT1; AbD 
Serotec/Morphosys, Düsseldorf, Germany). 
 
3.4.4 Competitive inhibition experiments with the generated mAbs 
Epitope recognition of the four PDC-specific mAbs was determined by cross-blocking 
experiments. Spleen single cell suspensions were first incubated with 100 µg/ml unconjugated 
mAb for 10 min at 4°C. Next, cells were stained with fluorochrome-conjugated mAbs of 
indicated clones. Impact of blocking was revealed by flow cytometric analysis (by change of the 
mean fluorescence intensity).  
 
3.5 Biochemical methods 
3.5.1 SDS-PAGE and Western blotting: 
Size fractionation of protein suspensions was performed by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE). 1-106 cells were washed with ice-cold 
phosphate buffered saline and sedimented before resuspension in sample buffer. Samples 
were then sonificated and boiled at 95°C for 5 min. For assessing the integrity of the targeting 
construct proteins were also resuspended in sample buffer. Samples (5-25 µl) were then loaded 
onto 4-20% Tris-glycin gels that have been obtained from Invitrogen (Novex gels) or Anamed 
and gel electrophoresis was performed on a X-cell Sure Lock Novex Mini cell System 
(Invitrogen) according to the manufacturers instructions. 
Protein markers of 20–150 kDa size were obtained form MBI Fermentas (Prestained Protein 
Ladder) or Bio-Rad (Prestained Ladder). After electrophoresis, gels were equilibrated with 
distilled water whereas PVDF membrane (Hybond-P, Amersham Biosciences) was activated 
with methanol and equilibrated with transfer buffer. Proteins were transferred onto the PVDF 
membrane via a semi-dry or semi-wet process in a Trans Blot SD semi dry transfer cell (Bio-
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Rad). Membranes were washed and blocked with FCS, BSA, or milk powder-containing 
phosphate buffered saline and subjected to antibody-detection, e.g. anti-OVA, anti-rat IgG(H+L), 
or anti-Py-20 antibodies were used. Finally, HRP-mediated signals were analyzed via the ECL 
detection kit (Amersham Pharmacia Biotech, Uppsala, Sweden). 
 
3.5.2 Induction and analysis of tyrosine phosphorylation 
PDCs were untouched isolated by MACS technology (see below) and pre-incubated for 30 
minutes in supplemented RPMI medium at 37°C. Anti-mPDCA-1 mAb or anti-Ter119 mAb (rat 
IgG2b isotype control) were added at a final concentration of 10 µg/ml. Five minutes later cells 
were wash in ice cold PBS buffer and lysed in Laemmli protein sample buffer. Cell lysates were 
sonicated, boiled, separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE), and transferred to PVDF membranes. After blocking with 5% BSA, membranes 
were probed with HRP-coupled anti-phosphotyrosine mAb Py-20 (BD Pharmingen). Immuno-
blotted proteins were visualized by chemiluminescence using enhanced chemiluminescence 
detection reagents (Amersham).  
 
3.5.3 Immunoprecipitation 
5x106 cells were resuspended in 1 ml lysis buffer and incubated for 30 min on ice. Optionally, 
cells were additionally sonicated. After lysis nuclei and debris were removed by centrifugation 
(13,000 rpm for 5 min). For “preclearing”, irrelevant antibody was added to the supernatant and 
incubated for 1 h at 4°C. 100 µl protein-G sepharose was washed with lysis buffer and added to 
the lysates. After overnight incubation anti-mPDCA-1 mAb was added to the precleared 
supernatant (after sepharose-bound irrelevant antibody was removed by centrifugation) and 
incubated for 2-4 hrs. Anti-mPDCA-1 mAb was detected by fresh sepharose (incubation for 2 
hrs) and washed with lysis buffer as well as low salt buffer before resuspension in SDS sample 
(Laemmli) buffer. Samples were stored at -20°C until SDS-PAGE or Western blot analysis. 
 
3.5.4 Immunoprecipitation after metabolic labeling 
To identify IFNα-induced and PDC-specific proteins cells were metabolically labeled with 35S-
Methionine before subsequent immunoprecipitation was performed: A 10 µCi/ml 35S-methionine 
working solution was prepared in pre-warmed (37°) long-term labeling medium lacking 
methionine. 5x106 cells were respuspended in 5-10 ml of the indicated medium and transferred 
to a 25 cm2 tissue culture flask and cultured for 16 hrs in the presence or absence of 102 U/ml 
recombinant murine IFNa. After washing, cells were lysed and subjected to immunoprecipitation 
as described above. Radioactive signaling of samples was visualized on x-ray films. 
 
3.5.5 Generation of antibody conjugates and fragments 
Anti-mPDCA-1 mAb or ChromePure rat IgG (Jackson Immuno Research Lab. Inc., West Grove, 
PA, USA) F(ab’)2 fragments were conjugated to OVA protein that had been activated with 
succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC, Perbio) according to 
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the manufacturer’s protocol as described elsewhere [Sapoznikov A, JEM 2007]. The F(ab’)2-
OVA conjugates were size fractionated to remove unconjugated OVA. For in vivo application 
the reagents were sterile filtrated (Millex GV filter unit 0.22 µm; Millipore, Carrigtwohill, Ireland). 
Construct integrity was evaluated by SDS-PAGE and Western blot analysis, and fragments 
were detected with HRP-conjugated polyclonal rabbit anti-rat Ig (H+L) (Jackson Immuno 
Research Laboratories) and HRP-coupled rabbit anti-OVA antibody (Research Diagnostics Inc., 
Concord, MA, USA), respectively. To asses specific in vivo targeting of PDCs, mice were 
subcutaneously (10 µg) or intraperitoneally (50 µg) injected once with Alexa488-conjugated anti-
mPDCA-1-F(ab’)2. Two hours after subcutaneous injection and 15 hours after intraperitoneal 
injection single cell suspensions were prepared from the popliteal LN and spleen, respectively, 
and were analyzed for specific in vivo labeling of PDCs, counter-stained against B220, Ly-6C or 
CD11c.  
 
To deliver model antigens to PDCs in vitro, spleen single-cell suspensions were incubated with 
OVA protein covalently coupled to FITC-conjugated anti-mPDCA-1-F(ab’)2 antibody fragment. 
For detection of PDC-specific targeting, cells were stained with Siglec-H. 
 
3.5.6 Enzyme-Linked Immunosorbent Assay (ELISA) 
ELISA readout was generally performed by measurement of the absorbance at 450 nm using a 
Microplate ELISA reader (MWG-Biotech, High Point, USA) via Softmax Pro v5.0.1 software 
(Molecular Devices, Sunnyvale, USA). 
 
3.5.6.1 Anti-IFNα-ELISA 
The capacity of PDCs to produce IFN-I and the impact of mPDCA-1 triggering was analyzed 
both in vivo and in vitro.  Animals received a dose of PDC-depleting anti-mPDCA-1 mAb and 
were infected with MCMV. Blood was collected by retro-orbital puncture at the indicated time 
points after treatment. Serum was prepared from whole blood by coagulation for 30 min at 37°C 
and centrifugation. Collected sera were analyzed with a Mouse IFN alpha Colorimetric ELISA 
Kit (PBL Biomedical Laboratories, USA). 
Alternatively, mice received 10 µg CpG ODN 2216 in combination with DOTAP (Roche 
Diagnostics), and serum IFNα was analyzed 6 hrs later. 
In vitro IFNα production by PDCs was assessed as follows: 105 isolated or enriched mouse 
PDCs were cultured in a 96-well plate in the absence or presence of a TLR9 stimulus (5 µg/ml 
CpG ODN) for 24 hrs. Subsequently, supernatant was analyzed by IFNα-specific ELISA (PBL). 
 
3.5.6.2 Anti-OVA-ELISA 
To determine the OVA content on generated mPDCA-1 and isotype targeting constructs, an 
OVA-specific ELISA was performed. Soluble OVA and different OVA-antibody fragments were 
coated for 60 min at 37°C onto high-binding capacity 96-well polystyrene microtiter plates 
(Greiner bio-one) in PBS. After washing (PBS, 0.1% Tween-20), the plate was incubated with 
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blocking buffer (PBS, 0,1% Tween-20, 5% BSA) at 4°C. After 12 hrs, the plate was washed and 
incubated with horseradish peroxidase (HRP-) coupled rabbit anti-OVA antibody (Research 
Diagnostics Inc., Concord, USA) for 1h at 37°C. After repeated washing, 100 µl tetramethyl 
benzidine substrate (TMB; Pierce) was added to the wells and incubated for 10 min. Reaction 
was stopped with 100 µl sulfuric acid (10%). OVA content of the conjugates was quantified by a 
standard curve, which was based on soluble OVA protein. 
 
3.6. Flow cytometric analysis 
The flow cytometric analysis of cells or particles is based on their physical and immunological 
characteristics. Beside their scatter properties, cells were investigated by fluorochrome-
conjugated antibodies within a fluid stream. The combination of scattered and fluorescent light 
emissions was detected and analyzed to define information about the physical structure and 
expression pattern of different molecules for each single cell. 
 
3.6.1 Tissue preparation 
Mice were either euthanatized by isoflurane inhalation or sacrificed by cervical dislocation. 
Peripheral blood was obtained from retro-orbital puncture or tail bleeding. Organs collected for 
different experiments included spleen, bone marrow, liver, thymus, lung, mesenterial and 
peripheral lymph nodes (popliteal, inguinal, cervical, brachial and axillary) as well as Peyer’s 
Patches. If indicated, spleen, liver, and lungs were subjected to Collagenase D (Roche 
Diagnostics) treatment in AnnexinV buffer for 35 min at 37°C. 
For single cell suspensions, collected organs were mechanically disrupted by passing through a 
cell strainer (40-100 µm nylon mesh; BD Biosciences, Franklin Lakes, USA). After centrifugation 
at 300xg for 10 min, cells were resuspended in staining buffer in case not otherwise indicated.  
 
3.6.2 General staining procedure for CDs and other cell surface molecules 
For standard flow cytometric analysis, 2x106 cells were resuspended in ice-cold staining buffer. 
Cells were stained with designated antibodies for 10 min according to manufacturer’s 
instructions, whereas Fc-receptors were blocked by simultaneous incubation with unlabeled 
anti-CD16/CD32 mAb. Cells were then analyzed on FACS Calibur or FACS Scan Flow 
cytometers (Becton-Dickinson, Heidelberg, Germany) using CellQuest software (Becton-
Dickinson) or FlowJo (TriStar, San Carlos, CA, USA). Cell debris and dead cells were excluded 
from the analysis based on scatter signals and PI fluorescence [Flow cytometry and cell sorting; 
A. Radbruch, editor. Berlin; New York: Springer-Verlag 1992]. 
 
3.6.3 Intracellular cytokine staining (ICS) 
3.6.3.1 Detection of IL-12, TNFα  and IFNα production in PDCs 
PDCs were activated in vitro with different TLR agonists. Four hours before ending of the culture 
Brefeldin A (10 µg/ml; Calbiochem) was added to prevent cytokine secretion. Subsequently, 
PDCs were fixed and permeabilized (Inside Stain Kit, Miltenyi Biotec) and intracellularly stained 
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for indicated cytokines (IL-12, IFNα, and TNFα) before flow cytometric analysis. 
 
3.6.3.2 Cytokine staining of IL-2, IL-4, IL-10, IL-17, IFNγ, and TNFα produced by T cells 
PDC-primed CD4+ T cells were expanded for eight days until restimulation with PMA [20 ng/ml] 
and Ionomycin [1 µg/ml] for 6 hours in vitro. In the last four hours the medium was 
supplemented with Brefeldin A as described before. Cells were fixed and permeabilized (Inside 
Stain Kit, Miltenyi Biotec) and stained for intracellular cytokines (IL-2, IL-4, IL-10, IL-17, IFNγ, 
and TNFα) before flow cytometric analysis. 
 
3.6.4 Internalization experiments 
For internalization of the mPDCA-1 antibody-receptor complex in vitro, FL or BM PDCs were 
isolated and stained with FITC-conjugated anti-mPDCA-1 mAb on ice. After washing cells were 
resuspended in medium and incubated at 37 °C for 0-120 min. To detect cell surface-bound 
antibody, cells were then labeled with biotinylated anti-FITC mAb followed by counterstaining 
with PE-conjugated anti-Biotin mAb. Mean fluorescence intensities of both FL-1 and FL-2 
signals were normalized (the starting MFI values were set to 100%).  
To demonstrate in vivo internalization of mPDCA-1, Alexa488-conjuagted anti-mPDCA-1(Fab2) 
mAb was administrated intraperitoneally. Next, spleen PDCs were isolated, fixed in 1.8% 
formaldehyde at room temperature and additionally stained for surface-bound mPDCA-1 with 
anti-mPDCA-1-Biotin followed by Alexa633-conjugated anti-Biotin mAb. Confocal laser 
scanning microscopy (CLSM) analysis showed either signals derived from in vivo administrated 
Alexa488-conjugated anti-mPDCA-1-F(ab’)2 or cell surface located, in vitro stained mPDCA-1 or 
merged pictures. 
 
3.6.5 Induction and analysis of intracellular calcium flux 
To detect Ca2+ released from intracellular compartments upon receptor triggering, 1-5x106/ml 
PDCs were loaded with a fluorochrome, which exhibited different extinction stages in the free 
and Ca2+-bound conformation (5 mM Indo-1; Molecular Probes). After washing with medium 
supplemented with FCS, cells were incubated for 45 min at 37°C before washing with PBS and 
kept on ice until analysis on a FACS Vantage Flow Cytometer Cell Sorter (BD; operated by C. 
Göttlinger, Institute of Genetics, University of Cologne). To define PDCs, cells were optionally 
stained with PE and APC-conjugated anti-B220 and anti-CD11c mAbs, respectively. The filter 
set-up of the FACS Vantage for Indo-1 (UV excitation only) was either a FL-5 424/44 nm BF 
filter (calcium bound Indo-1) or a FL-4 530/30nm BF filter (unbound Indo-1).  Calcium flux was 
measured as a ratio between calcium bound and unbound Indo-1 (FL-5/FL-4) versus time.   
To assess background signal intensity, ice-cold and Indo-1 loaded PDCs were first analyzed in 
the untriggered status. After signal detection of untreated PDCs, an aliquot of unconjugated 
anti-mPDCA-1 mAb was injected into the reaction tube and the modulation of the indo ratio was 
analyzed. Complete deflection of the calcium flux was measured by the addition of ionomycin (1 
mg/ml). 
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3.7 Biomolecular methods and gene expression analysis 
3.7.1 Standard biomolecular techniques: 
Standard methods were based on protocols as described in “Molecular Cloning. A Laboratory 
Manual. 2nd edition” [Eds. Sambrook J, Fritsch EF, Maniatis T, Cold Spring Harbor Laboratory 
Press, Cold Spring Harbour 1989]. 
 
3.7.1.1 Isolation of nucleic acids 
3.7.1.1.1 RNA isolation 
Total RNA was isolated using the NucleoSpin® RNA II Kit (Macherey-Nagel, #740955.x) 
according to the manufacturers protocol.  
Messenger RNA was isolated using the µMACS mRNA Isolation Kit (Miltenyi, #130-075-201, 
130-090-276) according to the manufacturers protocol. Recombinant RNase-free DNase I was 
obtained from Roche (#04716728001). 
 
3.7.1.1.2 DNA isolation  
Plasmid DNA was prepared from E. coli cultures using the NucleoSpin® Plasmid Kit (Macherey-
Nagel) according to the manufacturers protocol. 
DNA was isolated from agarose gels using either the Gel extraction kit (Macherey-Nagel) or the 
Agarose Gel DNA Extraction Kit (Roche, # 1 696 505).  
 
3.7.1.2 cDNA synthesis 
cDNA was synthesized from mRNA or total RNA by reverse transcription. A reaction mix of 10 
µl total volume was prepared: 
- 7 µl (total) RNA 
- 2 µl Oligo(dT) primer (920 pmol) 
- 1 µl random hexamers (100 pmol) were mixed and incubated for 10 min at 70°C. This 
first reaction mix was then stored on ice. 
On ice, a second reaction mix was prepared by adding 
- 16.5 µl RT buffer (Miltenyi) 
- 0.6 µl dNTP mix (25 mM each) 
- 3 µl Reverse transcriptase (RT, MACS-Script, Miltenyi). 
Both mixes were combined and incubated at 42°C. After 1 h another 1.5 µl RT were added to 
the reaction mix and incubated for an additional 1 h at 42°C. To digest contaminating RNA, two 
units of RNaseH were added and incubated for 20 min at 37°C. 
 
Alternatively, cDNA was directly synthesized “in column” via the µMACSTM One-step cDNA Kit 
(Miltenyi; #130-091-902). In this protocol cell lysates were mixed with poly(A) microbeads, 
applied to a MACS column, and reversely transcribed. 
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3.7.1.3 Polymerase chain reaction (PCR)  
Standard PCR was performed using the PicoMaxx High Fidelity PCR System (Stratagene, 
#600420) or according to the following protocol: 
- 1-100 ng template DNA  
- 200 µM dNTPs  
- forward and reverse primer (250 nM each) 
- 2 mM MgCl2 (only supplemented if Tag polymerase was used) 
- 1x PCR buffer 
- 1-5 U Tag (Pfu) polymerase /100µl reaction volume 
- Deionized H20 (ad 50 µl) 
 
Table 3.1 Cycler settings for standard PCR   
 
 
 
 
  
 
 
 
 
 
 
Amplified PCR products were purified with either the QIAquick PCR Purification Kit (Qiagen), 
the NucleoSpin® Extract II kit (Macherey-Nagel, #740609) or the High Pure PCR Product 
Purification Kit (Roche, #1 732 668). 
 
Reverse transcriptase (RT)-PCR was performed either via the Titan One Tube RT-PCR System 
(Roche, #11 855 476 001) or – for subsequent LightCycler analysis – via the LightCycler® RNA 
Master SYBR Green I kit (Roche; see 3.7.3).  
 
3.7.1.4 Primer design 
Homologous oligonucleotide sequences were generated based on sequence information 
deposited in the databases GeneBank or Nucleotide (NCBI). Primer sequences were chosen on 
criteria defined by Innis and Gelfand [Innis MA and Gelfand DH, Academic Press 1990]. The 
melting temperature was calculated according to the Wallace rule: Tm (°C) = 2 x ∑ (A + T) + 4 x 
∑ (G + C) [Wallace R, Nucleic Acids Res. 1979; Sambrook J and Russell DW, Cold Spring 
Harbor Laboratory Press 2001]. The following software simulated primer integrity and 
annealing: Amplify v1.2b (Bill Engels, University of Wisconsin, USA) and Sequencher 4.1 
(Genes Codes Corporation, Ann Arbor, USA).  
Nr. Step Temperature Time 
1 Denaturation 95°C 5 min 
2 Annealing 54-62°C 30 sec 
3 Primer extension 72°C 1 min 
4 Denaturation 94°C 30 sec 
5 Cycles (repeat Step 2-4) 15-35x 
6 Annealing 54-62°C 30 sec 
7 Final extension 72°C 5 min 
8 Store 10°C ∞ 
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3.7.1.5 DNA modification 
3.7.1.5.1 Restriction digestion:  
Qualitative restriction digest of DNA templates was performed by incubation for 1-2 hrs with 
appropriate restriction enzymes at a final concentration of 1 Unit/µg DNA according to the 
manufacturers protocols (NEB and MBI Fermentas). For preparative hydrolysis, DNA 
sequences were digested o/n. Resulting DNA fragments were isolated using the  NucleoSpin® 
Extract II Kit (Macherey-Nagel) after agaraose gel electrophoresis (see 3.7.1.1.2 DNA isolation). 
 
3.7.1.5.2 Dephosphorylation of vector DNA:  
Vector DNA was dephosphorylated at the 5’ end prior to ligation with insert fragements. Thus, 
DNA was subjected to Shrimp Alkaline Phosphatase (SAP) treatment according the 
manufacturers protocol (Roche, #11 758 250 001). 
 
3.7.1.5.3 DNA ligation  
For DNA ligation a commercial available kit was used (Rapid DNA Ligation Kit from Roche [#11 
635 379 001]) or the following ligation protocol was performed: 
- Vector and insert DNA were mixed in 10 µl volume with dH20 (at varying ratios of 1:1 to 
1:5). 
- 2 µl 10x ligation buffer, 
- 2 µl PEG 4000 (50%),  
- 1-2 Units T4-Ligase for sticky ends or 5 Units T4-Ligase for blunt ends were added and 
filled up with dH20 ad 20 µl.  
- An incubation for 1 h at 22°C or o/n at 16°C was followed by a heat inactivation of the 
T4-Ligase for 10 min at 65°C. 
 
3.7.1.6 E. coli transformation  
Transformation of plasmid DNA into competent E. coli bacteria was performed using the heat 
shock method.  
- Reaction tubes were pre-cooled on ice. 
- 2-5  µl plasmid DNA were mixed with 25-50 µl competent E. coli and incubated for 30 
min on ice. 
- Transformation was performed for 40-60 sec at 42°C (water bath). 
- Reaction mix was instantly incubated for 2 min on ice before adding 200-700 µl of pre-
warmed S.O.C or LB medium. 
- Bacteria were agitated for at least 1 h at 37°C (300 rpm) before plating and o/n 
incubation at 37°C. 
 
E. coli strains One shot Top-10 or DH5α (both Invitrogen) or XL-1.blue (Stratagene) were used 
for transformation. 
 
MATERIALS AND METHODS 
 
   27 
3.7.2 Gene chip microarrays 
For differential gene expression analysis RNA from PDCs, T cells, NKs, B cells, cDCs, 
macrophages, and cells lines, as well as sorted Sca-1+ and Sca-1- PDCs was compared.  
Amplification of RNA samples for microarray and quantitative real-time PCR (qPCR) 
experiments was performed by in vitro transcription (IVT) based on modified linear T7 
amplification [Eberwine J, Biotechniques 1996; Van Gelder RN, PNAS 1990].  
 
3.7.2.1 Identification of mPDCA-1 candidate genes (Agilent microarray) 
The Whole Mouse Genome Oligo Microarray Kit (Agilent Technologies, Waldbronn, Germany) 
was used to identify the antigen specifically expressed on PDCs and recognized by the anti-
mPDCA-1 mAb. Therefore, the differential gene expression profile of mPDCA-1-expressing and 
not expressing cells was compared. 
 
Fig. 3.1 Differential gene expression analysis on Agilent microarrays.  
(A) Schematic principle of sample processing and hybridization for differential gene expression analysis of mPDCA-
1+ and mPDCA-1- cells. (B) An impression of the signal distribution of a representative microarray is demonstrated. 
The regulation of each gene is displayed by Cy3 (red) and Cy5 signal (green). 
 
Total RNA was isolated via the Nucleospin RNA II RNA Extraction Kit (MACHEREY-NAGEL, 
Düren, Germany). After confirmation of the RNA integrity (2100 Bioanalyzer platform, Agilent), 
the target RNA was amplified and converted to Cyanine 3- or Cyanine 5- labeled cRNA. A 
mixture of differentially labeled target RNAs was hybridized to the Agilent oligo microarray. 
Hybridized microarrays were scanned with the ScanArray Lite (Packard Bioscience, Dreieich) 
and analyzed using the Imagene software version 4.1 (Bio-Discovery, Los Angeles, USA). The 
signal of each spot was measured in a fixed circle of 350 µm diameters and the background 
outside the circle within rings 40 µm distant to the signal and 40 µm wide. Local background 
was subtracted from the signal to obtain the net signal intensity and the ratio of Cy5/Cy3. The 
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ratios were normalized to the median of all ratios using only those spots for which the 
fluorescent intensity in one of the two channels was two-fold higher than the negative control. 
The microarray procedure is illustrated in Fig. 3.1. 
 
An overview of the differentially hybridized microarrays using different mRNA samples is given 
in Table 3.2:   
 
Table 3.2 Overview of the hybridization scheme and setup for the gene expression analysis on Agilent 
microarrays.  
Mouse genome microarrays (Agilent Technologies) consisting of about 22,500 mouse transcripts were used to 
identify the antigen recognized by the anti-mPDCA-1 mAb. In four different sets (chip I-IV) Sp2/0 cells, either 
untreated or cultured in the presence of IFNa, or after downregulation of mPDCA-1 were compared against each 
other. Set V consisted of PDCs vs. untreated Sp2/0 cells, demonstrating PDC-presence of regulated gene 
candidates.  
Sets VI+VII were reproductions with the same samples described for set I+II using whole-genome mouse chips 
(Agilent Technologies) consisting about 40,000 transcripts. 
 
 
 
3.7.2.2 Parallel identification and quantification of RNA (PIQOR microarray) 
PIQOR cDNA microarrays (Miltenyi Biotec) were used to compare gene expression profiles of 
FACS-sorted Sca-1+ and Sca-1- PDCs.  
About sorted 104 cells were resuspended in SuperAmp lysis buffer (Miltenyi) to enable mRNA 
isolation and amplification. Isolation was performed with the Nucleospin RNA II RNA Extraction 
Kit (MACHEREY-NAGEL, Düren, Germany). Due to limited starting material the µMACS One-
step T7 Template Kit (Miltenyi) was used to extract total RNA, followed by poly-A+ RNA 
enrichment and IVT based on T7 primers. Amplified RNA (aRNA) samples were again 
photometrically quantified (NanoDrop) and quality was confirmed by the Agilent BioAnalyzer. 
First strand cDNA was incubated for 60 min at 37°C with Terminal deoxynucleotidyl transferase 
followed by heat inactivation of the enzyme at 70°C. 5’-tagged cDNA was amplified and PCR 
products were purified using the NucleoSpin Extract II Kit (Macherey Nagel). Yield of cDNA was 
quantified by NanoDrop analysis and by capillary electrophoresis (Bioanalyzer). At last 250 ng 
of purified PCR product was labeled with either Cy3- or Cy5-dCTPs in a Klenow Fragment 
reaction (10 Units per sample) for 2 hrs at 37°C followed by heat inactivation at 70°C. Cy3/5-
labeled cDNA samples from either Sca-1+ or Sca-1- PDCs were combined and purified using the 
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CyScribe GFX Purification Kit (GE Healthcare) before hybridization to PIQOR mouse 
immunology microarrays, which contain cDNAs of 1,076 genes, spotted as four-fold replicates 
on different positions of the array. After 18 hrs of incubation, hybridized microarrays were 
washed with washing buffer, scanned and analyzed as described above. The mean of four 
spots representing the same cDNA was determined. As a qualitative measurement for the 
validity of the data and to check for the uniformity of the hybridization process, the coefficient of 
variation (cv) of the four ratios for the respective gene was calculated. Hybridization, scanning 
and data analysis were performed as described [Bosio A, Carcinogenesis 2002]. Image 
capturing and signal quantification of hybridized PIQOR microarrays were performed with the 
ScanArrayLite4000 Microarray Scanner and ImaGene software Version 5.0 (BioDiscovery, Los 
Angeles, USA).  
 
3.7.2.3 Microarray data mining  
Scanned images were analyzed using the Agilent Feature Extraction software (Version 9.1) by 
which the local background was subtracted from the signal to obtain the net signal intensity and 
the ratio of Cy5/Cy3. A rank consistency based probe selection for Lowess normalization was 
done. After filtering the data with respect to signal significance a two-tailed t test was used to 
determine signal versus background significance. Only those spots were used for which the 
fluorescent intensity in one of the two channels was twice the mean background of all 
“unflagged” spots. Only genes displaying net signal intensity 2-fold higher than the mean 
background were used for further analysis. Spots with p-values >0.01 were omitted.  
For analysis of PIQOR data, the normalized mean ratio of four corresponding spots, 
representing the same cDNA, was computed. After log2-transformation of the ratios, data were 
imported in TIGR MeV Version TM4 [Saeed AI, Biotechniques 2003]. Average linkage clustering 
of genes was done using Euclidean Distance [Eisen MB, PNAS 1998]. Gene ontology analysis, 
“clustering”, was carried out after gene annotation to verified pathways (Annotate, Miltenyi 
Biotec, unpublished). 
 
3.7.3 Quantitative real time RT-PCR (LightCycler)  
All oligonucleotide primers used in this work were purchased from Metabion GmbH (Martinsried, 
Germany). 
A real-time RT-PCR was performed to compare transcript levels of PDC-specific (mPDCA-1) 
gene candidates obtained form the microarray analysis. The LightCycler® RNA Master SYBR 
Green I kit (Roche Diagnostics GmbH/Roche Applied Science, Mannheim, Germany) was used 
for the amplification and detection of selected RNA targets, analyzed on the LightCycler 
platform. All assays were performed at least in duplicates. In principle, this method is based on 
the intercalation of an unspecific fluorochrome (SYBR green) during the DNA syntheses 
process of the PCR, which is measured after each cycle. The cycle number is determined at 
which the SYBR green emission increased above threshold level. From this signal an 
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exponential curve is calculated and compared to a standard curve for each primer pair, which 
demonstrated the amount of amplified DNA (LightCycler Software 3.5, Roche).  
Messenger RNA was prepared from MACS-isolated hematopoietic cell populations (e.g. PDCs, 
NK cells, B cells, or T cells) using the RNeasy Mini Kit (Qiagen, Hilden). After quantification, an 
equal amount of mRNA was used for the real time RT-PCR reaction. Messenger RNA amount 
was normalized by the expression of house keeping genes (murine β-actin, PPIA, Hprt-1, and 
GAPDH). For each candidate primer pairs were designed using the Primer3 software 
(Whitehead Institute for Biomedical Research; Rozen S, Bioinformatics Methods and Protocols: 
Methods in Molecular Biology 2000) and a standard curve with titrated amounts of mRNA was 
performed to confirm primer integrity and to determine the optimal reaction conditions. Melting 
curve analysis of amplified samples was performed to assess the specificity of the amplified 
PCR product by discrimination between primer-dimers, side reaction products, and specific PCR 
product. 
 
3.7.4 Generation of transfectants 
3.7.4.1 Cloning strategies 
The open reading frame of selected gene candidates were cloned in different vectors providing 
selection resistance, a HA-tag as well as the bi-cistronic expression of a truncated human CD4 
antigen for direct separation. The cloning strategies for two genes of interest, MPG1 and BST2, 
is demonstrated in Fig. 3.2. 
 
 
Fig. 3.2 Cloning strategies for L20315 (MPG1) and BST2 (BC027328) as well as generation of a full-length 
transfectants. 
(A) Cloning strategy of L20315 full length ORF without signal peptide into pDisplay vector is demonstrated. 
Abbreviations are explained in the result text. 
(B) Cloning strategy of BC027328 full length ORF into two vectors (pEHO and pMCAS.4IRES-II) via EcoRV and NotI 
is demonstrated. 
 
Briefly, the complete coding sequence of MPG1 was amplified by PCR from genomic murine 
DNA. Primer pairs used also provided a BglII restriction site (5’) as well as a SalI restriction site 
(3’) for the subsequent ligation into the L20315 vector backbone. The coding sequence of BST2 
was cloned without the start signal (ATG), which was provided by the pEHO and 
pMACS.4IRES-II vectors. BST2 was cloned via EcoRV (5’) and NotI (3’) and primer pairs were 
equipped with these restriction sites.  
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3.7.4.2 Transfection of eukaryotic cell lines 
Depending on culture conditions, two different transfection protocols (electroporation or 
lipofection) were performed for suspension or adhesively growing cells. During the exponential 
proliferation phase suspension cells were harvested and resuspended in fresh medium without 
FCS. After transfer into a sterile electroporation cuvette (Bio-Rad), 1-5x106 cells were mixed 
with 10-50 µg pre-diluted DNA and incubated for 15 min. Electroporation was performed using 
the Bio-Rad Gene Pulser II instrument with the following settings: 210-270 V, 0.975 µF, time 
constant 15-25 ms. After the pulse, cells were kept for 10 min at 37°C before subsequent 
culture in standard medium. 
Alternatively, adhesive cells were transfected using the FuGENE® 6 lipofection reagent (Roche). 
Standardly, a monolayer of 50-70% confluent cells was transfected with a mixture of DNA and 
FuGENE at different ratios. Normally, 2 µg DNA plasmid in 100 µl serum-free medium was 
premixed with 3-6 µl FuGENE, gently mixed and incubated for 30-45 min at room temperature 
to allow complex generation. Then the mixture was transferred onto the cells, which were 
cultured in standard (serum-containing) medium. After 12-36 hrs, culture dishes were 
supplemented with fresh media. 
 
3.7.4.3 Selection and enrichment of transfected cells  
MPG1- and BST2-transfected cells were selected via Neomic/Geneticin resistance provided by 
the vectors pDisplay and pEHO. In addition, the pMACS vector enabled the selection of CD4+ 
transfectants using anti-hCD4 mAb-conjugated microbeads to magnetically enrich cells that 
could be stained positive for CD4 and the wanted antigen. As the HA-tag was expressed 
intracellularly, it served only as control to confirm the successful cloning. Anti-mPDCA-1-
conjugated microbeads (clone JF-3D5) were used for magnetic separation of mPDCA-1+ cells. 
 
3.8 Microscopic and histological analyses 
3.8.1 Immuno-histochemistry of cryo sections  
Isolated and acetone-fixed peripheral lymph nodes were embedded in Tissue-Tec OCT 
compound (Miles Inc., Elkhart, USA) and stored at -80°C. 5 µm thick sections were placed onto 
microscope slides and stained in Tris-buffered saline (containing 2% FCS) with different 
antibodies for 1 h at RT: biotinylated anti-mPDCA-1, FITC-conjugated Ly-6C and APC-
conjugated anti-CD11c, followed by secondary incubation with Cy3-conjugated Streptavidin. 
Stained cryosections were sealed with Vectrashield (Vector, Burlingame, USA). 
 
3.8.2 Confocal laser scanning microscopy (CLSM) of single cell suspensions 
Mice received i.p. administration of Alexa488-conjugated anti-mPDCA-1-F(ab’)2 (50 µg/ml). 
After isolation of spleen PDCs, cells were centrifuged onto coverslips, fixed in PBS containing 
3,7% paraformaldehyde for 15 minutes before additional washing. Cells were then incubated for 
1 hour with Alexa633-conjugated anti-mPDCA-1 antibody and washed three times with PBS. 
For microscopic analysis, cells were covered and sealed as described above.  
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All cells were immediately analyzed by CLSM using the Axioskop 2 plus microscope (Zeiss, 
Göttingen). The following objectives were utilized: Plan-Neofluar 2,5x/0,075; Ph2 Plan-Neofluar 
20x/0,50; Plan-Neofluar 40x/0,75; Plan-Neofluar 63x/1,25 Oil (Zeiss). Filter set 15 (excitation 
BP546/12, beamsplitter FT 580, emission LP590) was used for fluorescent microscopy 
(488015-000, Zeiss).  
 
Microscopic pictures (transmitted light bright field) were taken using the digital camera AxioCam 
HR (Zeiss).  
 
3.9 Cell separation 
3.9.1 Principle of Magnetic Cell Separation (MACS) 
The MACS® technology allows the fast and reliable separation of cells according to specific cell 
surface markers [Miltenyi S, Cytometry 1990; Radbruch A, Methods Cell Biol. 1994; Abts H, J 
Immunol Methods. 1989]. In brief, monoclonal antibodies were covalently linked to 
superparamagnetic microbeads. Next, single cell suspensions were magnetically labeled by 
incubation with these beads. After extensive washing, cell suspensions were separated on high 
gradient magnetic columns. Cells labeled with the microbeads were retained on the column 
whereas unlabeled cells passed through and were collected as the untouched fraction. In 
general, this technology allows either depletion of unwanted cells and collection of the eluted, 
unlabeled fraction or direct enrichment of magnetical positive cells. After magnetic separation, 
purity of isolated cell subsets was analyzed by flow cytometry. Usually, more than 90% purity 
was obtained. 
 
3.9.2 PDC isolation 
PDCs were isolated via two kits: 
The “Mouse PDC isolation kit” is based on a depletion of unwanted cells (B cells, T cells, NK 
cells, myeloid cells, and erythrocytes) followed by an enrichment of B220+ cells, thus PDCs.  
The “Mouse PDC isolation kit II” enables an “untouched” isolation of PDCs by stringent removal 
of non-PDCs without the need for further enrichment. 
 
3.9.3 Isolation of T cells  
For isolation of splenic T cells in context of the microarray analysis, the “pan T cell isolation Kit, 
mouse” (Miltenyi) was used. 
For the isolation of OVA TCR transgenic T cells, spleen and LNs were collected and pooled. 
Single cell suspensions were depleted of CD11c+ and B220+ cells by magnetic sorting. Then 
either CD4+ (DO11.10 and OT-II mice) or CD8α+ (OT-I mice) cells were enriched with 
corresponding MicroBeads. 
 
3.9.4 Isolation of other hematopoietic cells 
For semi-quantitative analyses of the mRNA expression of different mPDCA-1 candidate genes, 
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several hematopoietic populations were isolated from spleen: 
- B cells via the mouse B Cell Isolation Kit,  
- NK cells via the mouse NK Cell Isolation Kit 
- Conventional DCs by enrichment via anti-CD11c MicroBeads 
- Macrophages (and other cells) was obtained by peritoneal lavage 
 
3.9.5 Principle of Fluorescence-Activated Cell Sorting (FACS) 
Flow cytometry is not only an excellent tool for the analysis of cells according to their cell 
surface properties, but also allows the separation of a heterogeneous mixture of cells [Cantor H, 
Herzenberg LA, Cell Immunol. 1975]. The so-called Fluorescence-activated cell sorting (FACS) 
is based on the same flow cytometric principle as mentioned in chapter 3.6. Here, cells become 
electrically charged after measuring the fluorescence characteristics and are deflected into 
reaction tubes based upon their charge.  
To obtain highly pure PDCs for T cell priming experiments, PDCs were magnetically separated 
via the Mouse PDC isolation kit II. Then the PDC-enriched fraction was labeled with FITC-
conjugated anti-B220 mAb and either PE-conjugated anti-Ly-6C or biotinylated anti-Siglec-H 
mAbs followed by PE-conjugated anti-Biotin mAb. B220+, Siglec-H+ or Ly-6C+ PDCs were 
isolated on a FACS Vantage Flow Cytometer Cell Sorter (BD; operated by C. Göttlinger, 
Institute for Genetics, University of Cologne). Purity of sorted PDCs was again checked by 
three-color FACS analysis (mPDCA-1, CD11c, and B220 expression), demonstrating an 
average purity between 97% to more than 99%. The positive fraction of PDCs contained less 
than 0.5% contaminating CD11chigh cDCs or CD11c- B220+ B cells. 
 
3.10 Biological assays 
3.10.1 Culture and in vitro maturation of PDCs 
Murine PDCs were isolated as described above and stimulated in the presence of Loxoribine 
[50 µM] as synthetic TLR7 ligand or the following CpG ODNs (5 µg/ml; Metabion) as synthetic 
TLR9 ligands. ODN sequences were: ODN-1668 (5’-tccatgacgttcctgatgct-3’), ODN-1826 (5’-
tccatgacgttcctgacgtt-3’), ODN-2006 (5’-tcgtcgttttgtcgttttgtcgtt-3), ODN-2216 (5’-
ggGGGACGATCGTCgggggg-3’), and ODN-2395 (5’-tcgtcgttttcggcgcgcgccg-3’). Capital letters 
indicate phosphodiester bases, whereas lower case designate phosphorothioate bases, which 
are nuclease resistant. Functional grade anti-CD40 mAb (clone FGK45.5) was used at a final 
concentration of 50 µg/ml for in vitro activation.  
 
3.10.2 In vivo maturation of PDCs  
Several TLR agonists were used to activate PDCs in vivo. 25 µg Poly-I:C [Bochtler P, JI 2008], 
5 µg Loxoribine [Asselin-Paturel C, JEM 2005], or different CpG ODNs (50-100 µg) were 
administrated i.v. 24 and 48 hrs later, the expression of co-stimulatory molecules (CD40, CD80, 
and CD86) and other molecules (e.g. MHC-I, -II, CD274 [PD-1L], 4-1BBL [CD137L]) was 
evaluated on PDCs by flow cytometry.  
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3.10.3 Analysis of PDC-T cell interactions („priming“) 
3.10.3.1 CFSE-labeling  
Isolated cells were washed with sterile PBS. 107 cells were resuspended in 1ml protein-free 
PBS and incubated with CFSE for 3 min at a final concentration of 1-5 µM at room temperature. 
CFSE loading was stopped by addition of an excess of FCS-supplemented medium. After 
extensive washing with FCS-containing medium, CFSE-labeling was confirmed by flow 
cytometric analysis (FL-1 channel). 
 
3.10.3.2 Priming of naïve CD4+ and CD8+ T cells in vitro 
Highly pure PDCs were either isolated from wild type BALB/c or C57BL76 mice (as described 
before) depending on background of OVA-TCRtg T cells used. 105 PDCs were pre-cultured 
without antigen or in the presence of different OVA antigens (100 ng/ml SIINFEKL; 5 µg/ml 
OVA323-339 peptide; OVA-conjugated to anti-mPDCA-1-Fab2, isotype control-Fab2 or soluble 
OVA in equal concentrations). Where indicated an additional stimulus (5 µg/ml CpG ODN) was 
administrated. 
On the next day PDCs were co-cultured with 2x105 CFSE-labeled OVA-specific CD4+ or CD8+ T 
cells isolated from DO11.10 or OT-I or OT-II mice for further 72 hrs. Naïve T cells (form pooled 
LNs and spleen) were thereby depleted for B220+ and CD11c+ cells (anti-B220 and anti-CD11c 
Microbeads, Miltenyi Biotec) and subsequently enriched for CD4+ or CD8+ T cells, respectively 
(anti-CD4 or anti-CD8a Microbeads, Miltenyi Biotec).  
T cell proliferation was measured by loss of CFSE intensity of either gated CD4+ KJ-26.1+ B220- 
cells or CD8a+ TCRvβ5.1/2+ B220- cells. 
To show the specificity of T cell priming by mPDCA-1-OVA targeted and stimulated PDCs, 
antigen-presenting cells were incubated with unconjugated anti-mPDCA-1 at saturating 
concentrations before co-culture with both CD4+ and CD8+ T cells. 
 
3.10.3.3 Analysis of T helper cell polarization 
CD4+ T cells isolated from DO11.10 mice were primed for three days in co-culture with total 
splenocytes, purified cDCs or PDCs from Balb/c mice in the absence or presence of a CpG 
stimulus, as described before. The OVA antigen was either OVA323-339 peptide or soluble OVA 
protein or OVA conjugated to the anti-mPDCA-1 mAb targeting construct and was supplied at 
the beginning of the culture. 
After initial priming, T cells were expanded in the presence of recombinant human IL-2 (R&D 
Systems, 20 U/ml) for seven days until cytokine was removed. On the next day, CD4+ T cells 
(purity >99%) were restimulated with PMA [20 ng/ml] and Ionomycin [1 µg/ml] for 6 hours in vitro 
whereas medium was supplemented in the last four hours with 1 µg/ml Brefeldin A 
(Calbiochem) to prevent cytokine secretion. Cells were fixed and permeabilized (Inside Stain 
Kit, Miltenyi Biotec) and intracellularly stained for indicated cytokines (IL-2, IL-4, IL-10, IL-17, 
IFNγ, and TNFα). 
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3.10.4 Proliferation assay 
To assess the proliferative capacity of different PDC subsets, mice initially received a single 
dose of BrdU (1 mg i.p. in PBS) to ensure immediate availability of the precursors. In parallel, 
BrdU was provided continuously in sterile drinking water  (0.8 mg/ml), which was changed every 
second day [O’Keeffe M, JEM 2002; Kamath AT, JI 2000]. Mice were sacrificed at indicated 
time points (day 0-20) and single cell suspensions of different lymphoid organs were prepared 
as described above. 
For the pulse/chase experiment, mice received BrdU as described above for five days. BrdU 
was then removed from the drinking water. Mice were sacrificed at indicated time points (day 
[5+] 0-20) and single cell suspensions were analyzed for BrdU incorporation. 
Incorporated BrdU was detected via the APC BrdU Flow Kit (BD Pharmingen). Briefly, cells 
were stained with FITC-conjugated anti-Sca-1 and PE-conjugated anti-mPDCA-1 mAbs in 
standard staining buffer. Then cells were fixed and permeabilized, followed by treatment with 
DNase to expose incorporated BrdU, which was finally detected by an APC-conjugated anti-
BrdU mAb. 
 
3.10.5 Endocytosis of DQ-OVA to demonstrate the antigen-uptake capacity  
To measure the OVA uptake and processing, mice were immunized with DQ-OVA (Invitrogen) 
(10 µg s.c. or 50 µg i.v.) and different cell populations were isolated from spleen or draining 
LNs. After extensive washing, cells were stained with indicated cell surface markers and 
analyzed by flow cytometry. Amount of OVA internalized and processed by the different DC 
populations was quantified as the mean fluorescence intensity within the FL1 (FTC) channel. 
Alternatively, cells were pulsed with 10 µg/ml DQ-OVA and cultured for 24 hrs before flow 
cytometric analysis. 
 
3.10.6 In vivo PDC depletion using the anti-mPDCA-1 mAb 
For specific PDCs depletion mice received a (single) administration of 500 µg anti-mPDCA-1 
mAb. Clone JF05-1C2 was used standardly, either i.p., i.v. or s.c. administrated. 
 
3.10.7 Transfer of PDCs and T cells  
3.10.7.1 Transfer of PKH67-labeled PDCs  
Isolated and sorted Sca-1+/- PDCs were labeled using the PKH67 Green Fluorescent Cell Linker 
Kit (Sigma). Briefly, PDCs were washed with PBS and ≤ 5x106 were resuspended in diluent 
buffer. 2 µl PKH67 reagent was prepared in 500 µl diluent buffer, before combining both mixes. 
After incubation for 3 min, unspecific labeling was blocked with excess of FCS. Cells were 
extensively washed before i.v. transfer into a syngenic host mouse. 24 hrs after transfer, grafted 
PDCs, identified by mPDCA-1 expression and PKH67 labeling, were analyzed in different 
lymphoid organs (spleen and liver) and assessed for their Sca-1 expression. 
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3.10.7.2 Transfer of CFSE-labeled OVA-transgenic T cells 
CFSE-labeling of isolated CD4+ or CD8+ T cells was performed as described above. About 
2x106 labeled T cells were administrated i.v. into a recipient mouse. 15 to 24 hrs later antigen-
targeted PDCs were inoculated s.c. or i.v. T cell proliferation was then measured 72 hrs later in 
draining LNs or spleen.  
 
3.11 Statistical analysis 
Statistical analyses were performed using the Prism software (GraphPad Software, San Diego, 
USA). Standardly mean or median ± SEM was used to analyze the results presented in the 
result chapter. If indicated the 2-tailed unpaired t test was used. Significance of the results was 
demonstrated as indicated.  
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4. RESULTS 
Plasmacytoid Dendritic Cells have a key function in the linkage of innate and adaptive immunity, 
and are involved in a variety of diseases and immunological disorders [Dalod M, JEM 2003; 
Rönnblom L, Arthritis Res Ther 2003; Nestle FO, JEM 2005]. Therefore their phenotypical and 
functional characterization is of particular importance. In contrast to their human counterpart, 
murine PDCs had been only marginally described. The lack of a specific marker further 
hampered the functional characterization of mouse PDCs and the disclosure of their 
immunological role. 
The first aim of this work was the identification of a novel receptor, which is only expressed on 
PDCs. Thus, at the beginning a specific mAb against PDCs should be generated, which also 
could serve as an appropriate tool for further studies of this cell type. Next, the molecular nature 
and functional characterization of the specific antigen was the main focus of this work as 
specifically expressed molecules are often connected to a unique function of the cell type. After 
the identification, further functional characteristics of this molecule were investigated; 
particularly with regard to the uptake and processing of antigens and the interaction with naïve 
T cells. Interestingly, by antibody-based characterization of PDCs, a heterogenic phenotype of 
PDCs was detected, which was further analyzed. 
Therefore, four distinct aims were addressed and structured as follows: 
• Generation of a mAb against a novel cell surface receptor specifically expressed by 
mouse  PDCs. 
• Identification and molecular characterization of the unknown molecule. 
• Functional implications of mPDCA-1 as antigen-uptake receptor of murine PDCs for 
efficient priming of naïve T cells. 
• Differential Sca-1 expression defines functional heterogeneity of mouse PDCs. 
 
4.1 Generation of monoclonal antibodies for the detection of PDC-specific cell surface 
receptors 
4.1.1 Contralateral footpad immunization  
For all immunization approaches PDCs were isolated from spleen of wild type (wt) BALB/c mice 
and subcutaneously (s.c.) inoculated into the hind footpad of Lewis or LOU rats. In different 
immunization attempts, murine Sp2/0 myeloma or freshly isolated murine NK cells were used as 
decoy and subjected to the corresponding, contralateral footpad as mentioned in Materials & 
Methods. After several rounds of immunization, cells from the popliteal LNs of the hind footpad 
that had been injected with PDCs were used for the fusion with a murine myeloma partner 
(Sp2/0 cells). 
To assess the specificity of the generated hybridomas several screening strategies (e.g. using 
with mouse anti-rat (mar) kappa (κ) mAb coated latex beads) were applied, from which the 
following strategy is described in detail: (1) Spleen single cell suspensions were incubated with 
hybridoma supernatant. (2) After washing, bound rat IgG was then detected via R-phycoerythin 
(PE)-conjugated marκ mAb. Lambda light chain positive clones were anticipated only in a minor 
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percentage rate for murine and rat IgGs and therefore ignored or excluded from this screening 
system. (3) PDCs were counterstained either with Allophycocyanin (APC)-conjugated hamster 
anti-mouse CD11c or rat anti-mouse B220 or Gr-1 mAbs. In case rat anti-mouse mAbs were 
used to identify PDCs, an intermediate blocking step with excess of irrelevant rat IgG mAb was 
applied to avoid (“block”) any interaction of the marκ secondary mAb with B220 and Gr-1 mAbs. 
The screening strategy to detect PDC-specific/recognizing clones is depicted schematically in 
Fig 4.1.1. Hereby, the signal derived from the marκ  staining had to be reviewed in the context of 
the PDC phenotype, thus on CD11cint, B220+ or Gr-1+ cells.  
 
Fig 4.1.1 Screening strategy to detect PDC-specific hybridoma clones. 
Balb/c splenocytes were incubated with hybridoma supernatants (1), followed by detection of bound rat Ig with PE-
conjugated mouse anti-ratκ mAb (2). Next, PDCs were counterstained with APC-conjugated hamster anti-mouse 
CD11c mAb (3), which also detects other dendritic cells, whereas PDCs show only an intermediate expression of this 
molecule. In the end, hybridoma clones that detect only CD11cint cells were regarded as potential candidates for a 
PDC-specific antibody. 
 
4.1.2 Antibodies that identify murine PDCs 
The majority of the screened clones were not specific for PDCs but recognized epitopes 
expressed also on other leukocytes. For further characterization of potential PDC-specific 
hybdridoma clones the antibodies were small-scale purified and fluorochrome conjugates were 
produced. Via these conjugates the staining pattern of each candidate clone on splenic 
leukocytes was flow cytometrically analyzed. Based on these experiments two different groups 
of PDC-recognizing clones were charted. 
(1) The first set of clones, although recognizing mouse PDCs, in fact also showed staining 
of other leukocytes, e.g. B cells and cDCs (Data not shown). Potential candidates were 
for example the clones 7H9 and 9B8 generated in the second fusion (JF02, Lewis rat). 
Because the aim of the project was the identification of a molecule specifically 
expressed on PDCs, both clones were stored but within this work not further 
characterized. Their potential might be evaluated in further experiments. 
(2) The next cluster of clones was comprised only of PDC-specific antibodies and multi-
color FACS revealed that they bind only e.g. CD11cint B220+ cells. An impression of a 
typical screening result of a negative clone (JF05-1D6; top) and a positive clone (JF05-
1C2; bottom) is given in the dotplots shown in Fig. 4.1.2: Whereas with clone 1D6 almost 
no visible staining on spleen cells was detected, clone 1C2 nicely stained CD11cint 
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B220+ cells, thus PDCs. The minor background staining might be FcR-dependent. A 
FcRIII/II blocking (with anti-CD16/32 mAbs) was not applicable because of the 
secondary staining system, as the marκ mAb would also detect the anti-CD16/32 mAbs. 
Taken together, this group comprised of four clones with similar staining pattern, 
originating from different fusions (JF05, Lewis rat; JF07, LOU rat) and recognizing cells 
with a PDC phenotype: JF05-1C2; JF07-3D5, -7B3, and -12A5.  
 
 
Fig 4.1.2 Staining of spleen cells with the PDC-specific clone JF05-1C2.  
Balb/c splenocytes were incubated with supernatant from hybridoma 1D6 (upper lane) or 1C2 (lower lane), 
followed by detection with PE-conjugated mouse anti-ratκ mAb. PDCs were counterstained with FITC-
conjugated B220 (left dotplot) and APC-conjugated hamster anti-mouse CD11c mAb (middle). The right 
dotplots showed marκ staining of gated B220+ CD11cint PDCs. 
 
4.1.3 Isotype designation and epitope determination (blocking experiments) 
The isotype of the resulting PDC-recognizing hybridoma clones was assessed in two 
experiments. Hybridoma supernatant or purified mAb was tested either by flow cytometric 
analysis (intracellular staining with secondary mouse anti-rat Kappa, IgG1, IgG2a, or IgG2b 
antibodies) or was analyzed with anti-rat IgG/M isotype strips (AbD Serotec, Düsseldorf, 
Germany), which gave a specific determination of both the light and heavy chain isotype (data 
not shown). 
Next, the epitope recognition of the four PDC-specific mAbs was determined by cross-blocking 
experiments. All four clones recognized the same antigen, which was termed “mouse 
Plasmacytoid Dendritic Cell Antigen 1” (mPDCA-1). To evaluate whether two antibodies detect 
the same epitope, spleen cells were pre-incubated with an excess of the one antibody followed 
by staining with fluorochrome-conjugated other antibody and vice versa. These blocking 
experiments demonstrated whether both clones recognized the same epitope (blocking), partial 
overlapping epitopes (fractional blocking) or different, non-overlapping epitopes (no interference 
with the staining). The results and the isotype information are shown in Table 4.1.1A+B. 
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A  Table 4.1.1A Overview of the outcome of the cross-blocking experiments 
Staining Blocking (with 100 µg/ml): 
 1C2 3D5 7B3 12A5 
1C2 - + - + 
3D5 + - -* - 
7B3 + - - - 
12A5 + - - - 
"-": blocking;  "+": staining; “*“: partial blocking 
B  Table 4.1.1B Isotype and recognized epitopes of different anti-mPDCA-1 clones 
Antigen Clone Epitope Host Isotype 
mPDCA-1 JF05-1C2 1A rat (Lewis) IgG2b, κ 
mPDCA-1 JF07-3D5 2A rat (LOU) IgG1, κ 
mPDCA-1 JF07-7B3 1B rat (LOU) IgG1, κ 
mPDCA-1 JF07-12A5 2A rat (LOU) IgG1, κ 
 
4.1.4 Flow cytometric analysis of mPDCA-1+ cells in lymphoid organs 
In the past, murine PDCs were characterized by the simultaneous expression of B220, CD11c, 
and Ly-6C. To confirm the specificity of the four generated mAbs against mouse PDCs, spleen 
cell suspensions from naïve Balb/c mice were stained with mAbs against mPDCA-1 and other 
markers and subjected to FACS analysis. Flow cytometric analysis revealed that mPDCA-1 is 
not expressed on lineage marker positive cells representing T (CD3, TCRα/β), B (CD19), NK 
(CD49b), or myeloid (CD11b) cells (Figure 4.1.3A). In contrast, mPDCA-1+ cells expressed 
B220+, CD11cint, and Ly-6C+, which is consistent with the PDC phenotype (Figure 4.1.3B). 
Furthermore, using four-color-FACS analysis it could be shown, that all B220+, CD11cint, and Ly-
6C+ cells are mPDCA-1+ and that there are no further mPDCA-1+ cells showing a different 
phenotype  (Figure 4.1.3C). These data clearly showed the PDC-specificity of the anti-mPDCA-
1 mAb. Additionally, counterstaining with other markers also showed a staining pattern 
characteristic for PDCs. mPDCA-1+ cells showed no expression of CD40, expressed only low 
levels of CD8a, CD86, and CD90, but intermediate levels of MHC-II (Fig. 4.1.3D). 
 
Altogether these data demonstrate that the anti-mPDCA-1 mAb is a useful and a specific 
instrument to investigate PDCs in mice. Furthermore, the identification and molecular 
characterization of the novel antigen is an important point of this work. 
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Fig 4.1.3 Determination of the specificity of the generated anti-mPDCA-1 mAbs on Balb/c spleen cells. 
(A) FACS analysis of mPDCA-1 expression on spleen cells stained with mAbs against linage markers representing T 
cells, myeloid cells, B cells, or NK cells. (B, C) Multicolor analysis of mPDCA-1 expression vs. PDC markers Ly-6C, 
B220, CD11c. Expression of mPDCA-1 is shown either directly against the indicated markers (B) or on gated B220+ 
Ly-6C+ cells (C). (D) Further phenotypic characterization of mPDCA-1+ cells. 
 
The flow cytometric analysis of splenocytes from naïve Balb/c mice revealed that mPDCA-1 is 
only expressed on cells that showed the PDC-specific phenotype (B220+ CD11c+ Ly-6C+). 
However, it has been demonstrated that PDCs from different lymphoid origins vary in their 
phenotype (expression of maturation markers, adhesion molecules) and also their frequency is 
different [O’Keeffe M, Blood 2003; Asselin-Paturel C, JI 2003; Kamogawa-Schifter Y, Blood 
2005]. Hence, the expression of mPDCA-1 on other lymphoid tissues, such as BM, LNs, lung, 
liver, thymus, Peyer’s Patches (PP) and others, was investigated. Analog to spleen cells, 
mPDCA-1 is also only expressed on cells showing PDC-specific phenotype (Fig. 4.1.4). The 
expression level of mPDCA-1 is comparable in all organs tested except of BM in which mPDCA-
1 was expressed at a lower level (data not shown).  
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Fig 4.1.4 Expression of mPDCA-1 on PDCs in different lymphoid organs.  
Shown is a multi-color flow cytometric analysis of mPDCA-1 expression on PDCs from different lymphoid organs. 
Single-cell suspensions of different organs were stained with mAbs against B220 and CD11c as well as mPDCA-1. 
 
The investigation of mouse PDCs is often hampered by the low frequency and viability of 
primary cells. To overcome these limitations PDCs can also be generated in vitro from BM 
precursors by culturing in the presence of FMS-related tyrosine kinase 3 ligand (Flt-3L). Hence, 
these in vitro generated PDCs were termed Flt-3L- or FL-PDCs. As shown in Fig. 4.1.5 mPDCA-
1+ cells among cultured cells display a typical PDC-phenotype, which is B220+ CD11c+ Ly-6C+. 
The expression level of mPDCA-1 on in vitro generated PDCs is comparable to that of freshly 
isolated BM-PDCs as demonstrated in Fig. 4.1.4. Thus, among BM cells cultured in the 
presence of Flt-3L mPDCA-1 shows a PDC-restricted expression pattern. 
Previously, the specific expression of mPDCA-1 on PDCs has been shown only for Balb/c mice. 
In this experiment the expression of mPDCA-1 was evaluated in different mouse strains. 
Therefore spleen cells were prepared from different mouse strains, and counterstained with 
mPDCA-1 and B220 for FACS analysis. It could be demonstrated that although PDC 
frequencies varied between different mouse strains (0.5-2.0%; Fig. 4.1.6A), mPDCA-1 was 
expressed only on PDCs and there were no significant, strain-specific differences in the 
expression pattern regarding specificity or expression level (Fig. 4.1.6B). Therefore mPDCA-1 
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can be considered as selective marker for PDCs, regardless of the mouse strain. 
 
Fig 4.1.5 Expression of mPDCA-1 on in vitro-generated PDCs. 
The dotplots demonstrate a flow cytometric analysis of Flt-3L treated BM cultures (day 10). Shown is the mPDCA-1 
expression on in vitro generated PDCs against characteristic PDC markers (CD11c, B220, and Ly-6C). 
 
 
Fig 4.1.6 Expression of mPDCA-1 on PDCs from different mouse strains.  
(A) Flow cytometric analysis of spleen single cells suspensions after staining with mAbs against B220 and mPDCA-1. 
Representative dotplots for each mouse strains are shown. (B) Bar diagram demonstrates the frequency of spleen 
PDCs of different mouse strains, based on the calculation of B220+ mPDCA-1+ cells (mean +/- SEM of n=1-3). 
 
4.1.5 Immuno-histochemical staining of mPDCA-1 (performed by Lars Ohl, Hannover 
Medical School) 
Beside flow cytometric application, the generated antibodies were also tested for their immuno-
histochemcial usage. The anti-mPDCA-1 antibodies seemed to be sensitive to paraffin-
embedding as no viable signals were obtained on Paraffin-sections of mouse lymphoid organs 
(data not shown). In contrast the distribution of PDCs could be analyzed on acetone-fixed 
cryosections of lymph nodes and spleens (C57BL/6 mice). Fig. 4.1.7 showed the localization of 
PDCs in peripheral lymph nodes that had been stained with anti-mPDCA-1 (red), Ly-6C (green), 
and CD11c (blue). In summary the in situ distribution of PDCs in LN sections based on the 
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mPDCA-1 staining demonstrated a similar distribution compared to conventional DCs but not 
direct co-localization. 
 
 
4.1.6 Effects of mPDCA-1 cross-linking on maturation and IFNα production of PDCs 
Next, the effect of mPDCA-1 ligation on the maturation status of PDCs was investigated. 
Triggering PDCs with anti-mPDCA-1 mAb neither led to an activation (upregulation of co-
stimulatory molecules CD40/80/86) of the cells nor had an effect on their viability (data not 
shown). 
As PDCs are regarded as the major type I interferon producing cells, it was essential to show 
whether triggering with mAbs against mPDCA-1 had an impact on the production of IFN-alpha. 
Triggering of mPDCA-1 in vitro with different clones led to a significant abrogation of interferon-
alpha secretion by PDCs after stimulation with CpG ODN 2216 (Fig. 4.1.8A). The inhibitory 
capacity of the four described anti-mPDCA-1 mAb clones was comparable to anti-Siglec-H, 
another PDC-specific mAb (e.g. clone 551.3D3), which has been previously described to block 
the IFNα production in PDCs and served as high control in this experiment [Blasius A, Blood 
2004]. 
 
Fig 4.1.7 Immuno-histochemical staining of mPDCA-1 on lymph 
node cryosections. 
 
Acetone-fixed cryosections of peripheral lymph nodes from C57BL/6 
mice were stained with anti mPDCA-1-Biotin, followed by 
counterstainings with Streptavidin-Cy3 (red), anti Ly-6C-FITC (green), 
and anti CD11c-APC (blue). Bar represents 100µm. Shown is a 
representative picture from confocal laser scanning analysis. 
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Fig 4.1.8 Effect of mPDCA-1 cross-linking on the in vitro cytokine production of PDCs. 
(A) Inhibition of the IFNα  production in PDCs after mPDCA-1 cross-linking. 
Isolated PDCs were cultured in the absence or presence of 5 µg/ml CpG 2216 for 24hrs. Additionally, 10µg/ml of 
different anti-PDC mAbs was supplemented: anti-mPDCA-1 (clones 1C2, 3D5, 7B3, and 12A5) or anti-Siglec-H mAbs 
(clone 551.3D3) were used. Interferon alpha secretion was measured in the supernatant via ELISA. The data shown 
represent the mean +/- SEM of three experiments. 
(B) Effect of mPDCA-1 and Siglec-H cross-linking on IFNα and IL-12 production by PDCs. 
BM-PDCs were cultured in the absence or presence of TLR7 and 9 agonists (Loxoribine and CpG ODN 2216, 
respectively) for 6hrs. If indicated, anti-mPDCA-1 clone JF05-1C2 or anti-Siglec-H clone 440c were supplemented. 
Dotplots show intracellular staining of Interferon alpha and IL-12 production. 
 
Beside IFNα, further pro-inflammatory cytokines like IL-12 and TNFα play a pivotal role in the 
initiation of immunological responses. Although cDCs were regarded as main IL-12 producers, 
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also murine, but not human PDCs are able to produce IL-12 upon TLR stimulation [Liu YJ, Annu 
Rev Immunol 2005; Dalod M, JEM 2002; Ito T, Blood 2006]. Here on the one hand the capacity 
of PDCs to produce IL-12 but also a possible effect of mPDCA-1 ligation on the cytokine 
secretion was investigated. As expected, TLR7 and 9 stimulation led to significant IL-12 
production by PDCs as demonstrated in intracellular stainings of CpG and Loxoribine-activated 
cells (Fig. 4.1.8B), whereas unstimulated PDCs produced neither IL-12 nor IFNα. Interestingly, 
beside single IFNα or IL-12 producers (3-6% IFNα+; 8-12% IL-12+ PDCs) also double-producing 
cells were detected (1.5-2%). Surprisingly, incubation of PDCs with antibodies against mPDCA-
1 and Siglec-H in vitro resulted in a (50-80%) reduction of IFNα secretion whereas the IL-12 
production was less affected.  
In summary, mPDCA-1 cross-linkage clearly demonstrated an inhibitory effect on the IFNα 
production of TLR-stimulated PDCs in vitro. Whereas the results obtained by ELISA showed a 
significant reduction, the intracellular cytokine stainings, which have been performed over a 
shorter time period (6 hrs vs. 24 hrs), indicated less apparent results. 
 
4.1.7 In vivo PDC depletion  
4.1.7.1 Depletion of PDCs after anti-mPDCA-1 administration 
Previously, the function of PDCs (in particularly during microbial or viral infections) was 
demonstrated by depleting them by the means of anti-Gr-1 mAb. Due to the promiscuous 
expression of Ly6G/C not only PDCs were depleted but also neutrophils, macrophages or 
activated T cells. The application of a PDC-specific mAb to deplete only PDCs might be more 
suitable for in vivo studies of this cell type.  
Based on other studies, in a preliminary experiment 500 µg of purified and unconjugated anti-
mPDCA-1 mAb (clone 1C2) was administrated. Interestingly, the majority of PDCs had been 
depleted 24 hrs later. To exclude the possibility that the disappearance of PDCs was based on 
a blocking effect of the antigen, the cells were subjected to multicolor FACS analysis by 
counterstaining with both a non-blocking anti-mPDCA-1 mAb (data not shown) and further PDC 
markers (B220 and Ly-6C; Fig. 4.1.9). This analysis demonstrated that PDCs were in fact 
specifically depleted (without affecting other cell populations, like T cells or cDCs; data not 
shown).  
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Fig 4.1.9 In vivo depletion of PDCs. 
BALB/c mice were treated with PBS only or with 500 µg anti-mPDCA-1 mAb (Clone JF05-1C2; i.p.). 24 hrs later, 
PDC frequency was assessed in spleen by FACS analysis after staining with PDC-markers B220, Ly-6C, and 
mPDCA-1. Shown is a representative experiment (n=5). 
 
All tested clones exhibited a significant and comparable PDC depletion capacity (Fig. 4.1.10). 
The depletion efficiency between the four clones varied in the organs analyzed: in general, 
clone 1C2 showed the highest depletion in spleen, liver, BM or PPs, and has been used for the 
depletion of PDCs to assess their role in MCMV infection (Krug A, Immunity 2004). For all 
following experiments it has been used at a dose of 500 µg as reported in 4.1.9. 
 
 
 
 
Fig 4.1.10 Comparison of the depletion efficiency of four different anti-mPDCA-1 clones.  
Mice were treated with different anti-mPDCA-1 clones: JF05-1C2; JF07-3D5, -7B3, and -12A5 (500µg each). 24 hrs 
after i.p. administration, PDC frequency in spleen was assessed by FACS analysis. The data shown represent the 
mean +/- SEM of two experiments. 
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To have a proper information of the quantity of antibody needed for an effective PDC depletion, 
the amount was titrated: 100, 200, and 500µg anti-mPDCA-1 mAb (clone 1C2) was injected and 
the depletion was assed 24 hrs later. In spleen and liver, more than 75% of PDCs were 
depleted, whereas only diminishing effects were detected in BM. It was evident that already a 
low dose (100µg) resulted in significant and efficient PDC depletion. However higher dosages of 
200 and 500 µg led to higher depletion of the cells in BM or PPs and LNs (Fig. 4.1.11).  
 
 
Fig 4.1.11 Titration of the anti-mPDCA-1 mAb effector dose for in vivo PDC depletion. 
Mice were treated with different doses of anti-mPDCA-1 mAb. 24hrs after i.p. administration, PDC frequency was 
assessed by FACS analysis (B220+ Ly-6C+ mPDCA-1+ cells) in different lymphoid organs. The data shown represent 
the mean +/- SEM of three experiments. 
 
To further test the impact of PDC depletion in different organs, several lymphoid tissues were 
investigated for PDC frequencies after intraperitoneal anti-mPDCA-1 administration. The results 
demonstrated that in spleen up to 80% of PDCs were specifically depleted, whereas in BM a 
reduction of maximally 50% could be detected. LNs displayed a heterogeneous effect: In some 
LNs (cervical + mesenteric LNs) an efficient depletion was observed, however other (peripheral) 
LNs demonstrated no depletion as Figs. 4.1.10-12 revealed. To improve the effect of the PDC 
depletion especially for in vivo studies a special protocol was developed (see Krug A, Immunity 
2004; Barchet W, EJI 2005): repeated antibody application at different time points led to 
significant and efficient (approx. 90%) PDC reduction in tested lymphoid organs, in particular in 
LNs (data not shown). 
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Fig 4.1.12 Depletion efficiency in different lymphoid organs after anti-mPDCA-1 mAb administration. 
As described above mice were treated with 500µg anti-mPDCA-1 clone JF05-1C2, (i.p.) and PDC frequency was 
assed 24hrs later in different lymphoid organs by FACS analysis. Bar diagram shows PDC frequencies of control 
mice (black) or anti-mPDAC-1 treated mice (dotted bars). Shown is one representative experiment out of 5. 
 
In the previously described experiments PDC depletion was achieved by intraperitoneal 
administration of anti-mPDCA-1 mAb. However, to evaluate the role of PDCs in inflamed skin 
e.g. in a psoriasis model (collaboration with A. Stratis, University of Cologne) a different 
application route should be more reasonable and was tested in this experiment. Mice received 
same amount of anti-mPDCA-1 mAb via i.p., i.v., and s.c. administration and PDC depletion was 
assessed 24 hrs later. The results suggested that in all cases PDCs were depleted significantly 
and to a comparable level as demonstrated previously only for i.p. administration (Fig. 4.1.13). 
In summary, PDC depletion reached 85-90% and could be achieved independently of the route 
of administration.  
 
 
 
Next the mPDCA-1-mediated in vivo depletion kinetic was analyzed, as there were no reports 
about the duration of this effect. After a single anti-mPDCA-1 administration PDC frequency (or 
repopulation) was assessed. A significant effect could be observed within the first day (up to 
70% reduction), whereas the maximum depletion was detected on day two, lasting until day four 
as illustrated in Fig. 4.1.14 (>90% depletion, depending on the lymphoid organ). Between days 
four and seven PDC frequencies increased again and reached base level after two to three 
Fig 4.1.13 Impact of the application route on PDC 
depletion efficiency. 
Mice were treated with 500µg anti-mPDCA-1 clone JF05-
1C2, and PDC frequency in spleen was assessed after 24 
hrs. Control represents untreated animals. The administration 
was performed either i.p., i.v. or s.c. The data shown 
represent the mean +/- SEM of 2 (i.v.) - 3 experiments. 
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weeks later. In principle this effect was valid for all organs tested, except of minor differences, 
e.g. in BM. In this organ the depletion was not that effective (see Figs. 4.1.10-12) and PDCs 
repopulated earlier. 
 
 
Fig 4.1.14 PDC depletion and repopulation kinetics. 
After administration of 500 µg anti-mPDCA-1 mAb (i.p.), PDC frequency was monitored 1-20 days later in different 
lymphoid organs by FACS analysis. Graph represents mean +/- SEM of two mice per time point. 
 
4.1.7.2 PDC depletion capacity of complete or F(ab’)2 anti-mPDCA-1 antibodies  
The anti-mPDCA-1 mAb was shown to be an effective tool for in vivo PDC depletion to 
investigate their function but the precise mechanism of this depletion remained unclear. It had 
been hypothesized that the PDC ablation could be induced by an intrinsic effect of the mPDCA-
1 molecule, although triggering with the mAb did not influence their viability in vitro (data not 
shown). Another mechanism might be due to complement-dependent lysis. Therefore a Fc-part 
lacking F(ab’)2 fragment of the antibody was generated by Pepsin A digestion. Resulting F(ab’)2 
fragments were purified by size-fractionation to remove the degraded Fc part or remaining 
complete mAb and Fab fragments, which were generated as side products. A typical impression 
of the size-fractionation and the subsequent SDS-PAGE is shown in the appendix (see 
Fig.7.1A+B+C). 
As expected, administration of complete anti-mPDCA-1- mAb resulted in efficient PDC depletion 
(approx. 75%) compared to PBS-treated mice. In contrast, the administration of 500 µg anti-
mPDCA-1 F(ab’)2 did not lead to a PDC-specific depletion in vivo as B220+ CD11cint mPDCA-1+ 
cells were still present (Fig. 4.1.15). Thus the mPDCA-1 F(ab’)2 fragment provided an eminent 
tool to investigate the function of the mPDCA-1 molecule in vivo. 
 
RESULTS 
 
 51 
 
 
Fig 4.1.15 PDC depletion capacity of complete or F(ab’)2 anti-mPDCA-1 mAb. 
24 hrs after i.p. administration of 500µg either complete anti-mPDCA-1 mAb (middle) or its Fab2 fragment (right 
dotplots), PDC frequency was assessed in spleen by FACS analysis of B220+ CD11c+ mPDCA-1+ cells. In the left 
dotplots, mice received only PBS diluent. One representative experiment of two is shown. 
 
4.1.7.3 Effect of PDC depletion on in vivo cytokine production after viral challenge or  
            CpG stimulation (viral infection experiments conducted by Anne Krug, St. Louis, USA) 
To assess the effect of PDC depletion on the cytokine production in vivo, C57BL/6 mice were 
infected with murine cytomegalovirus (MCMV). Mice previously treated with anti-mPDCA-1 mAb 
showed a markedly impaired IFN-α response in blood serum 36 hrs after MCMV infection 
compared to the control group as demonstrated in Fig. 4.1.16A. In contrast, serum levels of IL-
12p70 and IFNγ were significantly higher in PDC-depleted than in isotype control mAb-treated 
mice [Krug A, Immunity 2004, and data not shown].  
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Fig 4.1.16 Abrogation of IFNα production after in vivo PDC depletion. 
(A) MCMV infection following the depletion of PDCs in vivo shows an impaired IFNα response. C57BL/6 mice 
were either injected three times i.v. with 500 µg anti-mPDCA-1 mAb at time points 24 hr, 4 hr before, and 20 hr after 
infection (white circles, n = 4) or were left untreated (filled circles, n = 3). Blood sera were collected 36 hr after the i.p. 
infection with 5 × 104 PFU and serum IFN-α ELISA was determined by ELISA. (see Krug et al., Immunity 2004). 
(B) Inhibition of CpG-induced IFNα production after mPDCA-1-mediated in vivo PDC depletion. Mice were 
depleted of PDCs via i.p. administration of 500 µg anti-mPDCA-1 mAb. On the next day mice received i.v. 5 µg CpG 
ODN 2216 complexed with 30 µl of a cationic liposome preparation (DOTAP; Boehringer Mannheim). 6 hrs later, 
serum was collected and analyzed by IFNα-specific ELISA (PBL). Shown is the serum IFNα level of CpG-activated 
and additionally PDC-depleted mice (n=4 per group, samples were analyzed in duplicates). Mean +/- SEM were 
413.7 +/- 50.83 (Ø) vs. 97.55 +/- 17.77 (+mPDCA-1) as assessed by unpaired t test. Experiment was performed in 
collaboration with Stefanie Kurig (Miltenyi). 
 
In a different experiment the in vivo IFNα production after CpG activation was assessed. Mice 
received an administration of anti-mPDCA-1 mAb (i.p.; d-1) before challenge with CpG ODN 
2216. The scatter diagram demonstrated strong IFNα levels in the serum in contrast to 
significantly reduced IFNα amounts in PDC-depleted mice (mean reduction of approx. 75%; Fig. 
4.1.16B). Compared to viral challenge, CpG stimulation resulted in strong but less intensive 
IFNα production in vivo. 
These data clearly demonstrated the PDC-dependent IFNα secretion upon viral or microbial 
challenge in vivo.  
 
4.1.8 Signal transduction via mPDCA-1 
Since mPDCA-1 triggering abrogated the IFNα production in stimulated PDCs, the possibility of 
mPDCA-1 signaling was next investigated. In two experiments potential signal transduction 
cascades initiated by cross-linking of this receptor was analyzed as it was already shown for 
other human PDC antigens ILT-7 and BDCA-2 [Cao W, JEM 2006, Röck J, EJI 2007; Dzionek 
A, JEM 2001]. 
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Cytosolic calcium concentrations ([Ca2+]i) in PDCs were measured before and after anti-
mPDCA-1 mAb cross-linking to address whether mPDCA-1 mAb triggering leads to in signal 
transduction. As shown in Fig. 4.1.17A, ligation of surface mPDCA-1 with a specific mAb elicited 
a rapid and transient rise in [Ca2+]i in PDCs (red arrows), irrespective if isolated PDCs or spleen 
cells were used. Treatment with Ionomycin, a calcium ionophore that facilitated the sustained 
entry of extracellular calcium, induced the maximal effect of a global increase in [Ca2+]i, as 
indicated by arrow heads. 
 
Fig 4.1.17 Cross-linking of mPDCA-1 on PDCs results in calcium flux and overall protein-tyrosine 
phosphorylation in vitro. 
(A) PDCs, either within splenocytes suspension (left) or isolated (right) were loaded with Indo-1. In the pseudo-color 
density plots (FlowJo) is shown the increase of intracellular calcium (as demonstrated by alteration of the indo-1 
405/510 ratio after triggering with anti-mPDCA-1 mAb (Clone JF05-1C2) (arrow; upper lane)). Arrowheads indicate 
application of Ionomycin as high control. In the lower lane unstimulated spleen cells and PDCs, respectively, are 
plotted. 
(B) Triggering of mPDCA-1 induces protein tyrosine phosphorylation in isolated PDCs (90-96% purity). Cells were 
incubated with medium alone (1), with anti-mPDCA-1 mAb (JF5-1C2, IgG2b) (2), or with isotype antibody (3) for 5 min 
at 37°C. After washing, cells were resuspended in Laemmli buffer, sonicated, boiled, size-fractionated by SDS-
PAGE, transferred to PVDF membranes, and probed with horseradish peroxidase-coupled anti-phosphotyrosine mAb 
PY20. One representative experiment of three is shown. 
 
Next it was tested whether intracellular calcium mobilization was correlated with protein-tyrosine 
phosphorylation. Therefore an anti-phosphotyrosine immunoblotting on whole cell lysates of 
isolated PDCs was performed before and after incubation with anti-mPDCA-1 mAb. As shown in 
Fig. 4.1.17B, PDCs triggered via mPDCA-1 exhibited a significant increase in overall protein-
tyrosine phosphorylation, as compared with unstimulated or isotype control-treated PDCs.  
The results of these two experiments suggested a principle involvement of mPDCA-1 in signal 
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transduction. Further signaling and the disclosure of involved downstream pathways in PDCs 
should be analyzed in other experimental settings after disclosure of the molecular nature of 
mPDAC-1, e.g. by means of mPDCA-1 transfectants. 
 
4.1.9 In vitro and in vivo internalization of mPDCA-1 receptor-antibody complex 
It has been shown that mPDCA-1 triggering influenced the IFN-I production and was further 
involved in signal transduction. These characteristics were also reported for other PDC-specific 
antigens, such as BDCA-2, ILT7 or Siglec-H [Blasius A, Blood 2006; Cao W, JEM 2006, Röck J, 
EJI 2007; Dzionek A, JEM 2001]. At least BDCA-2 and Siglec-H were further shown to 
internalize upon antibody ligation. To test whether mPDCA-1 is also an endocytic receptor 
specifically expressed on mouse PDCs, the ability of mPDCA-1 to be internalized from the cell 
surface was analyzed.  
Therefore PDCs were isolated either from Flt-3L-treated BM-cultures or ex vivo from spleen. 
Cells were labeled with FITC-conjugated anti-mPDCA-1 mAb and cultured at 37°C for different 
lengths of time ranging from 5 min to 2 hrs. For detection of surface-bound antibody, a 
secondary staining was performed consisting of biotinylated anti-FITC mAb, followed by 
counterstaining with PE-conjugated anti-Biotin mAb. The constant FITC intensity in Fig. 4.1.18A 
demonstrated that the mPDCA-1 mAb was not sheared but was still present on the cell surface 
or intracellularly. In contrast, the secondary signal for surface-bound antibody rapidly decreased 
(up to 40% within the first 5 min and up to 80% after 30 min). This demonstrated that mPDCA-1 
is internalized in vitro upon mPDCA-1 mAb labeling through receptor-mediated endocytosis. 
 
Fig 4.1.18 Internalization of the mPDCA-1 mAb:receptor complex in vitro and in vivo.  
(A) Flt-3L–generated (FL) bone marrow (BM) PDCs were isolated and stained with FITC-conjugated anti-mPDCA-1 
mAb on ice. Cells were then incubated at 37 °C for the indicated time, followed by counterstaining with anti-FITC 
secondary system to detect cell surface-bound antibody (consisting of biotinylated anti-FITC and PE-conjugated anti-
Biotin mAbs.   
(B) Alexa488-conjugated anti-mPDCA-1-F(ab’) 2 was administrated intraperitoneally. 15 hrs later spleen PDCs were 
isolated, fixed with formaldehyde, and additionally stained for surface mPDCA-1 with anti-mPDCA-1-Biotin and 
Alexa633-conjugated anti-biotin mAb (red). Alexa488-conjugated anti-mPDCA-1 (green), was internalized as shown 
by merged confocal scan laser microscopy pictures. 
 
In addition, in vivo internalization of mPDCA-1 was assessed after i.p. administration of anti-
mPDCA-1-F(ab’)2 antibody conjugated to Alexa488 fluorochrome. After 15 hrs, spleen PDCs 
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were isolated, fixed and stained with PE-conjugated anti-mPDCA-1 mAb at the cell surface. 
Confocal analyses of isolated PDCs revealed the presence of administrated Alexa488-
conjugated mPDCA-1 (green signal) in intracellular compartments (Fig. 4.1.18B). The 
internalized mPDCA-1 mAb clearly contrasted to in vitro counterstained mPDCA-1 (red) that 
was only observed at the cell surface. These internalization results suggested that mPDCA-1 
could mediate delivery of bound mAb to endocytic pathways both in vitro and in vivo implying a 
function in antigen-uptake. 
 
Taken together, by contra-lateral immunization a panel of mAbs was generated, each 
specifically detecting mouse PDCs in all lymphoid organs tested. All mAbs recognized the 
same, presumably novel antigen, which has been termed mouse PDC antigen-1 (mPDCA-1). 
These PDC-specific mAbs provided the opportunity for exact identification and isolation of this 
DC subpopulation (e.g. via anti-mPDCA-1 fluorochrome conjugates or Microbeads; data not 
shown).  
Interestingly, mPDCA-1 cross-linking resulted in signal transduction as was evident by an 
increase in overall protein-tyrosine phosphorylation and calcium release.  Preliminary data also 
demonstrated that binding the receptor induced an inhibition of IFNα production in activated 
PDCs. The shown results further indicated that triggering the mPDCA-1 via the mAbs resulted in 
rapid and efficient internalization of the receptor:antibody complex, both in vitro and in vivo, 
further underlining a potential role of this receptor in antigen uptake.  
A very promising feature of the anti-mPDCA-1 mAb was the opportunity to deplete PDCs 
specifically in vivo. Therefore the anti-mPDCA-1 mAbs were not only useful for single-color 
identification of PDCs by flow cytometry, but also of great value for advanced studies to disclose 
the function and biological role of PDCs both in vitro and in vivo. 
 
4.2 Identification and molecular characterization of mPDCA-1 
4.2.1 Biochemical approaches to identify the mPDCA-1 antigen 
Peptide Mass Fingerprint (PMF) analysis after immuno-precipitation or immuno-blotting is a 
standard method for the identification of unknown antigens. Therefore anti-mPDCA-1 immuno-
blotting was performed on whole cell lysates of isolated PDCs. Unfortunately, no PDC-specific 
bands could be detected compared to cell lysates of others cells (data not shown). This might 
be due to the disintegration of the recognized mPDCA-1 epitope. For example a linear epitope 
recognized by the anti-mPDCA-1 mAb might be denaturized in the conditions of this 
experiment, and precluded the detection via the antibody.  
In another approach the unknown antigen should be identified by immuno-precipitation, but no 
reliable results were obtained by precipitating the mPDCA-1 molecule out of whole PDC lysates 
or prepared membrane fractions. In analogy to the above description, the parameters were 
modified regarding cell source and preparation method and further protocols were applied. For 
example, immuno-precipitation was performed after biotinylation of the cell surface of PDCs, 
thereby labeling the unknown antigen before immuno-precipitation via anti-mPDCA-1 mAb and 
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providing subsequent detection via the Biotin signal.  Also for these experiments no molecule 
resembling mPDCA-1 could be demonstrated.  
It could be demonstrated that the expression of mPDCA-1 was inducible on certain cell lines 
after IFNα treatment (see below, chapter 4.2.2). Therefore metabolic labeling and immuno-
precipitation from 35S-cultured cells were performed after induction of the mPDCA-1 expression. 
Methionine and Cysteine-free medium was supplemented with radiolabeled, sulfur-containing 
amino acids at the beginning of the experiments to enable the incorporation of 35S-methionine or 
-cysteine during the de novo protein synthesis. 18 hrs after IFNα treatment, cell lysates were 
prepared and subjected to immuno-precipitation using the anti-mPDCA-1 mAb. As for the 
above-described methods, no PDC-specific molecule was obtained by this procedure.  
 
4.2.2 Induction of mPDCA-1 expression in vivo and in vitro 
The above described biochemical methods did not lead to reliable results for the identification of 
the novel antigen, but in the meantime a promising observation has been made. It has been 
demonstrated that mPDCA-1 was expressed specifically on PDCs from naïve mice, but infected 
or otherwise stimulated animals often showed a increased “background staining” for mPDCA-1. 
This observation was consistent with data for another recently described PDC-specific antigen 
[Asselin-Paturel C, JI 2003]. Thus, it was investigated, whether the antigen could be detected 
also on other cells upon activation with CpG and further stimuli. Injection of viral or microbial 
compounds (e.g. Influenza virus and CpG ODNs) or recombinant IFNα resulted in a significant 
upregulation of mPDCA-1 on cells different to PDCs. In contrast to naïve mice, upon poly-I:C 
(Fig. 4.2.1A, B) or CpG treatment (Fig. 4.2.1C) this molecule was upregulated on e.g. B cells, 
NK cells or T cells, and other cDCs in vivo. Interestingly, among cDCs the highest upregulation 
was found within the CD8α+ compartment. This effect could be also shown in vitro in activated 
spleen cell cultures (data not shown). 
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Fig 4.2.1 Upregulation of mPDCA-1 expression in vivo. 
Balb/c mice were either left untreated (control) or activated with 25 µg poly I:C (A; B) or 50 µg CpG ODN 2216 (C). 15 
and 40 hrs later, spleen single cell suspension were prepared and mPDCA-1 expression on different cell populations 
was examined by flow cytometric analysis. Distinct cells were defined as follows: B cells (CD19+), NK cells (CD49b+ 
CD3-), NKT cells (CD49b+ CD3+), T cells (CD3+ TCRα/β+), PDCs (mPDCA-1high Siglec-H+), and Plasma cells (PC; 
CD19+ CD138+). cDCs were additionally divided into “myeloid” CD11chigh CD11b+, “lymphoid” CD11chigh CD8α+ or 
CD11chigh CD8α- subsets. In B the histogram analysis of  the upregulation of mPDCA-1 expression in different 
hematopoietic cell types is shown (as described in (A)): Cells were isolated from control mice (filled grey) or 15 hrs 
(red line) and 40 hrs (black line) after poly-I:C treatment, respectively. 
 
Screening of several cell lines revealed that upon IFNα induction a variety of murine cell lines 
upregulated mPDCA-1 on the cell surface as could be detected by flow cytometric analysis, e.g. 
1881 pro-B cells, Sp2/0 cells, Raw cells (data not shown). In contrast to IFNα-inducing 
reagents, other stimuli did not led to an upregulation of this marker on Sp2/0 cells, as was 
evident in Fig. 4.2.2.  
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Fig 4.2.2 Upregulation of mPDCA-1 expression on Sp2/0 cells. 
Sp2/0 cells were cultured for 24 hrs in medium or in the presence of different stimuli. Bar diagram shows the 
fluorescence intensity of mPDCA-1 expression as detected by flow cytometric analysis of these cells. Shown is the 
mean and SEM of 1-3 experiments. Insert demonstrates upregulation of mPDCA-1 expression 24 hrs after IFNα 
treatment (102 U/ml). 
 
The kinetics shown in Fig. 4.2.3 demonstrated a transient upregulation of the mPDCA-1 
expression in these cells after IFNα induction. Eight hours after IFNα-treatment, Sp2/0 cells 
showed a slight increase in mPDCA-1 expression, reaching a maximum after 1-2 days. A typical 
impression of the upregulation is shown in the insert, comparing untreated and IFNα-stimulated 
cells. This expression rapidly decreased after removal of IFNα in the cultures, reaching basal 
level within four days. 
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Fig 4.2.3 Kinetic of IFNα-induced upregulation of mPDCA-1 expression on Sp2/0 cells. 
Sp2/0 cells were left untreated (square symbols) or cultured in the presence of 102 U/ml recombinant IFNα (circles 
and triangles). 48 hrs after induction the cytokine was washed out (only triangles/grey line). The data shown 
represent mean +/- SEM of 2-8 experiments per time point and setting. The histogram shown in the insert exemplarily 
demonstrates the upregulation of mPDCA-1 expression after IFNα treatment (flow cytometric analysis). 
 
In summary, the results presented in these two chapters revealed that the expression of 
mPDCA-1 is inducible via IFNα.  
 
4.2.3 Identification of mPDCA-1 by differential gene expression analysis 
In this experiment the unknown antigen recognized by the anti-mPDCA-1 mAb should be 
identified by comparing the gene expression profile of cells expressing or not expressing 
mPDCA-1 as demonstrated previously by flow cytometric analysis. A detailed overview of the 
experimental settings (Sp2/0 cells, cultured with or without recombinant IFNα or after IFNα 
removal, and from freshly isolated spleen PDCs) is given in Fig. 3.1 of the Materials & Methods 
section. RNA was isolated from mPDCA-1 expressing or not expressing Sp2/0 cells as well as 
from freshly isolated spleen PDCs, converted into cDNA and thereby differentially labeled with 
Cy3 and Cy5 fluorochromes before hybridization on an Agilent mouse genome microarray. All 
hybridizations were performed as technical replicates (“dye switch”). After hybridization, 
fluorescence signals were scanned (Agilent Micro-array Scanner GB2505GB) and quantified 
(ImaGene, BioDiscovery). In Fig. 3.1 the procedure is shown schematically and a representative 
microarray picture is also given, demonstrating the regulation of each single gene on the basis 
of Cy5 (green) and Cy3 (red) signal distribution.  
Significantly regulated genes (two-fold background intensity) were included into subsequent 
analyses, where candidates had to fulfill the following criteria: (1) beside reproducible regulation 
upon IFNα stimulation, genes must be present on PDCs (shown by chip V); (2) the genes 
should not be expressed on other cells than macrophages or DCs); (3) a cell surface-bound 
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molecule was expected due to the cell surface staining with the specific anti-mPDCA-1 mAb. 
Thus, the gene should contain at least one trans-membrane domain (TMD). With these criteria 
the multiplicity of regulated genes should be limited to find the candidate for mPDCA-1. 
 
In the initial experiments a microarray from Agilent Technologies was used consisting of about 
22,500 mouse transcripts. In four different experimental settings (microarrays I-IV; see Materials 
and Methods, Table 3.2) Sp2/0 cells, either untreated or cultured in the presence of IFNα, or 
after downregulation of mPDCA-1 were compared against each other. On microarray V the 
differential gene expression of freshly isolated PDCs was compared to untreated Sp2/0 cells, 
demonstrating the PDC-presence of regulated gene candidates. Furthermore, Agilent 
Technologies provided a “whole-genome mouse chip”, consisting about 40,000 transcripts at a 
later time point. By the means of this extended microarray the gene expression profile of 
untreated and IFNα-stimulated Sp2/0 cells was reproduced as described for microarrays I+II 
(microarrays VI+VII). 
 
Upon the multiplicity of significantly regulated genes, the above-mentioned criteria were applied 
to shorten this list. In Table 4.2.1 a schematic overview of regulated genes within the separate 
chips is demonstrated, giving a summary of (1) the number and percentage of all present genes 
on each single chip, (2) the number of up/downregulated genes, and (3) the number of 
significantly upregulated genes. 
 
Table 4.2.1 Schematic overview of regulated genes within the seven separate chip hybridizations  
 
Micro-
array 
Genes present on 
respective microarray 
Genes up- 
regulated 
Genes down- 
regulated 
Upregulated candidates 
I ~ 6,500 (28.88%) 564 128 
II ~ 8,550 (38.00%) 500 579 
184 
III ~ 7,100 (31.55%) 558 220 
IV ~ 9,860 (43.82%) 349 939 
125 
94 
V ~ 7,260 (32.26%) 1,955 1,834  
VI ~ 11,160 (26.19%) 418 198 
VII ~ 15,880 (35.85%) 351 32 
129 
55 
 
Within the upregulated candidates, subsets were assembled from the different microarrays. In 
general, a final intersection was generated, which was listed in Table 4.2.2. Hereby, only 
genes were displayed that were upregulated on all chips. The differential gene expression 
analysis demonstrated the significant upregulation of more than 50 candidates. In a second 
screening step, the PDC-specific expression of regulated candidates should be evaluated by 
quantitative RT-PCR, comparing mRNA from PDCs and other hematopoietic cell types. The 
final proof should be given by staining with anti-mPDCA-1 mAb and flow cytometric analysis of 
transfected cell lines generated using cDNAs of selected candidates. 
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Table 4.2.2 Differentially regulated gene candidates after extensive Agilent microarray analysis. 
Genes are listed in alphabetical order according to their GeneBank Accession nomenclature. Demonstrated is the 
regulation on the different Agilent microarrays (∅ : mean ratio of chip I-IV). TMD: Trans-membrane domain: (-) n.d.; 
(+) 1 TMD; (++) more than 1 TDM. Reference.: K. Hofmann & W. Stoffel (1993) Biol. Chem. Hoppe-Seyler 374,166 
“TMbase - A database of membrane spanning proteins segments & TMpred - Prediction of Transmembrane 
Regions and Orientation“. (http://www.ch.embnet.org/software/TMPRED_form.html) 
 
 
4.2.4 Validation of mPDCA-1 candidates for PDC-specific expression by quantitative 
real time RT-PCR  
The expression in PDCs and selected hematopoietic cell populations of each regulated gene 
candidate that have passed all screening criteria was assessed by quantitative RT-PCR, 
performed on a LightCycler system (Roche). Messenger RNA of PDCs was amplified using 
primers specific for the investigated genes and was compared to mRNA of other hematopoietic 
cell types, e.g. T cells, NK cells, B cells, CD11chigh cDCs, macrophages or other cell lines. 
Before starting the analysis, for all mRNA sources a standard curve for selected housekeeping 
genes (β-actin, PPIA, GAPDH, and Hprt-1) was established to determine the absolute mRNA 
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level (see appendix, Fig. 7.2). Additionally, the integrity of each primer set was tested (data not 
shown). A list of all primers used in this work is also deposited in the appendix (Tab. 
7.1A+B+C). 
Table 4.2.3 Validation of candidates by quantitative real time RT-PCR analysis.  
The regulation of 45 genes was compared according to their mRNA expression in PDCs and T cell, normalized to β-
actin. 
Shown is the mean of the respective crossing-points of the LightCycler runs (n=2) and the difference between PDC 
and T cell mRNA. A negative numerical value represents a higher expression in PDCs. Highlighted in green are 
genes demonstrating a predominate expression in PDCs. 
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The results of 45 from 55 candidates that could be tested successfully by quantitative RT-PCR 
analysis are listed in Table 4.2.3. Here, the mean crossing-points of distinct gene candidates 
were compared between mRNA of PDCs or T cells, as the latter were negative for mPDCA-1. 
The crossing-point itself defined the cyclus in which the fluorescence started to increase linearly 
as measured in a LC run. In principle, the lower the value for a crossing-point the more nucleic 
acid has been detected. As an approximate value, a difference in the crossing-points (ΔCP) of 
“3” represents a nearly 10-fold upregulation. From these 45 candidates nine genes were 
significantly upregulated in PDCs compared to T cells (ΔCP=2-5), representing a 6->20-fold 
regulation. These candidates were depicted in green. Exemplary LightCycler runs are given in 
Fig. 4.2.4. For housekeeping genes β-actin and PPIA there were almost no differences in their 
crossing points between mRNA isolated from T cells and PDCs (A) as well as for NM_008331 
(Ifit1) (B). In contrast, the LightCylcer analysis for L20315 (MPG1) demonstrated an enormous 
difference in the crossing points if mRNA from T cells or PDCs was used (C). As shown in the 
representative LightCycler analysis, for PDC mRNA L20315 reached the crossing point after 
about 18 cycles compared to more than 24 cycles if T cell mRNA was used. 
 
Fig. 4.2.4 LightCycler curves indicating crossing points for L20315 and NM_008331 performed on different  
mRNA templates.  
Isolated mRNA of purified spleen PDCs or T cells was used as template for quantitative real time PCR analysis. RT-
PCR was performed using the LightCycler® RNA Master SYBR Green I kit (Roche Diagnostics). All assays were 
performed at least in duplicates. Messenger RNA amount was normalized by the expression of house keeping genes 
(murine b-actin, PPIA, Hprt-1, and GAPDH) (A). Differential transcript levels of two exemplary genes, NM_008331 
and L20315, are shown. Significant difference in the cycle numbers between PDCs and T cells were observed for 
L20315(C) in contrast to NM_008331 (B). 
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The performed real time PCR analysis could shorten the number of regulated genes, leading to 
a final list of nine genes that passed all criteria and demonstrated on the one hand high 
regulation in the Agilent analysis as well as predominant expression in PDCs compared to T 
cells (Table 4.2.4).  
 
Table 4.2.4 Final list of  mPDCA-1 candidates after microarray and RT-PCR analysis.  
Regulated gene candidates from the Agilent microarrays were validated by LightCycler analysis of PDC and T cell 
mRNA.Prediction of trans-membrane regions and orientation (TMD) was evaluated as described before. Values in 
parentheses showed scores of the TMD prediction, whereas only scores above 500 were considered significant. 
 
 
 
 
4.2.5 Cloning and generation of transfectants of potential mPDCA-1 candidates 
To identify the molecule recognized by the anti-mPDCA-1 mAb, genes that are present on the 
final candidate list have been cloned and full-length transfectants have been generated. 
According to their higher expression in PDCs compared to T cell mRNA, a more detailed 
expression analysis was performed for two examples (L20315 and BC027328), comparing their 
mRNA content in PDCs to a variety of other leukocyte cell types (Fig. 4.2.5A+B; representative 
LC runs for BC027328 and L20315 are attached in the appendix). It was demonstrated that both 
genes were predominantly expressed in PDCs in contrast to cells or cell lines from the lymphoid 
or myeloid lineage. The mean of the relative expression, normalized via β-actin content, is 
displayed below the bar diagrams. Interestingly, after IFNα-induction, only Sp2/0 cells showed 
high expression of BC027328 but not L20315 mRNA, which was comparable to native PDCs. 
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Fig 4.2.5 Differential expression of L20315 (MPG1) and BC027328 (BST2) mRNA.   
mRNA was prepared from indicated cell types and real-time RT-PCR was performed with primers for L20315 (A) and 
BC027328 (B) (n=2). Values were normalized for β-actin expression. Shown is the relative mRNA amount of 
indicated genes in different cell types (PDCs expression was set to 100%). 
 
Taken together, these two candidates showed promising results and the cloning and generation 
of transfectants are demonstrated in detail in the following.  
 
4.2.5.1 The macrophage-specific gene 1  
The L20315 gene coding for the macrophage-specific gene 1 (MPG1) was the first one cloned, 
because this candidate was both highly regulated in the differential gene analysis and also 
showed a predominant mRNA expression in spleen PDCs compared to all other cells tested as 
validated by quantitative real time PCR.  
The complete open reading frame (ORF) of MPG1 was inserted into the pDisplay vector without 
the leader sequence and start codon (ATG) that was provided by the vector backbone (see 
Materials and Methods). Sequence information of primers used for gene amplification is 
deposited in the appendix (Table 7.1D). 
 
After transfection of HEK293T cells, the construct was easily detected intracellularly via N-
terminal HA-tag of pDisplay-Vector as flow cytometrical analysis of intracellular HA staining 
revealed (Fig. 4.2.6). Using a commercial rabbit anti-rat MPG1 mAb (described to be also cross-
reactive with murine MPG1) staining of MPG1- but not MOCK-transfected HEK293T cells could 
be demonstrated. In contrast, detection with anti-mPDCA-1 mAbs showed no significant signal 
of this transfected cell line (compared to the isotype control or MOCK-transfected cells).  
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Fig 4.2.6 Cloning of L20315 (MPG1) and generation of a full-length transfectant.  
HEK293T cells were either transfected with the empty vector (MOCK) or with the pDisplay vector containing the 
L20315 sequence. Representative flow cytometric analysis of anti-HA, anti-MPG-1, and anti-mPDCA-1 stainings are 
shown. 
 
In general, several transfections with other cell lines were performed to avoid cell type-specific 
modulations: e.g. human HEK293T cells, rat RBL-1 cells, and mouse RAW cells were tested. 
The results demonstrated that at least RAW cells upregulated mPDCA-1 upon transfection with 
the MOCK vector (data not shown). Therefore, to exclude an unspecific induction of the 
mPDCA-1 only human and rat cell lines, but not mouse cells (such as RAW) were used from 
this point on. 
Taken together the positive staining both for HA and MPG1 showed the integrity of the 
construct; on the other hand, these results led to the suggestion that MPG1 was not identical to 
the mPDCA-1 antigen, although it was predominantly expressed on PDCs (at least on mRNA 
level). Nevertheless, future investigations might show further implications of this molecule and 
its role for PDCs. 
 
4.2.5.2 The Bone marrow stromal antigen 2  
Above-described results demonstrated that MPG1 was not detected by the anti-mPDCA-1 mAb. 
Hence, the next gene on the final list of regulated and validated gene candidates was cloned 
and transfectants were generated. BC027328, coding for the Bone marrow stromal antigen 2 
(BST2), was another highly regulated candidate that also showed a predominant PDC 
expression (see above).  
The gene organization (900 bp in length, CDS of 45-563 base pairs) led to the cloning strategy 
into two vectors as described in detailed in the Materials & Methods section. BST2 was cloned 
in either a pEHO or a pMACS.4IRES-II vector. While the first vector involved a Blasticidin 
resistance and a HA tag, the latter one vector did not provide a resistance gene, but enables 
bicistronic expression of BST2 together with a truncated human CD4 surface. As for BST2, the 
RESULTS 
 
 67 
N-Terminus was proposed to be located intracellular (based on a TMD prediction), the HA-tag 
should be detected by intracellular staining in pEHO-BST2 transfectants. In pMACS.4IRES-II-
BST2 transfectants the human CD4 protein should be co-expressed on the cell surface enabling 
effective enrichment of positively transfected cells via anti-CD4 microbeads.  
Cells transfected with the above-mentioned pEHO-BST2 vector or with the MOCK control could 
be both specifically detected via the HA-TAG (only intracellularly; data not shown), 
demonstrating the integrity of the vector. In contrast, with the anti-mPDCA-1 but not with the 
isotype control (rat IgG2b) mAb a significant staining was detected on the BST2 transfectants 
(Fig. 4.2.7A). The MOCK control did not show a significant staining. As for MPG1, transfectants 
were generated also for BST2 in several cell lines (HEK293T, 1881; and EL4.2), which gave 
similar results. To avoid any unspecific signals induced by unwanted activation of these cells 
(as shown in chapter 4.2.5.1), transfectants were not generated in RAW cells.  
 
Fig 4.2.7 Cloning of BC027328 (BST2) and generation of full-length transfectants.  
(A) HEK293T, 1881, and EL4.2 cells were transfected with the pEHO vector, either empty (MOCK) or containing the 
BC027328 sequence. Flow cytometric analysis of the mPDCA-1 expression is performed 24 hrs after electroporation 
(HEK293T) or after limited dilution (1881 and EL4.2; Mock control not shown). 
(B) Representative flow cytometric analysis of HEK2932T cells transfected with the pMACS.4IRES-II vector. Anti-
mPDCA-1 and anti-human CD4 stainings are shown after enrichment with anti-hCD4 microbeads (NEG/POS = 
magnetical negative/positive fraction). 
 
The pMACS.4IRES-II vector provided the opportunity to enrich transfected cells via the 
expression of human CD4. Fig. 4.2.7B demonstrated representative results of CD4 microbead-
enriched HEK293T cells after transfection. Whereas the Mock-transfected cells only showed an 
enrichment of CD4+ cells, BST2-transfected cells displayed both accumulations of mPDCA-1+ 
and CD4+ cells. Similar results were obtained by using anti-mPDCA-1 microbeads (clone JF07-
3D5; data not shown). 
In summary, all transfectants of the above constructs showed comparable and specific mPDCA-
1/BST2 expression as was evident by anti-mPDCA-1 FACS staining. 
 
In this second chapter, the molecular nature of mPDCA-1 was successfully revealed by a 
strategy based on the combination of differential gene analysis followed by the validation of 
potential candidates by quantitative RT-PCR and FACS analysis of generated transfectants. 
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Furthermore, a variety of PDC-regulated genes were found, either already known (e.g. Ly-6C 
(NM_010741) or other, IFN-I-inducible genes) or hitherto unknown molecules. In addition, the 
BST2 transfectant could be used for further experiments including internalization and signal 
transduction studies, and to analyze the function of the molecule and its immunological role, in 
particular in the modulation of IFNα production (as demonstrated in previous experiments) and 
for the uptake of antigens.  
 
4.3 Characterization of mPDCA-1 as novel antigen-uptake receptor on PDCs enabling 
priming and cross-priming of naïve T cells 
The immune system consists of specialized cell types for the recognition and the elimination of 
pathogens. On the effector side T lymphocytes play a pivotal role in adaptive immunity. Naïve T 
cells do not recognize native antigens, but only respond to antigenic peptides presented on 
major histocompatibility complex (MHC) molecules of so-called antigen-presenting cells (APCs) 
comprised of B cells, macrophages and mainly dendritic cells (DC) [Romani N, Res Immunol 
1989; Romani N, JEM 1994; Germain RN, Cell 1994; Brown MG, JI 1993; Carbone FR, Cold. 
Spring Harb. Symp. Quant. Biol. 1989]. The T cell population can be principally divided into 
cytotoxic CD8+ T cells (CTLs) that recognize antigenic peptides in the context of MHC class I, 
and CD4+ helper T cells, which respond to peptides loaded onto MHC class II complexes. The 
DC family comprises of at least five different subsets, suggesting the potential to initiate distinct 
responses to diverse challenges. PDCs were regarded as a distinct subset of Dendritic cells, 
which have a critical role both in the innate and adaptive immune defense against bacterial and 
viral infection [Liu YJ, Ann Rev Immunol 2005], by sensing viral or microbial structures through 
engagement of Toll-like-receptors (TLR) 7 and TLR 9 [Kadowaki N, JEM 2001] and (Myd88/ 
IRF7-dependent) secretion of massive amounts of type I interferons (IFN α, β, ω, τ) [Kawai T, 
Nat. Immunol 2004]. PDCs have also been proposed to play a direct role as APCs in the 
initiation of T cell responses by their constitutive presence in lymphoid organs, by expression of 
MHC molecules and by acquisition of DC morphology upon activation. Nevertheless, their DC 
characteristic relied on their capacity to prime naïve T cells, and in fact this is controversially 
discussed: Freshly isolated PDCs are poor T cell stimulators as human blood-derived PDCs did 
not stimulate naïve CD4+ T cells in a Mixed Leukocyte Reaction (MLR) unless cultured in the 
presence of virus (HSV) [Kadowaki N, Hum Immunol 2002]. On the other hand murine splenic 
PDCs failed to induce naïve CD4+ and CD8+ T cell proliferation to endogenous antigens even 
after virus exposure [Krug A, JEM 2003]. In contrast, peptide-pulsed PDC derived from Flt-3-
driven BM culture or spleen can promote the in vitro expansion of CD4+ T cells and TH 
polarization [Boonstra A, JEM 2003]. Adoptive transfer experiments showed that splenic and 
BM culture-derived PDC are capable to elicit responses of naïve CD8+ T cells to endogenous, 
but not exogenous antigens after CpG activation [Salio M, JEM 2004]. These conflicting results 
are likely due to the different source of PDCs used in the reports as well as their activation 
status. Recently, PDCs have been shown to play a critical role in the control of airway 
inflammation [de Heer HJ, JEM 2004; Smit JJ, JEM 2006] and regulation of alloimmune 
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reactivity and tolerance [Abe M, Transplant. Proc. 2005; Ochando JC, Nat Immunol 2006]. 
Additionally, we showed a direct interaction of PDCs with naïve CD4+ T cells in an antigen-
specific manner in vivo [Sapoznikov A, JEM 2007] characterizing PDCs as "bona fide" DC that 
can initiate adaptive immune responses. 
The aim of this project was to disclose the function of the recently described mPDCA-1 
molecule for antigen delivery and processing. Additionally, mPDCA-1-targeted delivery of 
antigens was utilized to analyze PDC-induced primary CD4+ and CD8+ T cell responses, which 
allows a better understanding of the principle role of PDCs in adaptive immunity. Although 
PDCs express MHC-II molecules and display further DC-features, including upregulation of co-
stimulatory molecules upon maturation and displaying a dendrite-like morphology, they were still 
not regarded as professional DCs [Kadowaki N, Hum. Immunol 2002]. Thus, it was of particular 
interest to show whether PDCs were acting as competent APCs.  
 
4.3.1 Endocytosis of DQ-OVA demonstrated the antigen-uptake capacity of PDCs 
A unique hallmark of DCs is the uptake of exogenous, soluble antigens for subsequent 
presentation to naïve T cells. PDCs were characterized to take up soluble antigens poorly 
[Grouard GM, JEM 1997; Dzionek A, JI 2000]. To investigate their in vivo endocytosis capacity 
the uptake of the model antigen DQ-OVA was investigated. DQ-OVA is a fluorogenic reagent 
that is invisible in its unprocessed form due to auto-quenching, but shows fluorescence upon 
entry into the endosomal cellular compartment. 24 hrs after s.c. and i.v. administration of DQ-
OVA only PDCs but not myeloid DCs or T cells were able to take up and proceed DQ-OVA into 
the endosomal/lysosomal pathways as was revealed by the FACS analyses (Fig. 4.3.1): 
approximately 15% of PDCs in contrasts to less than 0.5% of other cell types showed a positive 
signal. Interestingly, simultaneous activation via TLR9 signaling resulted in weaker signal 
intensities. In addition, only LN-PDCs but not cells from spleen could be stained for processed 
antigen (data not shown). The two murine cell lines 1881 (murine pre-B cells) and RAW 264.7 
(macrophage/monocyte-derived cells) ingested this antigen efficiently in vitro. Again, addition of 
CpG did not lead to increased uptake of DQ-OVA. Other experiments also showed an increased 
uptake of FITC-labeled Dextran at 37°C compared to 4°C, further underlining the capacity of 
PDCs to ingest exogenous antigens (data not shown). 
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Fig 4.3.1 Uptake and processing of DQ-OVA by PDCs in vivo.  
(A) To determine the endocytotic capacity of PDCs, mice received 20 µg DQ-OVA. 24 hrs after s.c. administration the 
antigen uptake and processing was evaluated by FACS analysis of cells isolated from draining LNs. If indicated, mice 
received additionally 10 µg CpG ODN 1668. The dotplots show FL1 signal derived from processed DQ-OVA on 
mPDCA-1+ CD11cint PDCs, mPDCA-1- CD11chigh cDCs, and CD3ε+ T cells. 
(B) Flow cytometric analysis of DQ-OVA uptake by PDCs, cDCs, T cells (in vivo) and 1881 and RAW cell lines (in 
vitro). The histograms display overlays of FL1 intensities of cells in the absence (grey filled lines) or presence of DQ-
OVA (red lines) or optionally of DQ-OVA in combination with CpG (black lines) as demonstrated in (A). The in vitro 
endocytosis capacity of 1881 and RAW cells is shown after culture for 24 hrs in the absence or presence of DQ-OVA. 
 
4.3.2 Generation of a PDC-specific in vitro and in vivo antigen delivery strategy  
Administration of the anti-mPDCA-1 mAb led to specific and efficient depletion of PDCs in vivo. 
It has been shown in chapter 4.1.7 that about 80-90% of PDCs in spleen were depleted after 
anti-mPDCA-1 mAb application in contrast to diluent or isotype control antibody. This efficient 
PDC depletion was also detected in other lymphoid organs, whereas administration of anti-
mPDCA-1-F(ab’)2 showed that in contrast to the complete mAb the F(ab’)2 fragment did not 
deplete PDCs (Fig. 4.1.15). These data suggest a complement-dependent lysis or an induction 
of antibody-dependent cell-mediated cytotoxicity (ADCC) of the complete anti-mPDCA-1 mAb.  
Thus, immunizing mice with a fluorochrome-conjugated F(ab’)2 fragment resulted in specific 
targeting of PDCs in vivo, as indicated by flow cytometric analysis of isolated spleen and LN 
cells (Fig. 4.3.2). These data demonstrate that anti-mPDCA-1-F(ab’)2 fragments allowed a 
specific in vivo targeting of PDCs without killing the cells. 
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Fig 4.3.2 In vivo PDC targeting via anti-mPDCA-1-F(ab’)2 antibody fragment.  
To demonstrate the in vivo specificity, mice received either a s.c. or i.v. administration of anti-mPDCA-1-F(ab’)2 
conjugated to Alexa488. Spleen and draining LNs (DLN) were isolated 2 and 15 hrs later, respectively. Dotplots show 
Ly-6C and B220 staining that had been performed on single cell suspensions. Hereby the mPDCA-1 staining (as 
demonstrated on the y-axis) is derived from administrated anti-mPDCA-1-F(ab’)2 fragment. 
 
After demonstration that the antibody-receptor-complex was internalized upon cross-linking (see 
Fig. 4.1.18), targeting OVA protein to PDCs was in the focus of the next experiments. As 
described elsewhere, full-length OVA protein was conjugated to the anti-mPDCA-1-F(ab’)2 mAb 
[Sapoznikov A, JEM 2007]. Purified fragments of the non-depleting anti-mPDCA-1-F(ab’)2 
fragments were covalently conjugated with OVA protein. Generated anti-mPDCA-1-F(ab’)2-OVA 
was purified by size exclusion chromatography as shown in the appendix (see Fig.7.1). 
Functional integrity of the construct was tested by Western blotting. As depicted in Fig. 4.3.3A, 
the conjugates were readily detected both via the kappa light chain and the OVA-fraction, 
whereas free OVA or unconjugated anti-mPDCA-1-F(ab’)2 fragments were only detected with an 
anti-rat IgG or anti-OVA antibody, respectively. Fig. 4.3.3C revealed that a FITC-labeled 
targeting construct was only detected on Siglec-H+ PDCs within a spleen single cell suspension, 
underlining that the targeting construct was delivered specifically to PDCs in vitro. The 
specificity of the antigen delivery had also been shown in vivo: i.v. and s.c. injection of the anti-
mPDCA-1-F(ab’)2-OVA construct resulted in specific labeling of CD11cint PDCs from spleen and 
DLNs as demonstrated by flow cytometric staining in Fig. 4.3.3B. Therefore targeting mPDCA-1 
might be a valuable approach for specific delivery of antigens to PDCs for presentation via 
MHC-I and -II molecules both in vitro and in vivo. 
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Fig 4.3.3 Characterization of selective PDC targeting and antigen delivery.  
(A) Western blot analysis of the generated OVA-conjugated antibody construct. Free OVA and unconjugated or OVA-
conjugated anti–mPDCA-1-F(ab’)2 antibody constructs were resolved by SDS-PAGE (4-12% gradient Tris-glycine 
gel) and, after immunoblotting, detected with anti–ratκ and anti-OVA antibody, respectively. Lanes 1 and 5 contain 
free OVA, lanes 2 and 6 contain the unconjugated anti-mPDCA-1-F(ab')2 antibody fragment, and lanes 3 and 4 as 
well as 7 and 8 contain two fractions of the anti–mPDCA-1–F(ab')2–OVA conjugate.  
(B) Specific in vivo targeting of PDCs with FITC-labeled anti–mPDCA-1–F(ab')2–OVA. Conjugates were injected i.v. 
or s.c. and, after 3 h, spleens and popliteal LNs were isolated. Dotplots demonstrate counterstaining with CD11c that 
has been performed on single-cell preparations from untreated (left dot plots) or in vivo–targeted cells (middle and 
right dot plots). The staining in the FL-1 channel is based on the in vivo-injected, FITC-coupled mPDCA-1-F(ab')2–
OVA construct.  
(C) Dotplots show spleen single cell suspensions of untreated mice that have been incubated for indicated times with 
anti-mPDCA-1-Fab2-OVA (conjugated to FITC fluorochrome). OVA-conjugated targeting construct is specifically 
directed to PDCs in vitro, as counterstaining with further PDC-specific marker Siglec-H revealed. 
 
4.3.3 Capacity of murine PDCs to prime antigen-specific CD4+ T cells in vitro  
4.3.3.1 Peptide-pulsed PDCs are able to induce naïve CD4+ T cell proliferation 
To confirm their general stimulatory capacity, PDCs from Balb/c were first co-cultured with 
CFSE-labeled CD4+ T cells from DO11.10 mice in the presence of an OVA peptide that could 
be loaded onto MHC-II molecules. As expected, T cells responded in a vigorous expansion 
(<1% vs. average 85-95%) if PDCs were loaded with peptide (Fig. 4.3.4B). The same results 
were obtained in the C57BL/6 background with CD4+ T cells from OT-II mice (data not shown). 
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Fig 4.3.4 Capacity of murine PDCs to present antigen to naïve CD4+ T cells.  
(A) PDCs were untouched isolated from several lymphoid organs by MACS technology and then sorted into B220+ 
Siglec-H+ or Ly-6C+ cells (FACS Vantage). Representative dotplot demonstrates the purity of isolated PDCs as 
revealed by subsequent flow cytometric analysis of B220 and Siglec-H expression.  
(B) Highly pure PDCs (97-99%) were isolated from Balb/c mice and cultured in the absence or presence of OVA 
peptide (OVA323-339; 5 µg/ml). Thereafter, PDCs (1x105 cells) were co-cultured with 2x105 purified and CFSE-labeled 
CD4+ T cells isolated from DO11.10 mice. Dotplots show the proliferation of CD4+ T cells (gated on viable KJ-26.1+ 
B220. cells) after 72 hrs. 
 
4.3.3.2 Activated PDCs prime naïve CD4+ T cells after antigen-uptake via mPDCA-1 
After demonstrating that PDCs per se were able to stimulate T cells, it was next investigated 
whether PDCs are able to efficiently process and present exogenous antigen (OVA protein) 
after antigen-uptake via the mPDCA-1 receptor. Therefore highly pure PDCs were enriched 
from spleen by MACS technology and subsequently sorted by FACS into B220+ and Siglec-H+ 
or Ly-6C+ cells. As shown in Fig. 4.3.4A, PDC purity normally reached over 97-99%, whereas 
cross-contamination of cDCs as determined by CD11c+ cell phenotyping was below 0.5% (data 
not shown). Isolated PDCs were incubated with anti-mPDCA-1-F(ab)2-OVA targeting construct 
or OVA-conjugated to isotype-matched irrelevant rat IgG F(ab)2 fragment - thereafter named 
control OVA construct - in the presence or absence of a CpG stimulus for 15 hours. CFSE-
labeled CD4+ T cells from OT-II mice (>95% purity) were then added to PDCs at a T cell:PDC 
ratio of 2:1 and subsequently co-cultured for additional 72 hours. T cell proliferation was 
examined by flow cytometry. PDCs targeted via mPDCA-1 were able to induce a strong 
antigen-specific CD4+ T cell response (Fig. 4.3.5A). In contrast, PDCs incubated with equal 
amounts of either soluble OVA (data not shown) or OVA control construct or in the absence of 
antigen did not result in visible T cell priming. Interestingly, only (CpG-) activated but not 
immature PDCs were able to prime naïve antigen-specific T cells. Stimulation with other 
reagents, e.g. the TLR7 agonist Loxoribine or different CpG ODNs also led to efficient T cell 
priming (Fig. 4.3.5B). The substantial T cell proliferation after mPDCA-1-mediated OVA uptake 
was comparable to OVA peptide (Fig. 4.3.5C). The titration of the antigen amount revealed that 
the mPDCA-1 targeting construct turned out to be an efficient vector to induce a T cell 
response. In a further experiment the efficiency of the antigen-uptake was investigated. To 
evaluate the required duration of antigen presence, the anti-mPDCA-1-F(ab)2-OVA targeting 
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construct was washed out from the co-culture after different time points. We found that the 
antigen had to be present at least for more than 15 hrs to elicit an efficient CD4+ T cell priming 
(Fig.4.3.5D). The maximum T cell response was induced if the antigen was present more than 
36 hrs.  
 
Fig 4.3.5 Murine PDCs targeted with OVA antigen via mPDCA-1 prime antigen-specific CD4+ T cells.  
(A) To show PDC-induced T cell priming, PDCs were targeted with anti-mPDAC-1-F(ab’)2-OVA or isotype matched 
control F(ab’)2-OVA (2.5 µg/ml OVA each). Cells were cultured in the absence or presence of CpG (5 µg/ml). 15 hrs 
later PDCs were co-cultured with CFSE-labeled CD4+ T cells from OT-II mice (in a PDC:T cell ratio of 1:2). Shown in 
the dotplots is the proliferation of CD4+ T cells after 72 hrs, thereby gated on viable TCR+ B220- CD4+ cells. 
(B) Impact of different activation stimuli on the CD4+ T cell priming capacity of PDCs. PDC:T cell co-culture 
was performed as described before with targeting OVA via mPDCA-1. Bar diagram indicates the influence of 
additional stimuli on PDC-induced T cell proliferation.  
(C) Bar diagram compares the efficiency of different OVA targeting constructs. PDCs were incubated with 
titrated amounts of OVA peptide or mPDCA-1 targeting construct and activated with CpG before co-culture with naive 
T cells. Shown is the median T cell proliferation and range after 72 hrs co-culture (n=2-4). 
(D) Influence of the antigen availability on the T cell priming capacity of PDCs. PDC:T cell co-culture was 
performed as described before modifying the time of antigen presence: anti-mPDCA-1-F(ab’)2-OVA was washed out 
after indicated times or not. Shown in the bar diagram is the proliferation of naive CD4+ T cells after 72 hrs. 
 
These results were generated not only in C57BL/6 background but also PDCs isolated from 
Balb/c mice were able to efficiently prime OVA-specific CD4+ T cells from DO11.10 mice (data 
not shown).  
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4.3.3.3 Priming capacity of PDCs from different lymphoid organs 
To analyze the priming capacity of PDCs from different lymphatic tissues, PDCs were isolated 
from lymph nodes, spleen, and bone marrow or were generated in vitro from FL cultures. PDCs 
were targeted with anti-mPDCA-1-F(ab’)2-OVA targeting construct and co-cultured with antigen-
specific T cells in the presence of a CpG stimulus as described above. In Fig. 4.3.6A the 
proliferation of CFSE-labeled OT-II CD4+ T cells is shown. Representative dotplots of PDCs 
from different lymphoid origins are depicted, demonstrating the proliferation of CD4+ T cells. The 
T cell proliferation initiated by PDCs isolated from LNs ranged from 58% to 78%. Spleen PDCs 
induce between 48% and 82% T cell proliferation, BM-PDCs between 47% and 91%, and finally 
in vitro generated PDCs 40% to 97% proliferation (Fig.4.3.6B). The overall mean proliferation 
ranged from 72% to 82%. These results indicated that activated PDCs from all lymphoid origins 
tested have a similar stimulatory capacity and were able to efficiently prime CD4+ T cells. 
Figure 4.3.6 PDCs from different lymphoid organs have similar capacities to prime naive CD4+ T cells in vitro. 
(A) PDC:T cell co-culture was performed as described before. In contrast to previous experiments, here PDCs were 
isolated from different lymphoid organs. Shown is the proliferation of naive CD4+ T cells after 72 hrs of co-culture with 
mPDCA-1-OVA targeted and CpG-activated PDCs. 
(B) Scatter diagrams summarize the priming capacities of PDCs derived from several lymphoid organs. Values 
represent mean proliferation of OVA-TCRtg CD4+ T cells from (A).  
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4.3.4 PDC-induced (cross-) priming of CD8+ T cells in vitro 
4.3.4.1 Cross-presentation and –priming capacity of mouse PDCs 
PDCs were often regarded to support CD8+ T cell priming by secretion of type I interferons 
[Yoneyama H, JEM 2005; Le Bon A, Nat Immunol 2003], which further activates/sharpens the 
cross-priming machinery of bystander APCs [Lapenta C, EJI 2006]. However, there were 
reports showing that only SIINFEKL-loaded PDCs are able to stimulate CTLs via peptide:MHC-I 
complexes, but not OVA protein loaded PDCs.  Thus, a direct evidence of the cross-priming 
capacity remains controversial [Lou Y, JI 2007; Liu C, J Clin Invest. 2008; Schlecht G, Blood 
2004].  
Here, isolated spleen PDCs were loaded with antigen and co-cultured with isolated and CFSE-
labeled CD8+ T cells from OT-I mice (as described in analogy to the CD4+ T cell experiments). 
Based on the previous experiments, PDCs were either left unstimulated or were activated with 
CpG. As shown in Fig. 4.3.7A, in the absence of antigen PDCs did not induce a T cell response, 
also upon CpG-activation. In contrast, SIINFEKL peptide-loaded PDCs were strongly stimulating 
CD8+ T cells. In this case, an additional stimulus showed no effect as also unstimulated PDCs 
presented the (exogenously loaded) peptide for efficient T cell priming. But if antigen was taken 
up via mPDCA-1, only activated PDCs efficiently cross-prime T cells, whereas soluble OVA 
[data not shown] or OVA conjugated to isotype-matched control antibody were unable to induce 
a significant T cell proliferation. At least higher concentrations were needed to induce similar 
responses (Fig. 4.3.7A+B). In all experiments in which PDCs had been incubated with OVA 
protein and had to process the antigen, a stimulus was required for optimal cross-presentation 
and T cell priming. 
 
Figure 4.3.7. CD8+ T cell proliferation showing the cross-priming capacity of murine PDCs. 
(A) In vitro cross-priming of naive CD8+ T cells by PDCs. Shown in the dotplots is a representative overview of 
the CD8+ T cell proliferation (OT-I) after 72 hrs co-culture with isolated spleen PDCs. PDCs were either left untreated 
or incubated in the presence of SIINFEKKL peptide, anti-mPDCA-1-F(ab’)2–OVA or OVA-conjugated to irrelevant rat 
F(ab’)2 for 15 hrs. If indicated PDCs receive an additional CpG stimulus (5 µg/ml CpG 1826). After this time period, 
highly pure (>95%) CFSE-labeled CD8+ T cells from OT-I mice were added to PDCs and co-cultured for additional 72 
hours. T cell proliferation was examined by flow cytometry. Dotplots show a representative overview of CD8+ T cell 
proliferation induced by spleen PDCs. 
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Figure 4.3.7. CD8+ T cell proliferation showing the cross-priming capacity of murine PDCs. 
(B) Priming of naive CD8+ T cells by PDCs after targeting with different OVA constructs. To compare the 
efficiency of different OVA targeting constructs PDCs were incubated with titrated amounts of soluble OVA, anti-
mPDCA-1-F(ab’)2-OVA, and isotype control F(ab’)2-OVA before co-culture with CFSE-labeled OVA-transgenic CD8+ 
T cells. Shown is the proliferation after 72h hrs of co-culture (mean and standard deviation of n=1-4). 
(C) Cross-priming capacities of PDCs from different lymphoid organs. PDCs from different lymphoid organs or 
generated in vitro were isolated and incubated in the presence of anti-mPDCA-1-F(ab’)2–OVA and CpG stimulus. 
PDCs were then co-cultured with CD8+ T cells to compare their cross-priming capacities. Scatter diagram shows the 
T cell proliferation after 72 hrs (n=6-9). Values represent mean proliferation of CD8+ T cells after co-culture. 
 
4.3.4.2 Cross-priming capacity of PDC from different lymphoid organs 
By comparing the cross-priming efficiency of PDCs from different lymphoid tissues, Fig. 4.3.7C 
indicates that there were no considerable differences in the capacity of PDCs to induce 
proliferation of naive CD8+ T cells: LN-PDCs induced 63-98% proliferation, PDCs from spleen 
demonstrated 78-99%, PDCs isolated from BM or generated in vitro (FL-PDCs) induced 55-97% 
and 52-95% proliferation, respectively. The mean proliferation ranged between approximately 
85-95%. 
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4.3.5 Receptor blocking elucidates specificity of mPDCA-1–mediated antigen delivery 
for priming of CD4+ and CD8+ T cells 
To show the specificity of antigen-uptake and processing via mPDCA-1, the receptor was 
blocked with excess of unconjugated anti-mPDCA-1 mAb during incubation with anti-mPDCA-1-
F(ab’)2-OVA. CpG-stimulated PDCs were then co-cultured with either CD4+ or CD8+ T cells as 
mentioned before. Fig. 4.3.8A+B shows that blocking the receptor almost abolished the CD4+ T 
cell priming. The mean proliferation was reduced from 71.01% (+/-5.33) to 2.43% (+/-0.51). In 
addition, proliferation of CD8+ T cells induced by anti-mPDCA-1-F(ab’)2-OVA-targeted PDCs 
was markedly inhibited (up to 95%) by blocking the receptor: 83.55% (+/-6.37) vs. 9.43% (+/-
3.16) (Fig. 4.3.8A+B). On the other hand, mPDCA-1 blocking had no effect on the uptake and 
processing of (high doses of) soluble OVA or the presentation of OVA peptide (data not shown), 
indicating that the inhibition of T cell priming after blocking the mPDCA-1 receptor did not 
influence other pathways involved in antigen presentation. 
 
Figure 4.3.8 Receptor blocking abolishes mPDCA-1–mediated priming of both CD4+ and CD8+ T cells. 
PDCs were loaded with anti-mPDCA-1-F(ab’)2-OVA and activated with CpG ODN 1826 before co-culture with OVA-
specific, CFSE-labeled CD4+ or CD8+ T cells as described earlier. To block the receptor, PDCs were incubated with 
excess of unconjugated anti-mPDCA-1 mAb (100 µg/ml) before adding the antigen.   
(A) Representative dotplots give an impression of T cell proliferation after mPDCA-1 mediated antigen-uptake (left 
dotplots) or after blocking the receptor (right dotplots).  
(B) Scatter diagrams summarize the effect of mPDCA-1 receptor blocking on antigen-specific CD4+ or CD8+ T cell 
proliferation. Here, unblocked priming experiments were compared to experiments in which mPDCA-1 was blocked. 
Shown is the relative T cell proliferation. 
 
In summary, these results indicated that mPDCA-1 might serve as a specific antigen uptake 
receptor for PDCs delivering its ligands for both MHC-I and MHC-II presentation. 
 
4.3.6 PDC activation: Up-regulation of co-stimulatory and MHC molecules (maturation) 
The experiments above demonstrated a strong effect of CpG and other TLR agonists on the 
priming capacities of PDCs. The influence of TLR7 and TLR9 triggering on the activation of 
these cells was of particular interest. Therefore, murine PDCs were activated with TLR ligands 
(Loxoribine or numerous CpG oligonucleotides) in vitro. After 24 and 48 hours, respectively, 
CD80 and CD86 expression on PDCs was determined by flow cytometry. Although there were 
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differences in the kinetics, Fig. 4.3.9A demonstrated a strong upregulation of the co-stimulatory 
molecules CD80 and CD86 upon activation in vitro with all CpG ODNs or Loxoribine. 
Administration of anti-CD40 mAb (clone FGK45.5) did not show significant effects in vitro. 
Interestingly, mouse (B type) CpG ODNs 1826 and 1668 as well as Loxoribine gave a slightly 
better impact compared to human CpG ODNs 2006 (B type) and 2216 (A type). In contrast, the 
amount of secreted interferon alpha was comparable between all CpG types (data not shown). 
This activation pattern was also observed by evaluation of further activation indicators (CD69), 
the co-inhibitory marker PD-L1 (also known as B7-H1 or CD274) as well as MHC-I and -II 
molecules, as was evident by Fig. 4.3.9B. 
 
 
 
Figure 4.3.9 In vitro activation and maturation of PDCs.  
(A) Effect of different stimuli on the expression of CD80 and CD86 on PDCs. BM-PDCs were cultured in medium 
alone or in the presence of different stimuli (5 µg/ml CpG, 20 mM Loxoribine, and 25 µg/ml anti-CD40 mAb). Flow 
cytometric analysis was performed 24 and 48 hrs later, respectively. Bar diagram shows the mean fluorescence 
intensity of CD80 and CD86 expression on PDCs, respectively (n=2). 
(B) TLR9 triggering resulted in upregulation of activation markers. Effect of in vitro CpG stimulation on the 
expression of CD40, CD80, CD86, CD69, CD274 (PD-L1), 4-1BBL, as well as MHC class I and II molecules on 
PDCs. Bar diagram demonstrates the relative expression [mean fluorescence intensity] of indicated markers of either 
medium-cultured or CpG-activated PDCs after 24 hrs as obtained by flow cytometric analysis. For co-stimulatory 
molecules and activation markers the y-axis is drawn is logarithmic scale, whereas the expression of MHC molecules 
is displayed linearly. Shown is the mean +/- SEM of n=4. 
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Figure 4.3.9 In vitro activation and maturation of PDCs.  
(C) Purified PDCs are cultured in the absence or presence of a stimulus (5 µg/ml CpG). 105 PDCs/100µl are seeded 
into 96-well culture plates and cultured for 24 hrs. Shown is a representative microscopic survey of untreated PDCs 
and activated PDCs demonstrating cluster formation. 
 
Taken together the stimulation of PDCs with TLR7 and TLR9 ligands resulted in an efficient 
upregulation of common co-stimulatory or co-inhibitory molecules, activation markers and MHC 
molecules, representing an activated state of PDCs. Beside these phenotypical changes also 
morphological modifications were apparent in vitro. In particular, CpG-activation of PDCs 
resulted in a typical “cluster formation” as shown in Fig. 4.3.9C. This phenomenon had also 
been described by Carine Asselin-Paturel for PDCs under inflammatory conditions (unpublished 
observations).  
 
4.3.7 PDC activation: Impact on antigen processing capacity? 
The above data demonstrate that PDCs loaded with OVA peptide or protein can prime naïve 
CD4+ and CD8+ T cells. Referring to the basic necessity of an additional PDC stimulation for 
efficient T cell priming it was still unclear to which degree this activation influenced only the 
upregulation of co-stimulatory molecules (see chapter 4.3.6) or led to an onset of the antigen 
processing and presentation machinery. Surprisingly, if PDCs were loaded exogenously with 
OVA peptide, an extra stimulation had no effect on the presentation capacity of PDCs, as 
demonstrated by identical CD4+ (Fig. 4.3.10A) or CD8+ T cell proliferation (Fig. 4.3.7A+B). A 
possible explanation could be that in this case the upregulation of co-stimulatory molecules was 
irrelevant and the activation influenced (only) the processing pathway.  
Expecting that an additional stimulus would have a significant effect on the priming capacity of 
PDCs at lower peptide concentrations, the following experiment was performed. PDCs were 
loaded with titrated amounts of OVA peptide in the presence or absence of a stimulus before 
co-culture with naïve CD4+ T cells. The results of the T cell proliferation showed that also at 
lower peptide concentrations no differing priming capacity was observed for activated or 
unstimulated PDCs. In general, below a certain threshold of the antigen dose no visible T cell 
proliferation was detected (Fig. 4.3.10B). Thus, the above hypothesis could not be confirmed 
and the impact of an additional PDC stimulation on the antigen processing and presentation or 
T cell priming capacity was still not resolved. 
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Figure 4.3.10 Influence of PDC activation on the T cell priming capacity. 
(A) Influence of additional activation on the peptide presentation of PDCs. Where indicated, isolated PDCs were 
loaded with 5 µg/ml OVA323-339 peptide and optionally received an additional stimulus, as described before. The 
scatter diagram shows T cell proliferation after 72 hrs co-culture with OVA-specific CD4+ T cells. Displayed line 
represents median of T cell proliferation. 
(B) Impact of PDC activation on the peptide presentation capacity as demonstrated by CD4+ T cell priming. To 
analyze if an additional stimulus is required for the presentation of peptides in lower concentrations, PDCs were 
incubated with titrated amounts of OVA323-339 peptide and then co-cultured with naive CD4+ T cells in the absence or 
presence of a CpG stimulus (5 µg/ml). Bar diagram shows the resulting T cell proliferation after 72 hrs. Demonstrated 
is the mean and range of n=3. 
 
At this point the following assumptions were hypothesized: In principle, PDCs were able to 
efficiently present exogenously loaded OVA peptide to T cells, independently of their activation 
status but this activation influenced the processing/presentation of OVA protein. To confirm this 
hypothesis processed OVA should be detected on MHC-I molecules via an anti-H-2kb:SIINFEKL 
specific mAb only if PDCs were activated. This mAb adequately stained SIINFEKL-loaded 
PDCs as shown by FACS analysis in Fig. 4.3.11A (and other dendritic cells; data not shown). 
Interestingly, additional CpG-activation further increased the signal intensity for peptide-loaded 
MHC-I molecules (Fig. 4.3.11B), possibly by upregulation of the MHC expression (Fig. 4.3.9B). 
Further experiments revealed the specificity of the antibody by blocking the staining, and 
demonstrated the detection limit of the antibody, which was about 5-50 ng/ml (Fig. 4.3.11C). In 
contrast, processed OVA was never detected on MHC-I molecules of PDCs and other 
professional APCs, although high (unphysiological) OVA concentrations were used. This may 
reflected the limited sensitivity of the antibody or the low amount of processed SIINFEKL 
sequences (Fig. 4.3.11D and data not shown). 
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Figure 4.3.11 Detection of processed OVA antigen in the context of MHC-I on PDCs.  
(A) Flow cytometric analysis of anti-H-2kb:SIINFEKL mAb staining (clone 25D1). Isolated PDCs from C57BL/6 
mice were cultured in the presence or absence of SIINFEKL peptide (100 ng/ml) and were stained for CD11c 
expression and SIINFEKL peptide in the context of MHC-I molecules on the next day. 
(B) CpG effect on SIINFEKL-MHC-I loading. PDCs were loaded with titrated amounts of SIINFEKL peptide in the 
absence or presence of CpG ODN 1826 [5 µg/ml].  Anti-H-2kb:SIINFEKL staining was performed 24 hrs after loading. 
Graph shows the mean fluorescence intensity of anti-H-2kb:SIINFEKL staining as assessed by flow cytometric 
analysis. 
(C) Blocking of H-2kb:SIINFEKL staining. SIINFEKL-loaded PDCs were stained with anti-H-2kb:SIINFEKL mAb in 
the presence or absence of excess of unconjugated anti-H-2kb:SIINFEKL mAb (cfin=100µg/ml) before flow cytometric 
analysis. 
(D) MHC-I presentation of processed OVA antigen on PDCs. PDCs were cultured for 24 hrs with titrated amounts 
of SIINFEKL peptide, soluble OVA or OVA conjugated to anti-mPDCA-1-F(ab’)2 targeting construct in the presence or 
absence of different stimuli. Bar diagram demonstrates flow cytometric analysis of anti-H-2kb:SIINFEKL stainings on 
PDCs as described before. 
 
Thus, these experiments did not resolved the influence of an additional activation on PDC-
induced T cell priming, and both hypotheses (the requirement of a second signal by co-
stimulatory molecules and the effect on the antigen processing and presentation machinery) 
were still questionable. 
 
4.3.8 Cytokine production of expanded CD4+ T cells after PDC-mediated priming 
Conventional and plasmacytoid DCs differed in their role to initiate adaptive T cell responses. It 
has been shown that PDCs were able to induce proliferation of antigen-specific, naïve CD4+ T 
cells after mPDCA-1 targeting [Sapoznikov A, JEM 2007]. Hereby the T cell priming was 
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associated with generation of cytokine-producing effector (memory) T cells, whereas also 
abortive T cell responses or anergy had been reported [Hawiger D, JEM 2001; Itano AA, Nat 
Immunol 2003; Sporri R, Nat Immunol 2005]. Therefore the cytokine production and polarization 
pattern was investigated after restimulation of effector-memory CD4+ T cells that had been 
initially primed with mPDCA-1-OVA-targeted, CpG-activated PDCs in vitro. TH1-polarized CD4+ 
T helper cells were characterized by the production of TNFα and IFNγ whereas the presence of 
IL-4, IL-5, IL-10, and IL-13-producing cells would suggest a TH2 polarization. 
The appearance of T cells producing IL-2, TNFα, and IFNγ demonstrated that under these 
circumstances mainly a TH1-polarization occurred. The secretion of this characteristic cytokines 
was shown by representative intracellular stainings in Fig. 4.3.12A. No difference between 
PDCs that were loaded with OVA peptide or targeted with anti-mPDCA-1-OVA or isotype control 
mAb conjugated to OVA protein could be detected.  
Few IL-4 producing T cells (TH2) were detected (Fig. 4.3.12B) only if peptide-loaded PDCs (but 
not spleen cells) were used. In contrast, PDCs incubated with the mPDCA-1 targeting construct 
did not induce the generation of IL-4 producing T cells.  
 
Figure 4.3.12 Cytokine profile of restimulated CD4+ T cells after PDC-mediated priming. 
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Figure 4.3.12 Cytokine profile of restimulated CD4+ T cells after PDC-mediated priming. 
CSFE-labeled CD4+ T cells (isolated from OT-II or DO11.10) were primed with (CpG-activated) syngenic PDCs after 
targeting OVA via mPDCA-1 as described earlier. 72 hrs after initial proliferation, T cells were expanded for additional 
seven days in the presence of recombinant human IL-2. One day after removal of IL-2, T cells were restimulated with 
PMA/Ionomcyin for 6 hrs prior to assessment of intracellular cytokine production by flow cytometric analysis. 
Resulting cytokine profiles are representatives of at least three independent experiments. Asterisks indicate that 
priming occurred in the presence of CpG. 
(A) TH1 cytokine profile of PDC- and cDC-primed T cells shown by intracellular staining of IL-2, IFNγ, and TNFα. 
(B) TH2 cytokine profile evaluated by intracellular staining of IL-4 vs. IFNγ after initial priming by PDCs and 
splenocytes.  
(C) Secretion of IL-17 and IFNγ (shown are intracellular stainings) upon PDC-induced priming. 
(D) IL-10 and IFNγ-producing CD4+ T cells were assessed comparing the outcome after PDC- and cDC-induced 
priming. cDCs are represented by CD11chigh cells isolated from spleen. 
 
Among the classical TH1/TH2 polarization, T cells were recently classified into other subsets 
according to the cytokine production and their function. Here, also the presence of IL-17-
producing T cells was evaluated (~7%; see Fig. 4.3.12C), demonstrating the induction of so-
called TH17 cells [Harrington LE, Curr Opinion Immunol 2006]. In general, after PDC-initiated 
priming the majority of resulting CD4+ T cells (50-75%) secrete IFNγ upon restimulation. 
Interestingly, about 10-20% of all CD4+ T cells were IFNγ IL-10 double-positive (Fig. 4.3.12D). 
The generation of these IFNγ+ IL-10+ T cells was preferably induced by PDCs but not cDCs. 
These cells might have a regulatory function. The production of the anti-inflammatory cytokine 
IL-10 is normally restricted to the TH2 linage, but can also be secreted by regulatory T cells 
(such as Treg and Tr1) [Groux H, JI 1997; Asseman C, JEM 1999; de la Rosa M, EJI 2004]. 
 
In summary, these data revealed that after targeting OVA antigen to mPDCA-1, PDCs initiated 
a functional CD4+ T cell immune response dominated by a TH1 phenotype. Beside the classical 
polarization and independent of the route they had acquired the antigen, PDC-mediated T cell 
priming also led to the generation of recently reported TH17 and IL-10+ IFNγ+ cells, which might 
support the role of PDCs in tolerance as well autoimmune diseases. 
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4.3.9 Conclusion 
Although PDCs were believed to link innate and adaptive immune responses by production of 
type I interferon, it remained controversial whether PDCs were in fact able to prime naïve T 
cells. Here the function of the recently described PDC-specific receptor mPDCA-1 investigated 
as well as the potential of PDCs to induce naive CD4+ and CD8+ T cell responses after targeting 
a model antigen (Ovalbumin) to mPDCA-1.   
Targeting of PDC with OVA-conjugated anti-mPDCA-1 mAb, but not with an equivalent amount 
of soluble OVA or OVA conjugated to isotype control antibody, resulted in strong proliferation of 
OVA-specific naïve CD4+ T cells. The same was observed for OVA-specific naïve CD8+ T cells 
showing that PDCs were capable of cross-priming exogenous antigens. Blocking the receptor 
with excess of unconjugated anti-mPDCA-1 mAb inhibited priming of CD4+ and CD8+ T cells. 
These results indicated that mPDCA-1 might serve as an antigen uptake receptor delivering its 
ligands for MHC-I and MHC-II presentation. Interestingly, processing and presentation of 
antigens taken up via mPDCA-1 were strongly dependent on stimulation, since only activated 
but not immature PDC were able to prime naïve antigen-specific T cells. In contrast, antigen 
uptake was independent of activation as unstimulated PDC also internalized the mAb-receptor 
complex.  
These results demonstrated that PDC could take up and process antigens for efficient priming 
of naïve T cells and thus combined innate and adaptive functions. Hereby mPDCA-1 served as 
beneficial antigen-uptake receptor for efficient antigen delivery.  
 
4.4 Heterogeneous Sca-1 expression defines two functional different PDC subsets 
4.4.1 Sca-1 is differentially expressed on PDCs 
Recently it has been reported that PDCs express Sca-1 [O’Keeffe M, JEM 2002]. But neither its 
function in these cells nor any differential expression could be demonstrated. Here it was shown 
that splenic PDCs from BALB/c mice as well as other strains display a heterogeneous 
expression of Sca-1. About 50% of mPDCA-1+ PDCs expressed Sca-1 at a very high level, 
whereas the other PDCs failed to express or expressed intermediate levels of this molecule 
(Fig. 4.4.1A, middle dotplot). 
Also in other lymphoid organs a differential expression of Sca-1 within the PDC population could 
be observed. Interestingly, the proportion of the Sca-1+ subsets showed an organ specific 
variation Fig. 4.4.1A. The frequencies of Sca-1-expressing PDCs in different lymphoid organs 
are summarized in Fig. 4.4.1B. Among organs tested the percentage of Sca-1+ PDCs was 
lowest in BM (10-20%) and increased through peripheral blood (20-25%) and spleen (50%) 
reaching its maximum in LN (70-85%), which could indicate a correlation between Sca-1 
expression and the maturation/activation status of PDCs. Additionally, as shown in Fig. 4.4.1A, 
PDCs expressed Sca-1 at the highest level in all organs tested, when compared to other cells 
analyzed. 
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Fig 4.4.1 Heterogeneous expression of Sca-1 on PDCs. 
(A) PDCs from different lymphoid organs of Balb/c mice were stained for mPDCA-1 and Sca-1. Dotplots demonstrate 
a representative flow cytometric analysis of the differential Sca-1 expression on PDCs within a single cell suspension 
from BM, spleen, and LNs. 
(B) The differential Sca-1 expression on PDCs from different lymphoid organs was further analyzed by flow 
cytometry. The bar diagram demonstrates the percentage of Sca-1+ PDCs within PDCs from different lymphoid 
organs. Shown is the mean and SEM (n≥2, with exception of liver [n=1]). 
 
In current literature there are reports showing homogeneous Sca-1 expression on PDCs 
[O’Keeffe M, JEM 2002]. This could be due to the fact that these studies were performed using 
C57BL/6 mice that are of the Ly-6.2 haplotype. Non-activated splenocytes from Ly-6.2 strains 
including C57BL/6, SJL, Sv129, AKR, and others show higher frequency of Sca-1+ cells 
compared to the Ly-6.1 strains such as BALB/c, C3H, NZB, and DBA [Yang L, JI 2005; Malek 
TR, JEM 1986; Ortega G, JI 1986; Codias EK, Immunogenetics 1989]. The high percentage of 
Sca-1+ PDCs in Ly-6.2+ C57BL/6 mice could induce the authors to the conclusion that the Sca-1 
expression on PDCs in this strain is homogenous. Consequently, the Sca-1 expression pattern 
was investigated in several Ly-6.1 and Ly-6.2 mouse strains. As shown in Fig. 4.4.2, a 
heterogeneous expression of Sca-1 on splenic PDCs was observed in all strains tested. In 
mouse strains that belong to the Ly-6.2 haplotype (AKR/J, C57BL/6 or SV129 mice), the 
majority (75-90%) of PDCs were Sca-1+. In contrast, in several other strains, such as Balb/c and 
FVB a more balanced ratio between Sca-1+ and Sca-1- PDCs (45-65%) was observed. In the 
Ly-6.1+ DBA/1 mice actually the majority of PDCs (~80%) failed to express Sca-1. 
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Fig 4.4.2 Strain-specific expression of Sca-1 on spleen PDCs. 
Spleen PDCs were isolated from different mouse strains and stained for the expression of Sca-1. The bar diagram 
displays the distribution of the Sca-1 expression on PDCs as evaluated by FACS analysis. Shown are mean and 
SEM (n=1-5). 
 
4.4.2 The expression of Sca-1 correlates with the developmental stage of PDCs 
Sca-1 has been previously described as an important indicator for stem cell/progenitor cells and 
is involved in T cell differentiation and proliferation. The initial results indicated that the 
expression of Sca-1 on PDCs could correlate with the maturation status of PDCs, since the 
proportion of Sca-1+ PDCs was lowest in BM and increased in the peripheral tissues reaching 
its maximum in secondary lymphoid organs (see chapter 4.4.1).  
To investigate the regulation of Sca-1 during PDC development, the incorporation of BrdU in 
developing PDCs was tested in vivo. Since PDCs in the periphery are regarded as non-dividing, 
resting cells [O’Keeffe M, JEM 2002], BrdU incorporation was only expected in PDCs newly 
developing from BM progenitors. Mice received intraperitoneal BrdU injections and four days 
later, BM and spleen cells were isolated and intracellular BrdU stainings were performed. Within 
the BrdU- PDCs an equal distribution of Sca-1+ and Sca-1- could be observed. In contrast, within 
the BrdU+ compartment the majority of PDCs (90%) failed to express Sca-1 (Fig. 4.4.3A). For 
BM-PDCs the majority of BrdU+ cells were within the Sca-1- compartment. 
 
Fig 4.4.3 Correlation of Sca-1 expression and PDC proliferation. 
(A). Mice received i.p. BrdU injection. Four days later single cell suspensions of sp leens (left dotplot) and BM (right 
dotplot) were analyzed for BrdU incorporation in PDCs (gated on mPDCA-1+ Sca-1+/-) as revealed by intracellular 
FACS staining. Dotplot gives a representative impression on the distribution of BrdU incorporation and Sca-1 
expression in spleen PDCs. 
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Fig 4.4.3 Correlation of Sca-1 expression and PDC proliferation. 
(B) Mice received a single i.p. BrdU injection (1 mg at day 0) and BrdU was then provided in drinking water until day 
5. From this day on until days 28, PDCs were isolated from indicated lymphoid organs, stained for PDC-specific 
marker mPDCA-1 and Sca-1 as well as intracellular BrdU to determine the BrdU incorporation. Bar diagrams 
represent the percentage of BrdU+ PDCs within both Sca-1+/- subsets, showing the mean and SEM from one 
experiment with two animals per time point based on data from the flow cytometric analysis. 
 
This preliminary experiment indicated that Sca-1- PDCs appear earlier in the development of 
PDCs than the Sca-1+ PDCs. These data also suggested a “developmental transition” of Sca-1– 
PDCs to Sca-1+ PDCs. To verify this hypothesis and to gain more data about the developmental 
processes and the Sca-1 expression a pulse/chase experiment was performed and the 
incorporation of BrdU both within the Sca-1- and Sca-1+ compartment of PDCs was analyzed in 
several lymphoid organs. For this, mice received an initial i.p. administration of BrdU and this 
thymidine analogue was also provided in the drinking water. Five days later, BrdU was removed 
from the drinking water and its incorporation was flow cytometrically assessed in both Sca-1+ 
and Sca-1- PDC subsets. 
As expected, a higher incorporation of BrdU was detected in the Sca-1- PDCs of all organs 
(except blood) in the first phase after removal of BrdU (Fig. 4.4.3B). In particular between days 
0 and 4 after removal, in spleen and LNs the discrepancy of incorporated BrdU between Sca-1+ 
and Sca-1- PDCs was biggest. Here, significantly more Sca-1- than Sca-1+ cells were found in 
BrdU+ PDC compartment. Further differences were observed in the BM, although in this organ 
the BrdU incorporation should be assessed earlier. For blood PDCs an inconsistent, not-
significant effect was detected. In contrast, at later times (between 7 and 15 days after BrdU 
removal) a shift in the proportion for BrdU+ between Sca-1+ and Sca-1- PDCs was detected: 
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Here, the highest BrdU contingent was found in Sca-1+ PDCs. In general, this shift was first 
observed in BM, followed by spleen and LNs suggesting a transition of Sca-1- to Sca-1+ PDCs 
by upregulation of this marker during their post-proliferation phase or at a more mature stage. 
Finally, about 15 days after BrdU removal BrdU+ PDCs from almost all organs disappeared, 
likely due to the restricted life span of PDCs of about 2-3 weeks. Another explanation might be 
that at this time point recently generated PDCs were excluded from the analysis as only BrdU+ 
PDCs were analyzed. 
 
4.4.3 The expression of Sca-1 correlates with the maturation level of PDCs  
The above-described results led to the suggestion that Sca-1 is differentially regulated during 
the life span of PDCs. In the past, Sca-1 was often described to be associated with T cell 
differentiation, but also cell adhesion and signaling [Codias EK, JI 1990; Flood PM, JEM 1990]. 
The Ly-6 family was also involved in regulation and function of T cell activation and thereby 
Sca-1 was expressed at high levels on T cells upon activation, regardless of the Ly-6 haplotype 
[Codias EK, JI 1990; Flood M, JEM 1990; Bamezai A, JI 1995]. Significantly more Sca-1+ PDC 
were detected in LNs compared to the BM, and BM-PDCs were regarded as less differentiated 
or activated. To test whether Sca-1 expression on PDCs correlated with the 
activation/maturation status, PDCs were stimulated with different TLR agonists and the 
expression level of Sca-1 was analyzed by flow cytometry. PDCs were isolated from spleen or 
BM and checked for purity and Sca-1 expression. In a first experiment, PDCs were cultured in 
the presence of CpG and analyzed for Sca-1 expression after 15 hrs. Comparing freshly 
isolated vs. CpG-stimulated PDCs, a strong upregulation of the Sca-1 expression was found 
after in vitro activation (Fig. 4.4.4A). The percentage of Sca-1+ PDCs increased upon stimulation 
from 46% to 93% (spleen PDCs) and from 7% to 42% (BM-PDCs). 
 
Fig 4.4.4 Sca-1 upregulation on PDCs upon TLR-mediated activation. 
(A) Sca-1 upregulation in vitro. PDCs were isolated from spleen (upper dotplots) or BM (lower dotplots) and checked 
for purity and Sca-1 expression. PDCs were then cultured for 15 hrs in the presence of 5 µg/ml CpG and analyzed 
again. Shown is a representative flow cytometric analysis of the Sca-1 expression on PDCs, gated on mPDCA-1+ 
cells. 
RESULTS 
 
 90 
(B) Sca-1 expression on PDCs after in vivo activation with synthetical TLR agonists and CD40 ligation.  
Shown in the upper dotplots is the Sca-1 distribution on B220+ mPDCA-1+ spleen PDCs before and 15 and 40 hrs 
after i.v. administration of 50 µg poly-I:C. In the lower dotplots spleen PDCs were cultured in the absence or presence 
of additional TLR stimuli. 24 hrs after activation with Loxoribine, CpG ODN 1668, or after treatment with 50 µg anti-
CD40 mAb (clone FKG45.5; rat IgG2a). PDCs were isolated, stained with Siglec-H and analyzed for Sca-1 
expression. 
 
Additional in vivo activation by i.v. administration of TLR3 ligand poly-I:C led to a significant 
upregulation of this marker within 15-40 hrs (Fig. 4.4.4B). After activation, almost all spleen 
PDCs were positive for Sca-1 and also the absolute expression level increased (indicated by 
staining intensity, Fig. 4.4.4B). This effect was also consistent in other organs tested, like BM, 
LNs, and liver (data not shown).  
When activated with anti-CD40 mAb or other types of CpG ODNs an upregulation of Sca-1 
expression could be observed as well (>90% of all spleen PDCs expressed Sca-1). Of all stimuli 
tested, only the TLR7 agonist Loxoribine showed a poor capacity to induce upregulation of Sca-
1 expression on PDCs (Fig. 4.4.4B). In general, these in vitro and in vivo results clearly 
demonstrated that PDCs upregulate the expression of Sca-1 upon activation and this molecule 
could serve as a sensitive marker for the activation status of murine PDCs.   
In a transfer experiment it was investigated whether Sca-1+ PDCs develop directly from the Sca-
1- subset. For this, Sca-1- PDCs isolated from spleen or BM were administrated i.v. into a 
second mouse. Transferred spleen PDCs that were detected 24 hrs later in both spleen and 
liver, predominantly upregulated this marker (approx. 75-90% of grafted PDCs were Sca-1+; Fig. 
4.4.5A+B). Not only the frequencies of Sca-1+ PDCs increased (Fig. 4.4.5B, left bar diagram), 
also the expression level of Sca-1 on grafted PDCs was upregulated in contrast to host PDCs 
(Fig. 4.4.5B, right bar diagram, and data not shown). Although there were no differences in the 
frequency, a significant dissimilarity in the expression level between grafted PDCs found in 
spleen or liver was demonstrated, possibly suggesting an influence of the organ environment. 
No variation was found comparing the origin of transferred PDCs, either derived from spleen or 
BM.  
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Fig 4.4.5 Upregulation of Sca-1 expression on transferred PDCs. 
(A) The dotplots give an impression of the isolation, labeling, and transfer process of PDCs within this experiment. 
PDCs were untouched isolated from spleen (93% purity) and subsequently labeled with a cell tracker (PKH67, 
Sigma). Flow cytometric analysis reveals the Sca-1 distribution before and 24 hrs after i.v. administration. The Sca-1 
distribution was then assessed only on transferred mPDCA-1+ pKH67+ PDCs (red gate). One representative 
experiment out of two is shown.  
(B) Bar diagram demonstrates expression of Sca-1 on PDCs before and 24 hrs after transfer as revealed by flow 
cytometric analysis. Shown is the mean frequency of Sca-1+ PDCs +/- SD of n=1-3 and the mean fluorescence 
intensity of Sca-1 expression. 
 
In summary these results demonstrated an evidence for the development of Sca-1+ PDCs from 
the Sca-1- type. 
 
Sca-1 was also described as an activation marker for T cells. Thus, a possible co-expression of 
Sca-1 and co-stimulatory molecules was investigated on PDCs in steady state or after 
activation. As demonstrated in Fig. 4.4.6, about 50% of spleen PDCs expressed Sca-1 but were 
negative for CD40, CD80 and CD86. A correlation of the few PDCs stained positive for the co-
stimulatory molecules (<5%) with Sca-1 expression was not observed in inactivated PDCs. After 
CpG activation only Sca-1+ PDCs were detected and almost all cells were also positive for CD40 
and CD86. The majority of PDCs (>80%) also expressed CD80. The co-expression of Sca-1 
with these common maturation markers implicated that the differential Sca-1 expression may 
describe two activation or developmental stages of PDCs. Whether the heterogeneous Sca-1 
expression further represent functional differences of the subpopulations, e.g. by differential 
cytokine secretion, will be tested later on.  
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Fig 4.4.6 Expression of co-stimulatory molecules in correlation with Sca-1 expression in both steady state 
and after CpG-activation. Isolated spleen PDCs were gated on the basis of Siglec-H expression and analyzed for 
Sca-1 expression in correlation with indicated markers. Shown are representative dotplots from the flow cytometric 
analysis of freshly isolated PDCs or 24 hrs after culture in the presence of 5 µg/ml CpG 1668. 
 
To gain further insights into the transcriptional profile of these PDC subsets, FACS-sorted Sca-
1- and Sca-1+ PDCs (Fig. 4.4.7A) were compared on PIQOR microarray chips. To this end 
mRNA was isolated from both PDC subsets (both from LNs and spleen), amplified, and 
hybridized to the “PIQOR Mouse Immunology” chip, which comprises more than 1,000 immuno-
relevant genes, that are spotted in quadruplicates. The microarrays were analyzed in analogy to 
the gene expression analysis described for the identification of mPDCA-1. 
 
 
Fig 4.4.7 Differential Gene regulation of Sca-1+ and Sca-1- PDCs.   
(A) PDCs were enriched from Balb/c spleen or LNs (data not shown), sorted into mPDCA-1+ Sca-1+ and mPDCA-1+ 
Sca-1- subsets (red squares; FACS Vantage) for subsequent PIQOR micro array analysis (as described in the 
Materials and Methods section). Amplified and labeled RNA was hybridized onto PIQOR Mouse Immunology chips 
(according to manufacturer's protocol).  
(B) Representative double-log scatter plot of the micro array analysis of Sca-1+ and Sca-1- PDCs (PIQOR Mouse 
Immunology microarray) demonstrates the signal intensities of all detected genes that pass quality control in a single 
spot. On the x-axis the signal intensity detected in the Cy3 channel is depicted, whereas the y-axis demonstrates Cy5 
signal intensity. Diagonals define the area of x-fold differential signal intensity. 
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A representative distribution of the signal intensities is shown in Fig. 4.4.7B and in the following 
table an overview of highly upregulated genes is listed, which demonstrated a signal intensity 
more than 3.5-fold higher compared to the background level and was present at least on 3 of 4 
micro arrays (see Table 4.4.1A+B). 
Tab. 4.4.1 A: Genes that are predominantly regulated on Sca-1- PDCs  
 
 
Tab. 4.4.1 B: Genes that are predominantly regulated on Sca-1+ PDCs 
 
 
In detail, genes significantly (> two-fold) over-represented in Sca-1- PDCs were e.g. IRF-5, 
RABGAP1, BCL, TRAIP, but also CD22 and CD163 as cell surface markers. In total about 30 
genes were preferentially expressed in this PDC subset and the distribution of the differential 
gene regulation in each microarray is demonstrated in Fig. 4.4.7C. On the other hand in Sca-1+ 
PDCs EGR1, OACT5, NFX1, PROCR, IPLA2, STAM2, and EDEM1 showed a more than 10-
fold higher expression, and also TNFR1, CD44, CD69, CD84 and MAP kinases 6 and 9 were 
significantly upregulated on mRNA level. Here, almost 100 genes were significantly over-
represented in Sca-1+ PDCs compared to Sca-1- PDCs (Fig. 4.4.7D). The complete list 
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containing the raw data +/s SD of all 1,070 genes regulated in all four hybridization settings is 
shown in the appendix (Table 7.2). 
 
 
Fig 4.4.7 Differential Gene regulation of Sca-1+ and Sca-1- PDCs.   
(C, D) The raw data of the microarray were  analyzed via MEV TIGR software. The table show an overview of the 
expression of genes that are predominantly regulated on Sca-1- PDCs (C) or Sca-1+ PDCs (D). Hereby only genes 
are considered that are at least 2-fold regulated and are present at least on 3 of 4 microarrays. Colors represent an 
over-represented (increased) expression (red), repressed expression (green), unaltered gene expression (black). 
Gray colors are used if no signal was detected. 
 
In Fig. 4.4.7E the regulated genes were clustered ontologenically. The four bar diagrams show 
the over-representation of several genes belonging to different ontology clusters (GOC). In 
general there were more genes derived from the Sca-1+ PDC compartment, which in particular 
belonged to the Toll/cytokine receptor or NF-κB pathways. Comparing the GOC of differentially 
regulated genes from both subsets directly demonstrated that significantly more regulated 
genes in Sca-1+ PDCs were represented in all pathways. Relative comparison (percentaged 
analysis) showed that the distribution of regulated genes was very similar but not identical 
between indicated GOC pathways. For example, genes belonging to cellular behavior, 
immunity, inflammation, Toll/cytokine receptor, NF-κB, and other signaling pathways were more 
represented in Sca-1+ PDCs, whereas more molecules that are involved in adhesion/migration, 
immune reactions and in particular in metabolic pathways were enabled in the Sca-1- 
subpopulation. 
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Fig 4.4.7 Differential Gene regulation of Sca-1+ and Sca-1- PDCs.   
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Fig 4.4.7 Differential Gene regulation of Sca-1+ and Sca-1- PDCs.   
(E) Gene ontology clustering. Gene ontology analysis was carried out after gene annotation (MIGO terms, GOA 
based extended) to verified pathways (Annotate, Miltenyi Biotec, unpublished). 
 
At this point further experiments were necessary to assign the results of the differentially 
regulated genes in the context of developmental differences between Sca-1+ and Sca-1- PDCs 
or their activation status. Additionally, these data might explain the functional properties 
reported in the next chapter. 
 
4.4.4 Correlation of the different Sca-1 expression with the cytokine production capacity  
   of PDCs 
Since PDCs were regarded as the major IFNα producers, a functional correlation of the Sca-1 
expression and their capacity to produce IFNα (and also other cytokines, e.g. IL-12 or TNFα) 
was assessed. In the past, differences in the IFN-I production of PDCs have been described. 
Krug et al. demonstrated that mature PDCs produced decreased amounts of IFNα after CpG 
induction [Krug A, EJI 2001]. In addition there were reports demonstrating that the capacity to 
produce IFN-I is restricted to immature PDCs and there is a functional dichotomy between 
IFNα-producing PDCs and PDCs inducing an adaptive immune response [Jaehn PS, EJI 2008; 
Iparraguirre A, J Leukoc Biol. 2008]. These data and the results obtained in the previous 
chapters led to the suggestion that Sca-1+ PDCs were more mature and were of a more 
differentiated stage. Thus, it was speculated that LN-resident Sca-1+ PDCs have a stronger T 
cell-stimulatory ability and produce less IFN-I compared to Sca-1- PDCs from the BM and vice 
versa. To test this assumption, untouched isolated spleen or BM-PDCs were cultured for 6 hrs 
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with CpG and/or Loxoribine in order to induce IFNα production, followed by intracellular 
staining. Flow cytometric analysis (Fig. 4.4.8A, dotplots) revealed that the majority of IFNα-
producing PDC belonged to the Sca-1- compartment indicating a functional difference between 
both PDC subpopulations. As shown by the staining intensity, BM-PDC produced higher per 
cell-amounts of IFNα when compared to spleen derived PDC. LN-derived PDCs were only weak 
producers (data not shown). Additionally, the IFNα production was also analyzed by specific 
ELISA. Untouched isolated PDCs as well as PDCs, which were additionally depleted of Sca-1+ 
cells, were cultured in the presence of CpG. After 24 hrs culture supernatants were harvested 
and examined for IFNα. PDCs, which have been previously depleted for Sca-1+ cells produced 
10-fold higher amounts of IFNα upon CpG stimulation, supporting flow cytometric data obtained 
from intracellular IFNα stainings (Fig. 4.4.8A lower bar diagram). Analysis of the IFNα secretion 
capacity of PDC isolated from different lymphoid organs further underlined this observation 
showing a clear correlation between produced IFNα amount and the percentage of Sca-1+ cells 
within the PDC compartment. BM-PDCs demonstrated a superior capacity to produce IFNα 
compared to PDCs from spleen, whereas LN-PDCs produce almost no visible IFNα (Fig. 4.4.8A 
upper bar diagram). 
 
Fig 4.4.8 Functional correlation of the Sca-1 expression and cytokine production capacity of PDCs. 
To assess cytokine secretion, PDCs were isolated from indicated lymphoid organs and cultured in the absence or 
presence of TLR agonists for 7 hrs (intracellular stainings) or 24 hrs (ELISA). CpG and Loxoribine were used at a 
final concentration of 5 µg/ml and 20 mM, respectively. To prevent secretion in case of intracellular staining, 
BrefeldinA was added in the last 4 hrs. 
(A) IFNα production was assed by intracellular staining of BM or splenic PDCs (dotplots).  
For ELISA PDCs were either isolated from different lymphoid organs (upper bar diagram) or spleen PDCs were used, 
which were either left untreated (representing a mixed Sca-1+/- populations) or were separated into Sca-1- PDCs 
(lower bar diagram). Here, inserted dotplots demonstrate the Sca-1 expression of used PDC subsets. Supernatants 
of unstimulated or CpG-activated PDCs were collected after 24 hrs and analyzed by IFNα-specific ELISA (PBL). 
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Fig 4.4.8 Functional correlation of the Sca-1 expression and cytokine production capacity of PDCs. 
(B) Dotplots demonstrate cytokine production in correlation to Sca-1 expression in isolated PDCs. Shown are 
representative intracellular stainings for IL-12 and TNFα production in untreated or TLR-triggered PDCs.  
 
Beside the differences in their IFNα production, the two Sca-1+/- PDC subsets differed also in 
their capacity to produce TNFα and IL-12 when stimulated with TLR7 ligand Loxoribine (Fig. 
4.4.8B). Interestingly, when stimulated with TLR9 ligand CpG, both TNFα and IL-12 were 
produced at significantly lower level and there was no difference between Sca-1+ and Sca-1- 
subset. 
 
In summary, the differential expression of Sca-1 on PDCs was in line with functional 
heterogeneity and might define two functional different subsets of PDC in mice.  
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5. DISCUSSION  
An effective immune response is based on the co-operation of a variety of distinct cell types that 
are appointed with different characteristics and properties. These cell types can be assigned 
either to the innate or the adaptive arm of immunity, but for some cell populations a fix 
assignment is not suitable, as they are known to function in the linkage or synchronization of 
both immune responses. In this context, PDCs are regarded to bridge innate and adaptive 
immunity, but it still remains unclear whether PDCs are able to initiate adaptive immune 
responses in an antigen-specific manner.  
To gain more insight into the complex interactions of PDCs a specifically expressed cell surface 
antigen should be identified and characterized, since molecules uniquely expressed by a single 
cell type often contribute to the specific function of these cells. At the beginning a panel of mAbs 
that all recognized murine PDCs was generated. After identification of the molecular nature of 
the novel antigen, further studies of the molecule were performed including the investigation of 
cytokine secretion or signaling. Functional characterization revealed a function of mPDCA-1 as 
an antigen-uptake receptor and demonstrated the role of PDCs in the interaction with naïve T 
cells. Finally, the heterogeneity and plasticity of PDCs are exemplified by the differential 
expression of Sca-1 on PDCs.  
 
5.1 Generation of PDC-specific monoclonal antibodies and phenotyping of mPDCA-1+ 
cells 
There are several techniques to identify specifically expressed genes. The generation of a mAb 
against PDCs provides the advantage for the identification of the detected antigen and the 
isolation of cells expressing this specific molecule. Furthermore, antigens could be cloned from 
a cDNA library followed by FACS analysis with a specific antibody [Zhang J, Blood 2006; 
Dzionek A, JEM 2001; Blasius A, JI 2006]. Other methods, including “Subtractive Hybridization” 
or “Differential Display”, only allow the identification of specifically transcribed genes but gain no 
information on the expression on protein level. These methods were less applicable for 
selectively expressed cell surface markers. Thus, the first aim of the work was the generation of 
a mAb against a PDC-expressed cell surface molecule. Unfortunately, the immune reaction 
against a specific molecule could interfere with the response against immuno-dominant 
antigens. In this study the recently described “contralateral footpad immunization method” was 
used to direct the immune reaction towards PDC-specific antigens [Brooks, PC, Journal of Cell 
Biology, 1993; Yin, AH, Blood 1997]. This technique is based on the fact that naïve B and T 
cells circulate through peripheral lymphoid organs until they detect an antigen [Breadly LM, 
Curr. Opin. Immunol 1996; Butcher EC, Science 1996; Picker LJ, Annu. Rev. Immunol 1992; 
Watson SR, Cell. Adhes. Commun 1998]. Upon recognition and additional activation these 
lymphocytes accumulate and arrest in the draining lymph node next to the site of infection 
[Jacob J, JEM 1992; Kearney ER, Immunity 1994; Ridderstad A, JI 1998; Tarlinton D, Curr. 
Opin.Immunol. 1998]. Thus, by the local administration of an antigen, B and T cells would be 
“trapped” in the draining lymph node. These specific lymphocytes were then depleted from the 
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periphery and a form of “local tolerance” against the administrated antigen would be induced. In 
this work, murine Sp2/0 cells or isolated NK cells were injected as decoy into the one hind 
footpad before inoculation with purified PDCs into the other. These decoy cells express a 
variety of strongly immunogenic antigens. Highly immunogenic antigens are e.g. MHC-II 
molecules. Thus, Sp2/0 cells were chosen for this reason. By the spatiotemporal separation an 
immune reaction against non-specifically expressed antigens was restricted to the one site. The 
other lymph node was expected to contain lymphocytes (B cells) specific for a PDC expressed 
molecule and finally four specific mAbs were obtained by repetitive immunizations. The clones 
JF-1C2, -3D5, -7B3, and -12A5 specifically detect PDCs in single cell suspensions of spleen 
and other lymphoid organs. The anti-mPDCA-1 mAbs does not cross-react with human PDCs 
(data not shown). Thus, the unknown antigen was termed “Murine plasmacytoid Dendritic Cell 
Antigen 1”. In the past this technique has been used to generate mAbs specifically recognizing 
human DC subsets [Dzionek A, JI 2000], whereas other PDC-detecting antibodies were 
generated differently by intraperitoneal or subcutaneous inoculation of PDCs [Asselin-Paturel C, 
JI 2003; Blasius A, Blood 2004] or cloned Fc-fusion proteins [Zhang J, Blood 2006], followed by 
screening on spleen cells, PBMC or transfected cell lines. In contrast to the utilized method, in 
other strategies a decoy was not applied, possibly leading to an increased amount of unspecific 
mAbs.  
These data demonstrate that contralateral footpad immunization is a reliable method for the 
generation of specific antibodies against cellular antigens without availability of the antigen. The 
local tolerance induced by this procedure might be beneficial for less immunogenic antigens. In 
contrast to other methods described above the obtained antibodies also facilitate the 
characterization of the novel molecule on protein level. 
 
Flow cytometric analysis revealed that mPDCA-1+ cells express no markers for lineage 
commitment, i.e. are negative for CD11b, CD19, CD49b, and CD138, and do not express the 
TCR. On the other hand, these cells express B220 and Ly-6C and display intermediate 
expression levels of CD11c. CD4 and CD8 were moderately expressed, whereas co-stimulatory 
molecules CD40, CD80, and CD86 were absent. MHC-II, typically expressed by APCs and 
DCs, is found at intermediate levels on mPDCA-1+ cells. The co-expression of B220, Ly-6C, 
CD11c and MHC-II as well as the absence of co-stimulatory molecules and lineage markers 
was shown to be characteristic for murine PDCs [Nakano H, JEM 2001; Asselin-Paturel C, Nat 
Immunol 2001; Björck P, Blood 2001]. Thus, mPDCA-1+ cells are phenotypically identical to 
PDCs. Multi-color FACS analysis demonstrated that the anti-mPDCA-1 mAb detects PDCs but 
does not react with other cells. This has been shown for PDCs in spleen and also in other 
lymphoid organs, including BM, liver, lung, thymus, peripheral and mesenterial LNs as well as 
Peyer’s Patches. Interestingly, the expression level of mPDCA-1 is not identical on all PDCs. It 
was shown to be highest on PDCs located in secondary lymphoid organs, such as spleen or 
LNs, but it is significantly lower expressed on BM-PDCs. This implicates that mPDCA-1 is 
upregulated during the development, as immature PDCs exist in the BM developing from CD34+ 
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DC progenitors [Banchereau J, Nature 1998; Kreisel FH, Cell Immunol 2006; Toma-Hirano M, 
EJI 2007]. A similar regulation was observed for other PDC markers, including Ly-49Q, Sca-1, 
or Siglec-H [Toyama-Sorimachi N, JI 2005; Blasius A, Blood 04]. 
The frequency of mPDCA-1+ cells in different lymphoid organs varies between 0.2% to 0.5% in 
LNs, about 0.3% to 0.8% in spleen, about 0.9% to 1.5% in BM. Thereby, the frequency and 
phenotype of PDCs were identical using either the mPDAC-1 mAb or a characterization based 
on CD11c, B220, and Ly-6C. In the meantime the data presented here regarding the frequency, 
phenotype and characterization of PDCs had been reproduced by other groups [Wendland M, 
PNAS 2007; Ohbayashi M, Exp Mol Pathol. 2007; Zucchini N, Int Immunol. 2008; Sung SS, JI 
2006]. Not only phenotypically but also functionally mPDCA-1+ cells resemble PDCs in vitro and 
in vivo. It was further shown that mPDCA-1+ cells were the main producers of type I interferon 
compared to mPDCA-1- cDCs. In these experiments, isolated DCs were stimulated with CpG 
ODNs in vitro. IFNα-specific ELISA revealed that mPDCA-1+ cells but not the mPDCA-1- subset 
produced significantly amounts of IFNα. Moreover, PDCs were also the major IFN-I producers 
in vivo as the depletion of mPDCA-1+ cells resulted in drastic reduction of virally or CpG-
induced IFN-I production [Krug A, Immunity 2004; Barchet W, EJI 2005; Schleicher U, JEM 
2007]. The administration of antibodies to deplete specific cell populations in vivo has been 
established previously [Fleming T, JI 1993]. As a F(ab’)2 fragment of the anti-mPDCA-1 mAb did 
not induce depletion of PDCs, the depletion by application of the complete mAb might be 
caused by activation of either the classical complement pathway or by antibody-dependent cell-
mediated cytotoxicity (ADCC) [Tao MH, JEM 1993; Xu Y, J Biol Chem. 1994; Golay J, Blood 
2000; Di Gaetano N, JI 2003].  
Recently, other groups also developed antibodies that recognize PDCs specifically. In the 
laboratories of Marco Colonna and Paul Crocker antibodies were produced (clones “440c” and 
“MB15”, respectively) reacting with the Sialic acid binding Ig-like lectin H (Siglec-H), which is 
also specifically expressed on murine PDCs [Blasius A, Blood 2004 and Blood 2006; Zhang J, 
Blood 2006]. Multi-color FACS analysis revealed that mPDCA-1 and Siglec-H were co-
expressed on PDCs. Blocking experiments showed that mPDCA-1 is not identical to the Siglec-
H antigen (data not shown). The group of Giorgio Trinchieri generated the 120G8 mAb [Asselin-
Paturel C, JI 2003] also reacting with an unknown antigen expressed on PDCs. Competitive 
inhibition experiments revealed that the staining of 120G8 could be completely blocked by the 
clone JF-1C2 and vice versa. Interestingly, other clones, such as JF-3D5 did not inhibit this 
staining. These blocking data suggested that the clones 120G8 and 1C2 reacted with identical 
epitopes or adjacent epitopes that were blocked by steric hindrance. Cross-blocking 
experiments with all four clones generated in the work presented here showed the existence of 
at least three different epitopes of the same antigen. One epitope is detected by the 1C2 clone 
but not by the others, whereas clones 3D5 and 12A5 recognize the same epitope. Blocking 
studies with clone 7B3 at least partially inhibited the staining of the other three clones. Further 
studies might be necessary to resolve the exact peptide sequence or epitope formation 
recognized by these antibodies including epitope mapping experiments or generation of 
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transfected cells after identification of the antigen. 
The anti-mPDCA-1 mAb was also used by our collaboration partners and other research groups 
for the identification of PDCs in flow cytometric analyses or immuno-histochemical stainings, 
and their findings supported the data reported in this work [Zucchini N, Int Immunol. 2008; Chan 
CW. Nat Med 2006; Taieb J, Nat Med 2006; Vosshenrich CAJ, JEM 2007; Caminschi I, JEM 
2007; Blasius AL, JEM 2007; Weslow-Schmidt JL, J Virol 2007].  
 
In this work the generation and application of a novel antibody was described that is highly 
specific for murine PDCs. Using the anti-mPDCA-1 mAb, PDCs can now be identified by single 
parameter analysis reducing the number of required markers (B220, Ly-6C, and CD11c) from 
three to one [Nakano H, JEM 2001; Asselin-Paturel C, Nat Immunol 2001; Björck P, Blood 
2001].  
 
5.2 Identification and functional characterization of mPDCA-1  
Several biochemical methods were performed to identify the molecular nature of the novel 
antigen. Western blotting and immune-precipitation experiments were carried out first, followed 
by peptide mass fingerprint analysis to discover the amino acid sequence. These techniques did 
not result in the identification of mPDCA-1, probably due to a lower affinity of the generated 
mAbs to the solubilized antigen or due to a masked epitope. Another reason might be the 
existence of a linear epitope, which could not be recognized by the antibody after denaturation. 
Limited number of PDCs further hampered these experiments. As the expression of mPDCA-1 
was transiently induced by IFNα treatment on several cell lines, mPDCA-1 should be identified 
by differential gene expression analysis.  
The main idea was that whole genome microarray analysis often resulted in a considerable 
quantity of regulated gene candidates. Using Agilent microarrays, mPDCA-1- cell lines were 
compared with IFNα-induced mPDCA-1+ cells or isolated PDCs. It was possible that beside the 
mPDCA-1 candidate also other genes such as IFN-I-responsive genes or other irrelevant genes 
would be regulated [Der SD, PNAS 1998; Baechler EC, PNAS 2003]. To create an intersection 
as little as possible mPDCA-1+ cells were also hybridized against cells that had downregulated 
mPDCA-1. Resulting candidates were further investigated by comparing the mRNA transcription 
levels in PDCs and T cells as well as in other hematopoietic cell types. Looking for a cell surface 
molecule, the mPDCA-1 candidate should contain a TMD and its expression should not be 
described on other cells. Microarray analysis and validation by real time PCR impressively 
showed that several transcripts were highly upregulated in PDCs. As the specific antibody was 
the only tool to identify the mPDCA-1 antigen, in the next step cell lines were transfected with 
the cDNAs of corresponding gene candidates. Flow cytometric analysis revealed that only cell 
lines transfected with the coding sequence of BST2 were specifically recognized by the anti-
mPDCA-1 mAb. All four anti-mPDCA-1 clones detected human and rat cell lines transfected 
with BST2 but not mock transfectants or cells expressing other regulated gene candidates, e.g. 
MPG1. The anti-mPDCA-1 mAb was also ideal for the enrichment of BST2-transfected cells. 
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The results of this work were supported at the same time by the group of Marco Colonna, 
performing gene expression cloning using a PDC-specific cDNA library [Blasius A, JI 2006]. The 
transfectants of both groups were specifically detected by the anti-mPDCA-1 antibody JF05-
1C2, although they generated a BST2 transfectant comprised of a different ORF and Start 
codon, suggesting a potential splice variant with a truncated N-terminal cytoplasmatic tail 
[Blasius A, JI 2006]. Taken together, BST2 has been confirmed as the antigen recognized by 
anti-mPDCA-1 antibodies. As BST2 is not a novel molecule, different names were given to this 
antigen: beside mPDCA-1 and BST2, the molecule has been named DAMP-1, HM1.24 or 
120G8 antigen and was designated as CD317 [Asselin-Paurel, JI 2003, Blasius A, JI 2006; Li X, 
Mol. Biol. Cell 2007; Vidal-Laliena A, Cellular Immunology 2005 (submitted to the 8th HLDA 
workshop)]. Since mPDCA-1 was established in PDC research, this term will be used in the 
following. 
 
The mPDCA-1 transcript codes for a small type II transmembrane glycoprotein of about 25-30 
kDa size, depending on the kind of glycosylation [Kupzig S, Traffic 2003; Ishikawa J, Genomics 
1995; Neil SJD, Nature 2008]. These data were in line with the prediction of two TMDs for 
mPDCA-1, based on statistical analysis of naturally occurring transmembrane proteins using the 
TMPred software [Hofmann K, Biol. Chem. Hoppe-Seyler 1993]. BST2 contains a conventional 
TMD near the N-terminus and a C-terminal signal sequence for a GPI anchor as well as two 
additional N-linked glycosylation sites at the extracellular domain [Kupzig S, Traffic 2006]. The 
suggested GPI anchor might explain the difficulty to immuno-precipitate the mPDCA-1 molecule 
from PDC lysates or membrane fractions. This was supported by the observation that only a 
specific Phospholipase C (PI-PLC) cleavage released the molecule out of the lipid rafts of the 
plasma membrane. Only after this treatment BST2 could be solubilized via Triton-X detergent 
[Kupzig S, Traffic 2003]. Thus, for successful immuno-precipitation of mPDCA-1 from PDCs a 
PI-PLC treatment should be tested before the application of different. Fig. 5.1 shows a model of 
the structure of the mPDCA-1/BST2 protein and its topology. 
 
Fig. 5.1 Predicted protein structure of the mPDCA-1/BST2 molecule. 
This model is based on data taken from Kupzig et al., Traffic 2003; Blasius et al., JI 2006; Rollason et al., J Cell Sci. 
2007; Ohtomo et al., Biochem Biophys Res Commun 1999; Ge et al., Blood 2006. Legend: Y: tyrosine; P: proline; M: 
methionine; K: lysine; x: any amino acid. 
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The remarkable topology of mPDCA-1 is similar to the neuropathologic form of the Prion protein 
[Hedge R, Science 1998; Hedge RS, Nature 1999], although no significant sequence homology 
was demonstrated. Based on the amino acid sequence mPDCA-1 shares homologies with the 
integral BAP31 protein of the endoplasmic reticulum, which has a chaperone-like or cargo 
receptor function and might regulate apoptosis [Hidvegi T, J Biol Chemistry 2007; Blasius A, JI 
2006; Wang B, Molecular and Cellular Biology 2004]. mPDCA-1 contains two N-terminal 
transport signals, (1) “Y-x-Y-x-x-x-P-M“ and (2) ”KKxx“ [Van Vliet C, Prog. Biophys. Mol. Biol. 
2003]. These motifs are supposed to sort proteins into secretory and endocytic pathways. This 
might enable a role of mPDCA-1 in cytokine secretion (in particular of IFN-I) or a potential 
function in the endocytosis of antigens for processing and presentation [Kaczorowski DJ, J 
Leuko Biol 2008; Blasius A, JI 2006]. Additionally, it has been shown that mPDCA-1 was closely 
connected to the Golgi apparatus and the trans-Golgi network [Blasius A, JI 2006, Kupzig S, 
Traffic 2003]. This and the localization within lipid rafts of the plasma membrane may give 
mPDCA-1 a function both in trafficking, signaling or protein sorting [Kupzig S, Traffic 2003].  
mPDCA-1 and its rat, monkey or human homologues had been already described in the past 
[Ohtomo T, Biochecm Biophys Res Comm 1999]. It was reported that human BST2 is 
expressed within the B cell linage (terminally differentiated B and plasma cells) and on several 
non-hematopoietic cell lines, and a function in B cell differentiation and growth of pre-B cells 
was speculated [Ishikawa J, Genomics 1995]. BST2 was also found on multiple myeloma cells, 
neoplastic B cells and on rheumatoid arthritis synovial cell lines [Goto T, Blood 1994; Ohtomo T, 
Biochecm Biophys Res Comm 1999; Ozaki S, Blood 1999], but the function on these cells 
remained unknown. Currently, the therapeutic application of this antibody in order to induce an 
ADCC response against BST2-expressing tumors is under investigation [Ozaki S, Blood 1999].  
 
It was demonstrated that mPDCA-1 is specifically expressed on PDCs of naïve mice. The 
expression was rapidly induced on other hematopoietic cells and cell lines upon TLR9 triggering 
or IFNα treatment as was shown by results of this work and by others [Asselin-Paturel C, JI 
2003; Blasius A, JI 2006, Bochtler P, JI 2008]. The IFNα-dependent upregulation of mPDCA-1 
might depend on the Interferon-stimulated response elements (ISRE) in the promoter region of 
BST2 as reported by Ohtomo et al. and Ge et al. Binding of IFN-I resulted in the activation of 
the JNK pathway. Beside three STAT3 DNA-binding sites the promoter contained further motifs, 
such as GATA1 binding elements, which also have an important role in BST2 transcription 
[Ohtomo T, Biochem Biophys Res Commun 1999; Ge Y, Blood 2006; Becker M, Mol Cancer 
Ther 2005; Matsuda A, Oncogene 2003]. mPDCA-1 was transiently upregulated on other 
hematopoietic cells and different cell lines, but the expression level was lower compared to 
PDCs. The data presented in this work demonstrated that PDCs showed highest expression 
levels of mPDCA-1, which remained unchanged under IFN-inducible conditions as reported 
elsewhere [Blasius A, JI 06]. It is speculative whether the strong but constant expression of 
mPDCA-1 on PDCs might be due to either an autocrine IFN-I secretion loop or was differently 
regulated in these cells. The function of upregulated mPDCA-1 on other cells than PDCs still 
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remains elusive, and further experiments are necessary. Very recently different groups have 
analyzed the role of human BST2. Cao et al. showed that BST2 might be the natural ligand for 
ILT7, another receptor expressed on human PDCs (Cao W, EB 2008, San Diego; The FASEB 
Journal 2008;22:1065.17; unpublished data). It might be of interest, whether mPDCA-1 also 
interacts with the murine ILT7 homologue. Further studies exploring the molecular nature, 
source or localization of a potential ligand might implicate the exact function of mPDCA-1 in 
PDCs. Recent data regarding the function of BST2 have been generated by studying cell lines 
or other BST2-expressing cells different from PDCs. In this context, the generation of a 
mPDCA-1 knockout mouse would be promising either to study the precise function of the 
molecule or the role of PDCs in general. Such a system would be superior to the existing Ikaros 
knockout mouse (Ik(L/L)) [Allman D, Blood 2006]. These mice lack peripheral PDCs but not BM-
PDCs. However, PDCs from these transgenic mice expressed lower levels of CD11c and were 
negative for B220 and Ly49Q. As these mice also showed reduced B cell numbers [Iparraguirre 
A, J Leukoc Biol. 2008] a system would be desirable in which only mPDCA-1 is silenced and not 
a transcription factor potentially affecting the lymphoid linage [Kirstetter P, EJI 2002]. As the 
knockout of mPDCA-1 would probably not affect the development of PDCs, the expression of a 
toxin, e.g. diphtheria toxin, under the mPDCA-1 promoter would be more applicable to deplete 
PDCs in vivo. [Jung S, Immunity 2002]. 
 
IFN-I production is the prominent function of PDCs and plays a role in both viral infections and 
some autoimmune diseases (SLE, psoriasis). Consequently, the impact of receptor triggering 
on important PDC functions was investigated in this work. Cross-linking of mPDCA-1 with the 
four antibodies generated in this work resulted in significantly impaired IFNα production in vitro. 
The inhibitory effect of mPDCA-1 triggering was comparable to the IFN-I abrogation induced by 
the Siglec-H-recognizing mAb 440c [Blasius A, Blood 2004; Blasius A, JI 2006]. Thus the IFN-I 
inhibition seems not to be a unique function of mPDCA-1, but PDCs express several receptors 
with similar characteristics. Human PDCs receptors BDCA-2 and ILT7 also demonstrate IFNα-
inhibiting functions [Dzionek A, JEM 2001; Cao W, JEM 2006]. They are currently discussed to 
have direct implications for autoimmune therapies, e.g. the abrogation of IFNα in SLE patients. 
The group of Patricia Fitzgerald-Bocarsly reported that cross-linking of BDCA-2 and -4, CD4, 
and CD123 on human PDCs led to the inhibition of IFNα production. It has been suggested that 
in this case IFN-I was regulated either at the level of IRF-7 translocation or by maturation of the 
cells [Fanning SL, JI 2006]. As mPDCA-1 triggering did not affect regulation of CD80/86 on 
murine PDCs (data not shown), further experiments had to be undertaken to reveal the INF-
inhibition pathway of mPDCA-1. Recently, Röck et al. as well as Cao et al. showed that a B cell 
receptor (BCR)-like signaling might suppress IFN-I responses in human PDCs, demonstrating 
the involvement of PLCγ2 or the FcεRIγ complex [Röck J, EJI 2007, Cao W, PLoS Biol. 2007; 
Swiecki MK, EJI 2007]. Targeting of PDC cell surface receptors PDC-TREM or DCIR with mAbs 
also led to impaired IFN-I production. In that case, a direct interaction with DAP-12 (PDC-
TREM) or a not specified “cross-talk” with TLR9 (DCIR) might be responsible for this effect 
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[Watarai H, PNAS 2008; Meyer-Wentrup F, Blood 2008]. In previous reports an interaction of 
mPDCA-1 with the adaptor protein DAP12 was excluded [Blasius A, Blood 2006; Kupzig S, 
Traffic 2003]. 
To elucidate possible mPDCA-1 downstream signaling properties, first signal transduction 
experiments were performed. As the ligand for murine BST2 was elusive, the anti-mPDCA-1 
mAb was used as surrogate ligand. It remained speculative whether the antibody recognizes 
the same epitope as the natural ligand, but in past specific antibodies were often used in similar 
approaches [Mahnke K, J Cell Biol 2000]. Here it was shown that ligation of the receptor 
resulted both in rapid and transient increase of the intracellular calcium concentration in 
combination with an overall protein-tyrosine phosphorylation, suggesting a signal transmission 
after mPDCA-1 triggering. 
In contrast to other receptors expressed on DCs such as Dectin-1, DCIR, DC-SIGN, or 
members of the Siglec family no classical signal motifs like ITAMs or ITIMs were found for 
mPDCA-1 [Blasius A, Blood 2006; Meyer-Wentrup F, Blood 2008; van Kooyk Y, Nat Rev 
Immunol 2003]. This might indicate that the signaling of mPDCA-1 depends on intracellular 
adaptor molecules, shown for example for Dectin-2 that also lacks classical signal motifs 
[Ariizumi K, J Biol Chem. 2000]. Structural data, such as the dual-tyrosine motif in the cytosolic 
domain, implicated that BST2 potentially interacts with other adaptor molecules (e.g. the µ1 and 
µ2 subunit of the AP1 and AP2 adaptor molecules) [Rollason R, J Cell Sci. 2007]. Kupzig et al. 
proposed that the cytosolic domains of BST2 might create a platform for the docking of 
signaling complexes [Kupzik S, Traffic 2003]. The exact mechanism of the mPDCA-1-mediated 
signal transduction for IFN-I inhibition remains unclear and so far no downstream key molecules 
were described to be activated after cross-linkage of this receptor. Hence, further experiments 
are necessary to identify the involved pathways. The observed tyrosine phosphorylation and 
calcium influx were also demonstrated for the human PDC-specific receptor BDCA-2. Here, 
signaling was dependent on Src kinases [Dzionek A, JEM 01] resulting in Syk, Slp65 and PLCγ2 
-mediated NF-kB activation [Röck J, EJI 07; Cao W, PloS 2007]. These molecules might be also 
attractive targets for mPDCA-1. 
 
The role of the mPDCA-1 mediated IFNα-inhibition is still unclear. The function of PDC-secreted 
IFN-I had been described earlier. Briefly, IFN-I has potent anti-viral and anti-proliferative 
functions. IFN-I induces the expression of several IFN-I-responsive genes, including 2’,5’-
oligoadenylate synthetase and synthetase-like proteins, MX2 or members of the IFIT family, and 
other anti-viral proteins resulting in the inhibition of viral replication [Der SD, PNAS 1998; 
Baechler EC, PNAS 2003]. IFN-I also induces the production of other pro-inflammatory 
cytokines and thereby activates NK cells or cDCs. PDCs have a bystander function in the 
induction of anti-viral reactions, as PDC-secreted IFN-I for example leads to the upregulation of 
MHC-I molecules on cDCs. The increased MHC-I presentation of viral peptides on infected cells 
then enables an efficient anti-viral response by CTLs [Le Bon A, Nat Immunol 2005; Dalod M, 
JEM 2003; Barchet W, Semin Immunol 2005]. Thus, the inhibition of IFN-I production after 
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triggering mPDCA-1 could be a viral escape mechanism by attenuation of immune responses. 
The interaction of human BST2 with viral proteins was recently observed as well as many DC-
expressed cell surface receptors, such as DC-SIGN or other lectin structures, interacted with 
viral proteins or glycoproteins [Neil SJD, Nature 2008; van Damme N, Cell Host Microbiol 2008; 
Geijtenbeek TB, J Biol Chem. 2002]. PDCs also have a regulatory function in the initiation of 
anti-tumor responses and are correlated with a negative outcome of cancer [Hartmann E, 
Cancer Res 2003; Vermi W, J Pathol 2003; Treilleux I, Clin Cancer Res. 2004; Zou W Nat Med 
2001; Munn DH, J Clin Invest 2004. Therefore, the natural ligand could be also a tumor-
expressed molecule or a soluble factor, which initiates a tumor-escape mechanism by 
abrogation of IFN-I. This would result in reduced orchestration of DC-mediated tumor responses 
including less tumor-reactive CD4+ and CD8+ T cells or NK cells, finally leading to the survival of 
the tumor. Recently, BST2 was identified as a tetherin member involved in the interaction with 
the Vpu protein of maturing HIV virions in vitro, preventing its release and leading to the 
inhibition of the viral replication and spreading [Neil SJD, Nature 2008; van Damme N, Cell Host 
Microbiol 2008]. Thus, in addition to the anti-viral effect of secreted IFN-l and expression of anti-
proliferative molecules, PDCs might be equipped with another antiviral function. In addition, the 
IFN-dependent induction of BST2 in other cells augmented the antiviral mechanism by further 
inhibition of virus spread. The interaction with the IFN-I pathway and the importance for HIV 
retention implicates that mPDCA-1 would be an attractive target for future immunotherapy of 
viral infections.  
A different effect was observed in autoimmune diseases, where PDC-secreted IFN-I is a major 
factor for the induction and development of the disorders [Nestle FO, JEM 2005; Christensen 
SR, Immunity 2006; Farkas L, Am J Pathol 2001; Blanco P, Science 2001; Cavanagh LL, 
Arthritis Res Ther 2005; Lande R, J Immunol 2004]. For example the high concentrations of 
IFNα in the sera of SLE patients were found to activate auto-antigen presenting cDCs to trigger 
T cell-mediated autoimmunity [Rönnblom L, Arthritis Res Ther 2003; Blanco, P, Science 2001]. 
This process is called “break of tolerance” [Palucka AK, PNAs 2005; Banchereau J, Immunity 
2006]. Other effects of IFN-I include the reduction of apoptosis of autoreactive T cells. PDC-
secreted IFNα as well as IL-6 and IL-8 further lead to the differentiation of plasma cells [Jego G, 
Immunity 2003; Poeck H, Blood 2004], producing antibodies against auto-antigens. As a 
consequence, the effect of mPDCA-1 triggering could be investigated in a murine SLE model. 
Suitable lupus models are e.g. New Zealand Black (NZB), New Zealand White (NZW), or MRL 
mice [reviewed by Banchereau J, Immunity 2006; Barrat FJ, EJI 2007]. Similar to the human 
BDCA-2 receptor, the abrogation of IFN-I would have a beneficial impact for the treatment or 
functional investigation of this autoimmune disease [Dzionek A, Hum Immunol. 2002].  
 
The most important function of DCs is the uptake, processing and presentation of exogenous 
antigens. For the antigen uptake DCs are equipped with a number of specific antigen uptake 
receptors including c-type lectins, scavenger and Fc receptors [Dzionek A, JEM 2001; Röck J, 
EJI 2007; Bonifaz L, JEM 2002 and JEM 2004; Dudziak D, Science 2007; Sancho D, J Clin 
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Invest. 2008; Zhang J, Blood 2006; Meyer-Wentrup F, Blood 2008]. Thereby, the expression-
pattern of antigen uptake receptors determines the spectrum of pathogenic structures, which a 
particular DC population can respond to. Thus, the endocytotic capacity of mPDCA-1 was 
investigated. It could be demonstrated that mPDCA-1 significantly internalized in vitro and in 
vivo following the ligation with the specific mAb. This observation indicated a potential function 
of this receptor in antigen-uptake. These results were supported by other groups, showing an 
efficient internalization of anti-mPDCA-1 mAbs [Kupzig S, Traffic 2003; Blasius A, Blood 2006]. 
Zhang et al. demonstrated only weak internalization of mPDCA-1, which can be explained by 
the usage of PDCs isolated from different lymphoid tissues or other antibody clones [Zhang J, 
Blood 2006]. Recently, Dudziak et al. demonstrated that the rate of internalization not necessary 
correlates with the efficiency of antigen presentation [Dudziak D, Science 2007]. The four anti-
mPDCA-1 mAbs generated in this study internalized with different kinetics. For example clone 
3D5 showed only poor internalization, whereas clone 1C2 showed similar kinetics as the 
antigen uptake receptors BDCA-2 and DEC205 [Dzionek A, JEM 2001; Bonifaz L, JEM 2002 
and JEM 2004]. As clone 3D5 recognizes a different epitope than clone 1C2, these data imply 
that 3D5 might induce another conformational change of mPDCA-1 as the other clones or bind 
an atypical, irrelevant domain. This might be a reason for the weaker internalization. In the 
opposite sense, the other clones might detect the epitope recognized by natural ligand of 
mPDCA-1. 
Different reports demonstrated a clathrin-mediated endocytosis (CME) of rat or human BST2. 
Rollason et al. reported a sequential interaction of the intracellular domain of BST2 with the AP2 
and AP1 adaptor complexes in a clathrin-mediated manner [Rollason R, J Cell Sci. 2007]. In 
addition, Kupzig et al. showed that BST2 cycled between the cell surface (“lipid rafts”) and the 
TGN  [Kupzig S, Traffic 2003]. Also co-localization with markers related to the CME pathway, 
such as transferrin and EEA1, had been reported. In contrast, BST2 failed to enter 
LAMP1/CD63+ late endosomes [Rollason R, J Cell Sci. 2007]. The efficient endocytosis of the 
receptor-antibody complex, delivery to the TGN as well as the co-localization to EEA1+ early 
endosomes were indications for a function as antigen-uptake receptor [Kupzig S, Traffic 2003; 
Rollason R, JCS 2008]. These implications were further underlined as many cell surface 
receptors on DCs are connected to the uptake of antigens. In contrast, mPDCA-1 did not co-
localize with lysosomes in opposition to other antigen uptake receptors such as BDCA-2 or 
DEC205 [Dzionek A, JEM 2001; Jähn PS, EJI 2007; Mahnke K, J Cell Biol 2000]. These latter 
observations were contradictory to the molecular structure of mPDCA-1 and the rapid 
endocytosis, and it had to be tested, whether mPDCA-1 in fact functions as antigen-uptake 
receptor.  
 
In the past PDCs were assigned only a minor role in the induction of adaptive immune 
responses unlike their contribution to innate immunity and tolerance induction [Yoneyama H, 
JEM 2005; Le Bon A, Nat Immunol 2003; Abe M, Am J Transplant. 2005; Grohmann U, Nat 
Med 2007; Kang H-K, JI 2007; Sharma MD, J Clin Inv 2007; Fallarino F, Curr Drug Metab. 
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2007; Lou Y, JI 07; Liu C, J Clin Invest. 2008]. In these studies PDCs were not targeted via 
specific antigen-uptake receptors and their poor T cell stimulation might be due to the fact that 
PDCs were not able to take up the antigens. Receptor-mediated endocytosis of antigens is 
more efficient and several molecules were shown to function as specialized antigen-uptake 
receptors such as BDCA-2, DCIR, DEC-205, or DC-SIGN [Dzionek A, JI 2000, Bonifaz L, JEM 
2002; Wang J, Immunology 2007; Aarnoudse CA, Int J Cancer. 2007]. Thus, in this work the 
role of mPDCA-1 as an antigen-uptake receptor and thereby the APC function of PDCs was 
tested. It was planned to use the anti-mPDCA-1 mAb as vector for antigen delivery to PDCs. 
Since PDCs are depleted rapidly and efficiently in vivo after administration of the mAb as 
described earlier, a F(ab’)2 fragment of the anti-mPDCA-1 mAb was generated, which did not 
induce the depletion of these cells. A model antigen was covalently conjugated to the non-
depleting F(ab’)2 anti-mPDCA-1 fragment, which specifically targeted PDCs both in vitro and in 
vivo. In this work Ovalbumin protein was chosen as an appropriate model, as several transgenic 
T cell readout systems were available. This targeting construct was designed to show whether 
mPDCA-1 functions as antigen-uptake receptor and PDCs could prime naïve T cells. The mere 
endocytosis is not sufficient for this function as other internalizing cell surface molecules, such 
as MHC, TCR or interleukin receptors are no antigen-uptake receptors.  
 
The general stimulatory capacity of PDCs was tested in a preliminary experiment. For this, 
PDCs were loaded exogenously with OVA peptide before co-culture with naïve, antigen-specific 
T cells. It was shown, that PDCs were able to initiate strong CD4 and CD8 T cell proliferation. 
These results indicated that peptide-loaded PDC efficiently present MHC-peptide complexes 
and stimulate naïve T cells. As even unstimulated, peptide-loaded PDCs induce T cell priming, 
the basic level of co-stimulatory molecules on PDCs might be sufficient for activation of the T 
cells. It cannot be excluded that PDCs were artificially activated in these in vitro experiments, 
although they did not upregulated significant amounts of co-stimulatory molecules. Another 
explanation is that the low level of co-stimulatory molecules on immature PDCs was 
compensated by unphysiologic excess of MHC-peptide complexes after peptide loading. Thus, 
only few co-stimulatory molecules were sufficient to stimulate naïve T cells. After confirming that 
PDCs were generally able to prime T cells, the uptake of OVA protein conjugated to the 
mPDCA-1 targeting construct for delivery into processing pathways was analyzed. Recent 
reports demonstrated an influence of the receptor for antigen delivery into distinct 
processing/presentation compartments. Antigens targeted to DEC205 or the Mannose receptors 
were efficiently cross-presented on MHC-I molecules, whereas DCIR2-delivered antigen was 
presented on MHC-II molecules [Dudziak D, Science 07; Burgdorf S, Science 07]. Beside the 
function of mPDCA-1 as antigen-uptake receptor it was investigated in the experiments 
presented here, whether targeted antigens were processed for MHC I or II presentation. In vitro 
CD4 priming experiments were performed at the beginning. Unstimulated PDCs did not prime 
antigen-specific naïve CD4+ T cells, although the uptake via mPDCA-1 was stimulus-
independent. In contrast, if PDCs received an additional stimulus, antigen delivery via   
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mPDCA-1 resulted in efficient CD4+ T cell priming. These differential in vitro results can be 
explained by the fact that immature DCs need an additional activation stimulus to efficiently 
prime naïve T cells. Bonifaz et al. and Steinman et al. demonstrated that cDCs, which were in 
vivo targeted with anti-DEC-205-OVA antibody construct, also needed a stimulus to initiate a T 
cell response [Bonifaz LC, JEM 2002 and 2004; Steinman RM, Ann N Y Acad Sci. 2003]. In 
contrast, immature cDC induced anergy or apotosis of the T cells (“peripheral tolerance”) 
although they presented antigen (first signal) but did not provide a second signal via co-
stimulatory molecules [Hawiger D, JEM 2001]. To induce a strong T cell response Bonifaz et al. 
used CD40L-activated cDCs. As PDCs express only low levels of CD40, in this work the TLR9 
ligand CpG was used, which is an established PDC stimulus [Meyer-Wentrup F, Blood 2008]. 
In contrast to peptide-loaded PDCs, which stimulated naïve T cells without further stimulation, 
the presentation of native antigen in vitro clearly depended on additional activation. It is still 
speculative, whether in this case the activation had an impact on the upregulation of co-
stimulatory molecules to produce a second signal. On the other hand it was possible that PDCs 
could process endocytosed antigen only after activation, underlining the affection of the 
processing/presentation pathway.  
 
To assess the efficiency of mPDCA-1-mediated antigen uptake, the OVA quantities necessary 
for efficient CD4+ T cell priming were directly compared. Targeting OVA via mPDCA-1 was 
always and significantly superior to soluble OVA or OVA-targeted via isotype control antibody 
(Fig. 4.3.5A+C). The minimum concentration of mPDCA-1-OVA required for a detectable effect 
was about 250 ng/ml in vitro (Fig. 4.3.5C), which was in line with our previous results 
[Sapoznikov A, JEM 2007]. In contrast, if soluble OVA protein instead of peptide had been used 
as model antigen, amounts of 100-500 µg or up to several milligrams were described to induce 
a PDC-mediated T cell response [Mouries J, unpublished data; #PB-2497, ECI congress, Paris 
2006]. However, the amount needed for the induction of CD4+ T cell proliferation was clearly 
higher for PDCs targeted via mPDCA-1 compared to DEC-205-targeted cDCs [Sapoznikov A, 
JEM 2007; Bonifaz LC, JEM 2002 and 2004]. This difference may be due to unique natures of 
the receptors but more likely due to distinct priming or processing capacities of PDCs and cDCs 
[Salio M, JEM 2004; Sapoznikov A, JEM 07].  
It was demonstrated that mouse PDCs induced a strong proliferation of naïve CD4+ T cells after 
taking up OVA antigen via mPDCA-1 in vitro. In previous experiments we had already 
demonstrated that antigen delivery via mPDCA-1 PDCs induced a persistent response of naïve 
CD4+ T cells in vivo, shown by the presence of IFNγ-producing effector memory T cells 
[Sapoznikov A, JEM 2007]. To test whether the in vitro PDC-induced T cell expansion was 
associated with the generation of productive but not anergic T effector cells, the proliferation 
and cytokine production was studied after expansion [Hawinger D, JEM 2001; Itano A, Nat Imm 
2003; Sporri R, Nat Imm 2005]. In these experiments restimulation of PDC-primed T cells 
resulted in a strong IL-2 and IFNγ production and also TNFα secretion, which was comparable 
but not identical if splenocytes or cDCs were used as APCs. This cytokine profile as well as the 
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absence of IL-4 producing CD4+ T cells suggests a TH1 polarization [Openshaw P, JEM 1995]. 
This phenotype was expected as the CpG stimulus needed for optimal priming resulted in the 
production of IFNα (and IL-12) by PDCs, and the presence of these cytokines typically favored 
a TH1 polarization. Interestingly, about 10-20% IFNγ and IL-10 producing CD4+ T cells were 
detected if PDCs but not cDCs primed naïve T cells. In the past several groups also 
demonstrated the generation of IFNγ IL-10 double-positive CD4+ T cells after PDC-priming, 
probably caused by IFN-I [Dzionek A, Hum Immunol. 2002; Kadowaki N, Hum Immunol 2002; 
Ito T, JEM 2007; Bochtler P, JI 08;Rutz S, PNAS 2008]. The data of the in vitro cytokine 
production clearly showed that PDCs are able to stimulate naïve CD4+ T cells after mPDCA-1 
targeting, resulting in a productive response that includes IFNγ-producing effector T cells, 
comparable to a cDC-induced TH reaction. 
 
In the past it was shown that PDCs present peptides to antigen-specific CD4+ T cells but were 
less competent to take up and process exogenous proteins for efficient cross-presentation to 
CD8+ T cells in contrast to cDCs [Schlecht G, Blood 2004; Lou Y, JI 2007; Liu C, J Clin Invest. 
2008]. As in this work PDCs efficiently process antigens and prime naïve CD4+ T cells in vitro, 
next the cross-priming capacity of PDC after antigen-delivery via mPDCA-1 was investigated. It 
was shown that after mPDCA-1 receptor-mediated uptake PDCs efficiently cross-present 
exogenous antigens in vitro. Compared to soluble or isotype control targeted antigen, 
significantly lower antigen amounts were needed to induce maximum T cell response, 
underlining the efficiency of mPDCA-1 mediated antigen uptake. This cross-priming of CD8+ T 
cells could be prevented by blocking of the receptor with excess of unconjugated anti-mPDCA-1 
mAb. Identical results were obtained for CD4+ T cells, underlining the specificity of antigen 
delivery via mPDCA-1. In contrast to other reports that propose only a synergistic role for PDCs 
in the activation of CD8+ T cells by production of IFN-I but no direct effect on T cells, these in 
vitro data clearly showed the cross-priming capacity of PDCs [Lou Y, JI 2007]. These different 
results may be based on different experimental settings, highlighting mPDCA-1-mediated 
antigen delivery. It was further shown that the receptor pathway is critical for the direction of 
antigens into distinct processing compartments, i.e. for subsequent MHC-I or MHC-II 
presentation [Dudziak D, Science 07; Burgdorf S, Science 07]. The result of the work presented 
here impressively demonstrated that OVA antigen was presented on both MHC-I and II 
molecules after mPDCA-1 targeting. No prevalence for the processing compartment was 
pbserved.  
Similar to the CD4+ T cell priming, cross-presentation of OVA protein to CD8+ T cells required 
an additional stimulus. The importance of PDC activation has been also described for Siglec-H 
eliciting a cytotoxic CD8+ T cell response [Zhang, J, Blood 06]. Interestingly, compared to the 
CD4+ T cell priming higher antigen amounts were necessary for the induction of CD8+ T cell 
proliferation. This effect might be explained either by differential requirements for the cross-
presentation pathway or by the fact that the cross-presentation process is less efficient and only 
a part of the antigens gains access to this pathway. For example for cross-presentation via the 
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TAP-dependent pathway the endocytosed antigen has to be exported from the phagosome into 
the cytosolic proteasome. Degraded antigens were then transported into the endoplasmatic 
reticulum, where they bind to MHC-I molecules [Kovacsovics-Bankowski M, Science 1995]. 
Using specific proteasome inhibitors, e.g. MG132 or epoxomycin [Burgdorf S, Nat Immunol 
2008], it could be tested whether PDCs use this pathway for cross-presentation of mPDCA-1 
targeted antigen. Salio et al. suggest that PDCs might lack essential prerequisites for the cross-
presentation of exogenous antigens [Salio M, JEM 2004], but the data shown here indicate that 
PDCs possess functional cross-priming machinery.  
 
The priming capacity of PDCs from different lymphoid organs was investigated. PDCs from LNs, 
spleen, and BM as well as in vitro generated PDCs were able prime CD4+ T cells. They also 
demonstrated an almost identical cross-priming capacity. These results are conflicting with other 
reports that demonstrated differences between PDCs from several lymphoid organs. It was 
shown that LN-PDCs but not spleen PDCs could induce a CD4 response in vivo, probably due 
to functional specialization [Sapoznikov A, JEM 2007]. Interstinly, only LN but not spleen PDCs 
were able to take up DQ-OVA in vivo. Also differences between liver and spleen PDCs in 
antigen uptake, cytokine production and their allo-activation potential had been reported [Shu S-
A, Clinical and Experimental Immunology 2007]. In this study the induced T cell response 
depends on mPDCA-1 mediated antigen delivery. The influence of the antigen-uptake receptor 
for adaptive immune responses has been described earlier [Jähn P, EJI 08, Bonifaz L, JEM 
2002 and 2004; Zhang J, Blood 06; Dzionek, JEM 2001]. On the other hand the uptake of 
soluble or untargeted antigen was less efficient. It is speculative whether PDCs from different 
organs have in general an unequal endocytic capacity that affects their T cell response. As 
PDCs poorly take up antigen unspecifically, e.g. by macropinocytosis, but rather receptor-
mediated [Dzionek A, JI 2000; Dzionek, JEM 2001; Jähn PS, EJI 2008], the conflicting results 
can be explained more likely with either their maturation state [Toma-Hirano M, EJI 2007; 
Toyama-Sorimachi N, JI 2005] or by differentially regulated antigen processing machinery 
[Kamogawa-Schifter Y, Blood 2005]. In this work a stimulus was applied. This may imply that 
PDCs from several lymphoid organs basically differ in their priming capacities, e.g. are 
differentially matured or do not have the identical cellular equipment for an adaptive immune 
response. After receiving an activation stimulus they become synchronized. These 
considerations may explain the contradictory reports about their general priming capacity in the 
past, and explain that after activation PDCs are able to elicit the same T cell priming.  
 
The data presented in this work clearly suggest the importance of additional PDC stimulation for 
optimal T cell response in vitro after uptake via mPDCA-1. The relevance of an additional 
activation of PDCs was reported previously, as only activated PDCs were able to induce an 
adaptive T cell response [Schlecht G, Blood 2004; Lou Y, JI 2007; Liu C, J Clin Invest. 2008]. 
Interestingly, as also unstimulated cells internalized the receptor-antibody complex, the 
activation did not influence the antigen-uptake. The expression of mPDCA-1 on PDCs was not 
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affected upon activation or culture condition. The precise mechanism of an additional stimulus 
for T cell priming remains elusive: Stimulation resulted on the one hand in upregulation of co-
stimulatory and MHC molecules on PDCs, on the other hand it is not implausible that the 
processing and presentation machinery is turned on. 
In the past it was reported that IFNα-matured cDCs showed an increased cross-presentation 
capacity, suggesting a “licensing” by IFN-I, which increases the presentation of viral peptides on 
MHC-I. This mechanism facilitates the recognition of infected cells by cytotoxic T cells [Lapenta 
C, EJI 2006; Le Bon A, Nat Immunol 03]. In this work it has been demonstrated that upon 
activation co-stimulatory markers such as CD40, CD80, and CD86 and also MHC-I and -II were 
upregulated on PDCs. These data suggested that the priming also depends on the “second 
signal”, provided by co-stimulatory molecules [Bonifaz LC, JEM 2002 and 2004; Steinman RM, 
Ann N Y Acad Sci. 2003]. Conflicting with this hypothesis, it was shown that peptide-loaded 
PDCs could prime T cells without additional activation. As it was still possible that a strong and 
superior first signal, as represented by the huge amount of OVA peptide, would supersede the 
need for co-stimulation [shown by the activation of CD8+ T cells; Wang B, JI 2000], the impact of 
an additional CpG-stimulus was assessed by titration of the peptide amount. It could be 
demonstrated that also in lower peptide concentrations the stimulus had no positive effect upon 
PDC-mediated T cell stimulation, which argues against the requirement of additional co-
stimulation. 
In the second hypothesis the additional stimulus activates the antigen processing and 
presentation machinery, resulting in an increased presentation of OVA antigen onto MHC 
molecules. In order to monitor the MHC-I restricted presentation of OVA-derived peptide on the 
cell surface of PDC targeted with anti-mPDCA-1F(ab’)2-OVA, cells were stained with mAb 
recognizing the OVA peptide in the context of MHC-I (H-2kb) molecules [Porgador A, Immunity 
1997]. After CpG-activation MHC-I molecules were upregulated on PDCs, which could be due to 
the auto- and paracrine effect of IFNα, which was produced by PDCs after CpG stimulation. The 
upregulated MHC-I expression was also detected by increased anti-SIINFEKL:H-2kb mAb 
staining of peptide-loaded PDCs. Unfortunately, processed OVA protein was not detected on 
MHC-I molecules on PDCs, possibly due to the low number of presented peptides. Although 
PDCs were incubated with up to 25 µg/ml OVA protein (mPDCA-1-OVA) or up to 2 mg/ml 
soluble OVA, no processed OVA could be detected on surface MHC-I. One reason can be that 
the immunogenic sequence (SIINFEKL) is only about 2.5% of the complete OVA protein. Thus, 
proteolytic degradation of the protein results in the generation of many irrelevant peptides but 
few immuno-dominant peptides [Boscardin SB, JEM 2006], which elucidates the differential 
outcome between loading with OVA protein and OVA peptide. Another explanation addresses 
the limited sensitivity of the antibody. Although several staining methods were applied to 
enhance the signal intensity (Fluorescence amplification by the FASER system [Shimizu K, JI 
2006]) or magnetofluorescent liposomes [Kunkel D, Cytometry A. 2003], no processed antigen 
was detectable. Obviously, the peptide amount that could be achieved via the targeting of OVA-
anti-mPDCA-1 mAb constructs were dramatically lower than the quantity required for the 
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detection of processed antigen by the specific antibody. Other groups used highly unphysiologic 
concentrations of OVA protein. Burgdorf et al. exposed DCs to 5 mg/ml soluble OVA to visualize 
processed antigen by immunofluorescene, thereby underlining the limited sensitivity of the 
antibody [Burgdorf S, Science 2007]. The hypothesis that the stimulus activates the antigen 
processing machinery was further underlined by the finding that also in lower peptide 
concentrations the stimulus had no positive effect upon PDC-mediated T cell stimulation. In this 
situation the co-stimulus can be disregarded, as the amount of antigen was critical, which could 
be increased by activation of the processing machinery. Due to a limited readout system the 
exact impact of an additional activation cannot be revealed at this point and further experiments 
are necessary that show sensitivity as high as the antigen-specific T cells, e.g. detection of 
MHC-peptide complexes by recombinant TCRs. 
 
In contrast to the in vitro priming experiments presented in this study, we did not need an 
additional activation for CD4+ T cell priming in vivo (which has been performed in collaboration 
with Steffen Jung, Israel). For these experiments a recently developed diphtheria toxin receptor 
(DTR)–based system was applied that allowed the conditional ablation of CD11chigh cDCs. In 
these transgenic mice the DTR is co-expressed with the Itgax gene, which encodes the ax 
subunit of the CD11c integrin leading to the expression in CD11c+ cells. Administration of 
Diphtheria toxin resulted in the depletion of all cDCs but not PDCs [Jung S, Immunity 2002; 
Sapoznikov A, JEM 2007]. After depletion of cDCs, mice were immunized with mPDCA-1-OVA 
or DEC-205-OVA targeting constructs after adoptive transfer of OVA-specific T cells. 
Surprisingly, also in the absence of cDCs a strong proliferation of CD4+ T cells but not CD8+ T 
cells could be detected, when OVA was targeted to PDC via mPDCA-1 but not via DEC-205 
[Sapoznikov A, JEM 2007]. The priming of naïve CD4+ T cells was also observed if mPDCA-1-
OVA was administrated, and PDCs or cDCs were subsequently isolated and in vitro co-cultured 
with OVA-specific CD4+ T cells. Interestingly, after targeting OVA via mPDCA-1 only PDCs but 
not cDCs induced a strong T cell response, further underlining the specificity of the targeting 
procedure and the priming capacity of PDCs. Only LN but not spleen derived PDCs could 
induce a CD4+ T cell response, contradictory to the in vitro data presented in this work, in which 
an equal priming capacity was shown for all PDCs tested. Further experiments are necessary to 
resolve these conflicting results, e.g. further functional characterization of the PDCs used for 
these studies. In the work presented here PDCs from different lymphoid tissues were in vitro 
activated for efficient priming. In the in vivo experiment no activation signal was applied. It is 
speculative whether the activated PDCs in vitro were actually comparable to the “untreated” 
PDCs in vivo, which also might receive other signals from the environment. Thus, the 
experimental setups might be a reason for the opposing results. A major difference between the 
results obtained in this work and in collaboration with Steffen Jung was observed for the 
activation of CD8+ T cells. On the one hand we described that PDCs were not able to cross-
present exogenous antigens in vivo, either soluble or targeted via mPDCA-1. These data were 
explained by the lack of the phagosome-to-cytosol pathway required for cross-presentation 
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[Sapoznikov A, JEM 2007; Salio M, JEM 2004]. As in this work, PDCs efficiently cross-prime 
CD8+ T cells after antigen targeting via mPDCA-1 in vitro, the former conclusion had to be 
revised: PDCs do have the ability to present exogenous antigen on MHC-I molecules, but for 
the initiation of a CD8+ T cell response an additional activation of PDCs is obligatory. The 
missing activation signal clearly distinguished these two experimental setups. As a 
consequence these new data indicate that PDCs have an overall capacity to process antigens 
for CD4+ and CD8+ T cell priming. Thus, the cross-presentation of exogenous antigen is no 
longer considered as a unique property of CD8α+ cDCs but PDCs and cDCs are able to 
generate cytotoxic T cells. This study provides evidence that PDCs may represent an attractive 
target to boost the efficacy of vaccines by induction of a CD8+ T cell response. 
 
In summary, in this work it was shown that PDCs have not only a secretory function by 
production of IFNα but also the role of mPDCA-1 as novel antigen-uptake receptor was 
highlighted. The mPDCA-1-mediated antigen uptake resulted in significant priming and cross-
priming of antigen-specific CD4+ and CD8+ T cells.  
 
5.3 Heterogeneous expression of Sca-1 defines functionally different PDC subsets 
The characterization of PDCs by the classical cell surface receptors B220, Ly-6C, and CD11c 
as well by specific markers mPDCA-1 and Siglec-H demonstrated a homogeneous population 
[data not shown; Blasius A, Blood 2004]. Further phenotyping revealed that PDCs exhibited a 
differential expression of the Sca-1 antigen, describing two subpopulations, Sca-1+ and Sca-1- 
PDCs.  
The Sca-1 protein, also termed lymphocyte activation protein 6A (Ly-6A), is a small molecule of 
about 18 kDa in size and was originally identified on activated lymphocytes, in particular T cells 
[Yotoku M, JI 1974]. Sca-1 is a member of the Ly-6 multigene family encoding several highly 
homologous, glycosylphosphatidylinositol (GPI)-anchored membrane proteins [Sinclair AM, 
Blood 1993; Reiser H, PNAS 1988]. It has been mainly used as "stem cell or progenitor marker” 
to describe Sca-1+, c-kit+ linage- hematopoietic stem cells [Ito M, Stem cells 1996]. There was 
only one report in which PDCs had been shown to be positive for this marker [O'Keeffe M, JEM 
2002]. But neither a differential expression pattern within the PDC population nor functional 
implications of the expression had been shown.  
Interestingly, the percentage of Sca-1+ PDCs differed depending on their localization. In BM 
only 10% to 15% of PDCs expressed Sca-1. In contrast, in blood and spleen the percentage of 
Sca-1+ PDC increased to 25% and 50%, reaching the highest proportion in lymph nodes 
(>80%). Sca-1+ PDCs also showed the highest Sca-1 expression level compared to other cells 
of tested tissues. As DCs generally develop from CD34+ progenitors in the BM and then migrate 
into the periphery [Banchereau J, Nature 1998], the heterogeneous expression in differential 
lymphoid tissues might imply a transition of Sca-1- to Sca-1+ PDCs during their hematopoietic 
development. It is speculative whether Sca-1- PDCs in the BM were the earlier, immature 
subsets, compared to the more differentiated Sca-1+ PDCs that were found in the periphery. 
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Thus, expression of Sca-1 might reflect developmental stages of PDCs and Sca-1- appear 
earlier in the development. To underline this hypothesis the following in vivo proliferation 
experiments were performed. Within the Sca-1- compartment of BM and spleen PDCs, a higher 
BrdU incorporation could be demonstrated. These preliminary data implicated that PDCs were 
negative for Sca-1 at the beginning of their development and upregulated this marker later. 
Additional pulse/chase experiments should then demonstrate the transition of Sca-1- into Sca-1+ 
PDCs. Immediately after the BrdU pulse, a higher incorporation of BrdU was detected in Sca-1- 
PDCs of all organs. The greatest discrepancy between Sca-1+ and Sca-1- PDCs was observed 
in spleen and LNs. These results indicate that Sca-1- PDCs were the first population of PDCs, 
supporting the preliminary data. Hypothesizing that Sca-1- PDCs develop into Sca-1+ PDCs, at 
a later time a higher BrdU proportion was expected within Sca-1+ PDCs. After BrdU removal, a 
shift in the proportion for BrdU+ cells between Sca-1+ and Sca-1- PDCs was detected first in the 
BM, followed by spleen. At this point the highest BrdU contingent was found in Sca-1+ PDCs, 
according to the above hypothesis. This tendency was detected in LN-PDCs not until a later 
point. These data suggested the transition of Sca-1- to Sca-1+ PDCs by upregulation of this 
marker during their post-proliferation phase or by maturing PDCs. Transfer experiments, 
showing that grafted Sca-1- PDCs become predominately Sca-1+, also supported the 
development of Sca-1+ PDCs from Sca-1- cells. These data also excluded the possibility that 
Sca-1 expression characterizes distinct or separated PDC subsets.  
Other groups recently investigated the development of PDCs by differential expression of cell 
surface makers. In the BM, immature PDCs (Ly-49Q-) as well as mature PDCs (Ly-49Q+) were 
described, whereas in the periphery only Ly-49Q+ PDCs were found [Omatsu Y, J Immunol 
2005; Toyama-Sorimachi N, J Immunol 2005; Kamogawa-Schifter Y, Blood 2005]. For Sca-1 
also low expression in the BM and an increased expression on PDCs in the periphery could be 
detected. Collectively, these data show that the expression of Ly-49Q and Sca-1 tends to be 
regulated in a similar way. In contrast, both Sca-1+ and Sca-1- PDCs are found in the periphery. 
This heterogeneity is not restricted to the BM like Ly-49Q. Thus, Sca-1 defines developmental 
PDC subsets in the whole organism. In general, a co-regulated expression of both markers was 
not found. Another report showed the existence of CD4- and CD4+ PDCs and it was 
hypothesized whether these are two distinct subsets or rather reflect two developmental stages 
of the same population [O'Keeffe M, JEM 2002]. They could show that PDCs up-regulated the 
expression of the CD4 molecule upon activation and demonstrated that CD4- PDCs were the 
immediate precursors of CD4+ PDCs.  
 
It was hypothesized that organ-depending differences of the Sca-1 expression correlate not only 
with the development but also with the activation status of PDCs. As Sca-1- PDCs appear 
earlier they might reflect a rather immature stage, whereas Sca-1+ PDCs comprise the more 
mature form of these cells. The differential Sca-1 regulation on PDCs from different organs was 
subsequently investigated under activating conditions. Although in steady state no correlation to 
the expression of co-stimulatory molecules was detected, it has been shown that PDCs 
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upregulated Sca-1 upon TLR7 or TLR9 stimulation both in vitro and in vivo. Upon CpG 
activation the expression of Sca-1 as well as CD40, CD80, and CD86 were upregulated. These 
co-stimulatory molecules are known to be upregulated upon activation [O’Keeffe M, JEM 2002; 
O’Keeffe M, Blood 2003]. In a different context it was shown that Sca-1 expressed on T cells 
was involved in activation or differentiation [Codias EK, JI 1990; Flood M, JEM 1990; Bamezai 
A, JI 1995], Sca-1 might indeed serve as an activation marker and Sca-1+ PDCs reflect a more 
activated form of PDCs. As in steady state Sca-1- and Sca-1+ PDCs exist, the latter might be 
inadequately activated, express only low levels of co-stimulatory molecules.  
The results from these proliferation and activation experiments led to the following theory, 
depicted in Fig. 5.2.  After development from PDC progenitors so-called pre-PDCs are found in 
the BM, which further develop into immature PDCs, characterized by the expression of mPDCA-
1, Siglec-H and other PDC markers, but lack the expression of Sca-1. Immature PDCs migrate 
into the periphery where they persist in a non-dividing form [O’Keeffe, M, JEM 2002]. During this 
process and upon further activation signals PDCs upregulate the expression of Sca-1. As an 
activation is normally the signal for accumulation in the LNs, the dominate presence of Sca-1+ 
cells in LNs might reflect an activated status of these cells.  
 
Fig. 5.2 Model of the Sca-1 expression during PDC development 
In contrast to highly proliferative PDC precursors, early PDCs (as defined by mPDCA-1 and Siglec-H expression) do 
not proliferate. They reflect a rather immature phenotype, do not express Sca-1 and migrate into the periphery. Upon 
stimulation, immature PDCs upregulate the expression of Sca-1. In this activated or matured stage, PDCs mainly 
found in peripheral lymphoid organs such as the LNs. 
 
It was speculated whether the expression of Sca-1 is associated with functional differences, in 
particular whether it correlated with the cytokine secretion. In the human system it has been 
shown that the ability of PDCs to produce IFN-I depends on their activation and maturation 
status [Krug A, EJI 2001]. Immature PDCs secrete IFNα upon TLR activation but are not able to 
respond if restimulated in the matured stage [Jähn P, EJI 2008; Krug A, EJI 2001]. In this work 
in the Sca-1- PDC compartment more IFNα-producers were detected upon TLR stimulation and 
Sca-1- PDCs also had a higher capacity to produce TNFα. No significant differences could be 
observed regarding the IL-12 production. The differential cytokine production between Sca-1+ 
and Sca-1- PDCs corresponded to the maturation status of PDCs, according to the above 
theory, which suggests that only immature PDCs are capable to produce IFNα. Other 
observations revealed that PDCs with immature dendritic cell characteristics produced IFNα 
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upon activation and acquired a more mature phenotype and dendritic morphology [Zuniga EI, 
Nature Immunol 2004]. Sca-1- PDCs predominantly located in the BM were regarded as more 
immature and were the major IFNα producers. On the other hand, matured Sca-1+ PDCs were 
mainly located in the LNs and produced less cytokines. A differential production of pro-
inflammatory cytokines within the PDC population had been observed: For example after viral 
stimulation not all but only 15% to 20% of PDCs secreted IFNα. IL-12 was produced by 15% to 
35% and between 10% and 60% of PDC responded with TNFα secretion [Zucchini N, Int 
Immunol. 2008]. Heterogeneous PDC responses were also reported by others [Jomantaite I, 
EJI 2004; Chen L, JI 2006]. These differences might be explained by compartmentation of PDC 
responses to infections or by lack of TLR expression [Jomantaite I, EJI 2004]. Iparaguierre et al. 
reported about two different types of murine PDCs, depending on either CpG or Influenza 
activation [Iparaguirre A, J Leukoc Biol. 2008]. They showed that virally activated PDCs respond 
with high IFN-I production whereas CpG-stimulated PDCs produce less interferon and acquire a 
more matured and DC-like phenotype. For human PDCs also heterogeneity between IFNα 
production and antigen presentation capacity was observed depending on the kind of activation 
[Jähn PS, EJI 2008]. The reason for the differential cytokine responses might be that Sca-1+ 
and Sca-1- PDCs are equipped with a different set of cell surface or adapter signaling molecules 
necessary for appropriate responses against microbial challenge [Kamogawa-Schifter Y, Blood 
2005]. Alternative, PDCs have already downregulated these molecules after upregulation of 
Sca-1. Sca-1+ PDCs, that contain matured PDCs or PDCs in a later developmental stage, might 
have a different function as the Sca-1- counterpart, for example a higher T cell stimulatory 
capacity. In collaboration with Steffen Jung we demonstrated that only LN-PDCs but not spleen 
PDCs were capable of priming naïve CD4+ T cells both in vitro and in vivo [Sapoznikov A, JEM 
2007]. In the in vitro experiments of the work described here, PDCs from all organs were able to 
prime PDCs. These conflicting results might be explained by the application of an additional 
TLR stimulus that subsequently led to the upregulation of Sca-1 expression. As LN-PDCs were 
highly positive for Sca-1 it was planned to compare the priming capacities of Sca-1+/- PDCs 
directly. Although this would be a good opportunity to assess a differential priming capacity, the 
experiments are critical as for efficient T cell priming an activation of PDCs was mandatory. 
Thus, all PDCs would upregulate Sca-1 and discrimination between both subsets would be 
difficult.  
To find further functional differences, gene expression profiles of both PDC subpopulations 
were investigated. By microarray analysis a set of genes was found, significantly over-
represented in Sca-1+ or Sca-1- PDCs. Differentially transcribed cell surface receptors were e.g. 
CD22 and CD163 on Sca-1- PDCs and CD44, CD69, EGRI, PROCR, and TNFRI on Sca-1+ 
PDCs. Upon Gene Ontology Clustering several biologically and immunologically relevant 
pathways were analyzed. In Sca-1+ PDCs a variety of genes were observed, belonging to cell 
adhesion and migration, stress, immunity and inflammation pathways as well as TLR/cytokine 
signaling. As Sca-1+ PDCs are regarded to be the more mature cells, which already received a 
stimulus, these results could support the higher differentiation level. On the other hand relatively 
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more genes involved in metabolic processes were present in Sca-1- PDCs. This might indicate 
the earlier developmental stage of this subset and the focus on cytokine secretion. As the 
regulation of the obtained genes was only shown by microarray analysis, further validation 
either by quantitative PCR or in particular on protein level by ELISA or flow cytometric analysis 
is mandatory. The confirmation might demonstrate if the differential Sca-1 expression 
substantially correlates with the presence of specifically expressed or regulated proteins 
representing a distinct function.  
 
In conclusion, it was demonstrated that the expression of Sca-1 defines two functionally 
different populations, which are spatially separated in different lymphoid organs. The 
consequence of this heterogeneity was not answered conclusively. Immature Sca-1- PDCs, 
possessing the higher ability to produce IFN-I, might have a strong role in innate immunity. In 
contrast, further differentiated Sca-1+ PDCs might be involved in adaptive immunity, possibly by 
interaction with T cells. Sca-1 can be regarded as an appropriate marker to detect activated 
PDCs. Although Sca-1 is commonly used as stem cell marker, its function on terminally 
differentiated cells, PDCs, is still unclear. Proliferation and transfer experiments indicated that 
the Sca-1- population appears earlier in the development of PDCs.  
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6. OUTLOOK 
This work revealed central aspects of the mPDCA-1 receptor, including the inhibition of IFN-I 
production, signal transduction, endocytosis, and a potential role as antigen-uptake receptor. 
 
PDC-derived IFN-I is considered to be a pathophysiological factor in several autoimmune 
diseases, such as SLE or psoriasis. The abrogation of IFNα by mPDCA-1 triggering in vivo 
would be an attractive therapeutical target, which can be tested in several murine lupus models. 
The mechanism of TLR-induced inhibition of interferon production had not been resolved. 
Cross-linking of mPDCA-1 resulted in overall protein-tyrosine phosphorylation and calcium 
mobilization. To identify key molecules of the involved signal transduction pathway, it could be 
tested whether specific inhibitors of protein-tyrosine kinases, such as PP1 and PP2 that inhibit 
members of the src-family, or PTK, might abrogate the signaling [Dzionek A, JEM 2001]. The 
mPDCA-1 signaling pathway could be further investigated by identification of adaptor 
molecules, such as AP1+2, since the receptor lacked classical signal motifs [Rollason R, J Cell 
Sci 2007; Röck, EJI 2007]. The signaling pathway might be involved in the inhibition of IFNα or 
could also affect the endocytosis of the receptor. Since some anti-mPDCA-1 clones internalized 
but others not, it should be investigated whether the non-internalizing clones also induce 
phosphorylation and calcium flux. In other reports using BST2 transfected cells, the 
internalization of the receptor-antibody complex was caused by clathrin-mediated endocytosis 
(CME) [Kupzig S, Traffic 2003; Rollason R, J Cell Sci 2007]. It has to be shown whether this is 
also the responsible mechanism in isolated PDCs. After mPDCA-1 ligation the modification of 
clathrin heavy chain or cytoskeleton modulation could be investigated [Röck J, EJI 2007]. The 
future identification of the natural ligand of mPDCA-1 will help to understand the in vivo function 
of this receptor. Currently, two ligands of human BST2 are reported, suggesting on the one 
hand an antagonistic interaction with the HIV accessory molecule Vpu [Neil SJ, Nature 2008; 
van Damme N, Cell Host Microbiol 2008] and on the other hand binding of the ILT7 receptor 
expressed on human PDCs [Cao W, unpublished data]. Further studies have to show whether 
this is also true in the murine system. The generation of a recombinant mPDCA-1 fusion protein 
might be useful to identify cells expressing the ligand, which then can be used to create a cDNA 
library for further screenings. For the isolation of the ligand and further exploration of the 
mPDCA-1 signalosome the generated mPDCA-1/BST2 transfectants might be a promising tool. 
The generation of an mPDCA-1 knockout mouse might further reveal its function.  
As several cell surface receptors expressed on DCs have a role in the uptake of antigens, it is 
currently elusive whether mPDCA-1 is also endocytosed after binding of the natural ligand. It 
has been shown that using the antibody as vector the mPDCA-1-mediated uptake of exogenous 
antigens resulted in processing and loading on MHC-I and -II molecules for efficient priming of 
naïve CD4+ and CD8+ T cells. The anti-mPDCA-1-F(ab’)2-OVA targeting system could be used 
to target e.g. tumor antigens directly to PDCs to assess their capacity in the generation of CTL 
or other anti-tumor responses. The B16 melanoma (OVA-) tumor model is an attractive target to 
study the role of PDCs and define if these cells directly induce a CTL response against the 
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tumor cells in vivo [Lou Y, JI 2007; Liu C, J Clin Invest. 2008]. Also the delivery of other 
antigens including viral proteins should be investigated to assess the potential of PDCs in 
vaccination trials. Future approaches might also involve the spatiotemporal co-localization of 
antigen and stimulus. Thus, a nano-particle system consisting of anti-mPDCA-1 mAb, TLR 
agonists, and model antigens would be a promising tool to study the capacity of PDCs to 
enhance immune responses [Zhang XQ, J Pharm Sci. 2007; Hao S, Immunology. 2007; Suzuki 
Y, Cancer Res. 2004].  
 
Highly important for the outcome of these studies is the activation stage of the PDCs, since it 
was shown that the priming capacity of PDCs clearly depends on appropriate stimulation. Two 
distinct subsets of murine PDCs can be defined by differentially expression of Sca-1, which also 
indicates heterogeneity in developmental and maturation stages as well as in their capacity to 
produce cytokines. Other reports showed a functional dichotomy for both human and mouse 
PDCs in the induction of innate or adaptive immune responses [Iparaguirre A, J Leukoc Biol. 
2008; Jähn PS, EJI 2008; O’Keeffe M, JEM 2002; Omatsu Y, JI 2005]. As Sca-1- PDCs produce 
higher amounts of IFNα, it might be interesting whether the Sca-1+ PDC subset is characterized 
by a superior T cell priming capacity. Further studies are required to assign the precise role of 
Sca-1 in he functional outcome of PDC responses. For example a dissimilar localization or 
migratory capacity of Sca-1+ and Sca-1- PDCs could be assessed. To track PDCs in vivo, in 
these experiments the expression of a fluorescent protein (GFP) under the mPDCA-1 promoter 
would be beneficial.  
 
In summary, additional information of the exact function of the mPDCA-1 molecule and 
functional experiments will be crucial for understanding the role of PDCs both in steady state 
and (auto-) immunity. 
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7. APPENDIX 
 
 
 
Fig.7.1 Pepsin digestion of anti-mPDCA-1 mAb to generate F(ab‘)2 fragments.   
(A) Anti-mPDCA-1 mAb (clone JF05-1C2) was re-buffered in 0.1 M sodium actetate buffer (pH 4.2). The antibody 
was then incubated for 48 hrs at 37°C in the presence of 10% Pepsin A (Sigma). To check the progress of 
fragmentation aliquots were subjected tp SDS-PAGE and visualized by Coomassie staining. (B) Digested anti-
mPDCA-1- fragments were then size-fractionated by gel filtration using a Superdex-200 column. (C) Individual 
fractions were again subjected to SDS-PAGE analysis and visualized by Coomassie staining. 
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Fig. 7.2 LightCycler standard curves for four murine house keeping genes: β-actin, GAPDH, PPIA, and Hprt-1 
(A) Representative standard curves for house keeping genes. RT-PCRs were performed with titrated amounts of 
mRNA (ranging from 1pg to 5ng) isolated from PDCs and T cells, respectively, using the LightCycler® RNA Master 
SYBR Green I kit (Roche Diagnostics). All assays were performed at least in duplicates. 
(B) Table gives an overview of the above LightCycler runs and obtained crossing points (given is the mean +/- SEM 
of the crossing points of indicated housekeeping genes for two amounts of PDC and T cell mRNA. 
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Tables 7.1 Primer sequences 
 
 
Table 7.1A Primer for housekeeping genes 
 
 
 
 
 
Table 7.1B Primer for real time RT-PCR (LightCycler)  
Primers were selected for an optimal melting temperature (Tm) of 60°C 
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Table 7.1C Primer for real time RT-PCR (LightCycler) designed by Miltenyi Biotec 
Reference: LIMS v1.3, Miltenyi Biotec, Bergisch Gladbach (former name: Memorec Biotec), unpublished data 
 
 
 
 
Table 7.1D Cloning primer for MPG1 and BST2 
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Table 7.2 List of differentially regulated genes in Sca-1+ and Sca-1- PDCs from spleen and LNs 
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Sorted Sca-1- PDCs and Sca-1+ PDCs we hybridized on a PIQOR mouse immunology chip. A value below “1“ 
demonstrates an over-representation of the mRNA transcript in Sca-1- PDCs. A value over “1” indicates a 
predominant transcription in Sca-1+ PDCs. Values represent mean regulation of four replicates on different positions 
of the array. Standard error is given in parenthesis. 
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9. PUBLICATIONS, POSTERS, AND ABSTRACTS 
9.1 Publications in peer-reviewed journals: 
Immunity. 2004 Jul;21(1):107-19. 
TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that 
activate antiviral NK cell function. 
Krug A1, French AR2, , Barchet W1, Fischer JA5, Dzionek A5, Pingel JT3, Orihuela MM3, Akira S4, Yokoyama WM3, 
Colonna M1. 
1Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110 USA, 2Department of Pediatrics, Washington University School of 
Medicine, St. Louis, MO 63110 USA, 3Department of Medicine and Howard Hughes Medical Institute, Washington University School of Medicine, St. Louis, USA, 4Department 
of Host Defense, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan, 5Miltenyi Biotec, Bergisch Gladbach, Germany 
Natural interferon-producing cells (IPC) respond to viruses by secreting type I interferon (IFN) and interleukin-12 (IL-
12). Toll-like receptor (TLR) 9 mediates IPC recognition of some of these viruses in vitro. However, whether TLR9-
induced activation of IPC is necessary for an effective antiviral response in vivo is not clear. Here, we demonstrate 
that IPC and dendritic cells (DC) recognize murine cytomegalovirus (MCMV) through TLR9. TLR9-mediated cytokine 
secretion promotes viral clearance by NK cells that express the MCMV-specific receptor Ly49H. Although depletion of 
IPC leads to a drastic reduction of the IFN-alpha response, this allows other cell types to secrete IL-12, ensuring 
normal IFN-gamma and NK cell responses to MCMV. We conclude that the TLR9/MyD88 pathway mediates antiviral 
cytokine responses by IPC, DC, and possibly other cell types, which are coordinated to promote effective NK cell 
function and MCMV clearance. 
 
Eur J Immunol. 2005 Jan;35(1):236-42. 
Dendritic cells respond to influenza virus through TLR7- and PKR-independent pathways. 
Barchet W1, Krug A1, Cella M1, Newby C, Fischer JA3, Dzionek A3, Pekosz A1,2, Colonna M1. 
1Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA, 2Department of Microbiology, Washington University School of 
Medicine, St. Louis, Missouri, USA, 3Miltenyi Biotec, Bergisch Gladbach, Germany  
Natural interferon-producing cells (IPC) secrete type I IFN (IFN-alpha and -beta) in response to influenza virus. This 
process is independent of viral replication and is mediated by Toll-like receptor 7 (TLR7), which recognizes single-
stranded RNA (ssRNA). DC also express TLR7 but its function in DC response to influenza virus is unknown. To 
address this, we compared the DC and IPC responses to influenza virus and ssRNA oligoribonucleotides (ORN) that 
activate TLR7. When stimulated by ORN in vitro and in vivo, DC matured and produced inflammatory cytokines but 
not IFN-alpha. DC did secrete IFN-alpha in response to influenza virus. However, this response was independent of 
TLR7 signaling and required viral replication but not dsRNA-activated protein kinase (PKR). We conclude that DC 
and IPC are hard-wired to secrete IFN-alpha via different pathways, reflecting their complementary but distinct roles 
in anti-viral immunity. 
 
J Exp Med. 2007 Apr 16;204(4):893-906. 
NK cell activation in visceral leishmaniasis requires TLR9, myeloid DCs, and IL-12, but is independent of 
plasmacytoid DCs. 
Ulrike Schleicher1,2, Jan Liese1, Ilka Knippertz2, Claudia Kurzmann1, Andrea Hesse1,2, Antje Heit3, Jens A. A. 
Fischer4, Siegfried Weiss5, Ulrich Kalinke6, Stefanie Kunz1, and Christian Bogdan1,2 
1Institute of Medical Microbiology and Hygiene, University of Freiburg, D-79104 Freiburg, Germany, 2Institute of Clinical Microbiology, Immunology and Hygiene, University of 
Erlangen, 91054 Erlangen, Germany, 3Institute of Medical Microbiology, Immunology and Hygiene, Technical University of Munich, 81675 München, Germany, 4Department of 
Research and Development, Miltenyi Biotec GmbH, 51429 Bergisch-Gladbach, Germany, 5Department of Molecular Immunology, Helmholtz Zentrum für Infektionsforschung, 
D-38124 Braunschweig, Germany, 6Department of Immunology, Paul Ehrlich Institute, 63225 Langen, Germany 
Natural killer (NK) cells are sentinel components of the innate response to pathogens, but the cell types, pathogen 
recognition receptors, and cytokines required for their activation in vivo are poorly defined. Here, we investigated the 
role of plasmacytoid dendritic cells (pDCs), myeloid DCs (mDCs), Toll-like receptors (TLRs), and of NK cell 
stimulatory cytokines for the induction of an NK cell response to the protozoan parasite Leishmania infantum. In vitro, 
pDCs did not endocytose Leishmania promastigotes but nevertheless released interferon (IFN)-alpha/beta and 
interleukin (IL)-12 in a TLR9-dependent manner. mDCs rapidly internalized Leishmania and, in the presence of TLR9, 
produced IL-12, but not IFN-alpha/beta. Depletion of pDCs did not impair the activation of NK cells in L. infantum-
infected mice. In contrast, L. infantum-induced NK cell cytotoxicity and IFN-gamma production were abolished in 
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mDC-depleted mice. The same phenotype was observed in TLR9(-/-) mice, which lacked IL-12 expression by mDCs, 
and in IL-12(-/-) mice, whereas IFN-alpha/beta receptor(-/-) mice showed only a minor reduction of NK cell IFN-
gamma expression. This study provides the first direct evidence that mDCs are essential for eliciting NK cell 
cytotoxicity and IFN-gamma release in vivo and demonstrates that TLR9, mDCs, and IL-12 are functionally linked to 
the activation of NK cells in visceral leishmaniasis. 
 
J Exp Med. 2007 Aug 6;204(8):1923-33.  
Organ-dependent in vivo priming of naive CD4+, but not CD8+, T cells by plasmacytoid dendritic cells. 
Anita Sapoznikov1, Jens A. A. Fischer2, Tami Zaft1, Rita Krauthgamer1, Andrzej Dzionek2, and Steffen Jung1 
1Department of Immunology, The Weizmann Institute of Science, 76100 Rehovot, Israel, 2Miltenyi Biotec GmbH, 51429 Bergisch Gladbach, Germany 
Plasmacytoid dendritic cells (PDCs) play a pivotal role as cytokine-secreting accessory cells in the antimicrobial 
immune defense. In contrast, the capacity of PDCs to act as antigen-presenting cells in naive T cell priming remains 
unclear. By studying T cell responses in mice that lack conventional DCs (cDCs), and by the use of a PDC-specific 
antigen-targeting strategy, we show that PDCs can initiate productive naive CD4(+) T cell responses in lymph nodes, 
but not in the spleen. PDC-triggered CD4(+) T cell responses differed from cDC-driven responses in that they were 
not associated with concomitant CD8(+) T cell priming. Our results establish PDCs as a bona fide DC subset that 
initiates unique CD4(+) Th cell-dominated primary immune responses. 
 
Cutting Edge: The Journal of Immunology. May 2008; 180: 6457 - 6461  
CNS Plasmacytoid Dendritic Cells Regulate the Severity of Relapsing Experimental Autoimmune 
Encephalomyelitis  
Samantha L. Bailey-Bucktrout1, Sarah C. Caulkins1, Gwendolyn Goings1, Jens A. A. Fischer2, Andrzej Dzionek2, and 
Stephen D. Miller1  
1Department of Microbiology-Immunology and the Interdepartmental Immunobiology Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611 USA, 
2Miltenyi Biotec GmbH, 51429 Bergisch Gladbach, Germany.  
Plasmacytoid dendritic cells (pDC) have both stimulatory and regulatory effects on T cells. pDCs are a major CNS-
infiltrating DC population during experimental autoimmune encephalomyelitis (EAE), but unlike myeloid DCs (mDC) 
have a minor role in T cell activation and epitope spreading. We show that depletion of pDCs during either the acute 
or relapse phases of EAE resulted in exacerbation of disease severity. pDC depletion significantly enhanced CNS but 
not peripheral CD4+ T cell activation, as well as IL-17 and IFN-γ production. Moreover, CNS pDCs suppressed CNS 
mDC-driven production of IL-17, IFN-γ and IL-10 in an IDO-independent manner. The data demonstrate that pDCs 
play a critical regulatory role in negatively regulating pathogenic CNS CD4+ T cell responses highlighting a new role 
for pDCs in inflammatory autoimmune disease. 
 
9.2 Publications in submission/preparation: 
Manuscript in submission: 
Heterogeneous Sca-1 expression on murine plasmacytoid dendritic cells defines developmental 
and functional differences 
Jens A. A. Fischer, Jürgen Schmitz, and Andrzej Dzionek 
 
Manuscript in preparation: 
Identification and functional characterization of mPDCA-1 as a novel antigen-uptake receptor for murine 
PDCs enabling (cross-) priming of  naïve CD4+ and CD8+ T cells. 
Jens A. A. Fischer, Jürgen Schmitz, and Andrzej Dzionek 
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9.3 Posters & Abstracts: 
Joint Annual Meeting of Immunology of the Austrian and German Societies, September 3-6, 2008, Vienna, 
Austria 
Cross-priming capacity of activated and mPDCA-1-targeted Plasmacytoid Dendritic cells (#2008-A-488-
OEGAI) 
Jens A. A. Fischer1 2, Sonja Schmucker1 3, Stefan A. Kaden1, Tobias Voelkel1, Jürgen Schmitz1, and Andrzej 
Dzionek1 
1Miltenyi Biotec, Bergisch Gladbach, Germany; 2University of Cologne, Cologne, Germany; 3Presenting author 
Plasmacytoid Dendritic cells (PDCs) are a distinct subset of dendritic cells and have a central role as sentinels for 
pathogens. PDCs produce large amounts of interferons upon microbial stimulation and are believed to link innate and 
adaptive immune responses. However, their exact function as antigen-presenting cells for the initiation of adaptive 
immune responses is controversially discussed and it remains unclear whether PDC are in fact able to prime naïve T 
cells. In this study we investigated the function of the recently described PDC-specific receptor mPDCA-1. Cross-
linking of mPDCA-1 resulted in a rapid internalization. Targeting of PDCs with OVA-conjugated anti-mPDCA-1 mAb, 
but not with an equivalent amount of soluble OVA or OVA conjugated to isotype control antibody, resulted in strong 
proliferation of OVA-specific naïve CD4+ T cells. PDCs were also able to cross-present mPDCA-1-targeted OVA 
protein to naïve CD8+ T cells. Blocking the receptor with excess of unconjugated anti-mPDCA-1 mAb inhibited 
priming of CD4+ and CD8+ T cells. These results indicate that mPDCA-1 may serve as an antigen uptake receptor for 
efficient priming of CD4+ and CD8+ T cells. Interestingly, processing and presentation of antigens taken up via 
mPDCA-1 was strongly dependent on stimulation, since only activated but not immature PDC were able to prime 
naïve antigen-specific T cells. In contrast, antigen uptake was independent on activation as unstimulated PDC also 
internalized the mAb-receptor-complex. Our results demonstrate that PDCs take up and process antigens, delivering 
its ligands for MHC-I and MHC-II presentation and thus combine innate and adaptive functions. 
  
2eme Journee Scientifique Miltenyi Biotec - Cancer Immunotherapy, July 2008 in Paris, France   
Biological functions of plasmacytoid dendritic cells: Antigen-specific activation of T cells versus production 
of type I interferon. 
Peter S. Jähn, Jens A. A. Fischer, Andrzej Dzionek and Jürgen Schmitz 
Miltenyi Biotec GmbH, Bergisch Gladbach, Germany  
Plasmacytoid dendritic cells (PDC) also referred to as type I interferon producing cells (IPC) are believed to act as a 
link between innate and adaptive immunity by producing type I interferon, and subsequently triggering adaptive T cell 
mediated immunity by differentiating into mature DC. However, it remains controversial to which degree PDC play a 
direct role as APC in the activation of naïve and memory CD4+ and CD8+ T cells and to which degree APC functions 
and production of type I interferon are directly linked. 
To analyze whether human and mouse PDC can act as APC, we decided to adopt a strategy involving antibody 
mediated targeting of antigen to PDC-specific receptors: BDCA-2 (CD303) for human PDC and mPDCA-1 (BST-2, 
CD317) for murine PDC. Independent on Toll-like receptor (TLR) ligand stimulation antigen is rapidly endocytosed by 
these receptors and traffics via early sorting endosomes to emerging MHC-enriched compartments (MIIC). In vitro 
restimulation of human CMV-specific CD4+ effector memory T cells and in vitro priming of murine naïve ovalbumin 
(OVA)-specific T-cell receptor transgenic CD4+ and CD8+ T cells, however, are dependent on appropriate TLR 
ligand stimulation of PDC.   
Most interestingly, at least in human PDC processing and presentation of CMV antigen and production of type I 
interferon are mutually exclusively induced by distinct CpG oligonucleotides. Type B CpG oligonucleotide (CpG-B)-
stimulated PDC efficiently process and present CMV antigen and are thus capable of stimulating CMV-specific CD4+ 
effector memory T cells. CpG-A stimulated PDC produce large amounts of type I interferon and express programmed 
death-1 ligand 1 (PD-1L), a molecule which is known to inhibit T cell activation via PD-1 ligation. CpG-A plus CpG-B 
co-stimulated PDC behave like CpG-B stimulated PDC, indicating that CpG-B induction of antigen processing and 
presentation in PDC concurrently inhibits type I interferon production. 
Our results suggest that innate and adaptive immunity are not linked at the level of individual PDC which first produce 
type I interferon and then differentiate in mature DC, but rather at the population level, where depending on the 
stimulation received, individual PDC either contribute to the innate response by production of IFN-alpha or to the 
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adaptive response by antigen presentation and stimulation of T cells. 
 
Experimental Biology 2008 in combination with AAI 2008, San Diego, USA (The FASEB Journal. 
2008;22:1068.23) 
Plasmacytoid Dendritic cells prime naïve CD4+ and CD8+ T cells after antigen uptake via mPDCA-1 
Jens A. A. Fischer1,2, Monika Janz1, Tobias Voelkel1, Jürgen Schmitz1, and Andrzej Dzionek1 
1R&D, Miltenyi Biotec GmbH, Bergisch Gladbach, Germany; 2University of Cologne, Germany 
Plasmacytoid Dendritic cells (PDC) produce large amounts of IFN upon microbial stimulation and are believed to link 
innate and adaptive immune responses. However, it remains controversial whether PDC are in fact able to prime 
naïve T cells. Here we investigated the function of the recently described PDC-specific receptor mPDCA-1. Ligation 
of mPDCA-1 with specific mAb resulted in a rapid internalization of the complex. Targeting of PDC with OVA-
conjugated anti-mPDCA-1 mAb, but not with an equivalent amount of soluble OVA or OVA conjugated to isotype 
control antibody, resulted in strong proliferation of OVA-specific naïve CD4+ T cells. The same was also observed for 
OVA-specific naïve CD8+ T cells. Blocking the receptor with excess of unconjugated anti-mPDCA-1 mAb inhibited 
priming of CD4+ and CD8+ T cells. These results indicate that mPDCA-1 may serve as an antigen uptake receptor 
delivering its ligands for MHC-I and MHC-II presentation. Interestingly, processing and presentation of antigens taken 
up via mPDCA-1 was strongly dependent on stimulation, since only activated but not immature PDC were able to 
prime naïve antigen-specific T cells. In contrast, antigen uptake was independent on activation as unstimulated PDC 
also internalized the mAb-receptor complex. Our results demonstrate that PDC take up and process antigen for 
efficient priming of CD4+ and CD8+ T cells and thus combine innate and adaptive function. 
 
DC2007 (Dendritic Cell Vaccination and other Strategies to tip the Balance of the Immune System), 2007 in 
Bamberg, Germany 
Highly efficient antigen targeting to murine plasmacytoid dendritic cells (PDC) using mPDCA-1-specific 
antibody conjugates: PDC activation dependent priming of naive CD4+ T cells  
Jens A. A. Fischer, Jürgen Schmitz, and Andrzej Dzionek  
Miltenyi Biotec, Bergisch Gladbach, Germany   
PDC represent a distinct subset of dendritic cells characterised by their plasmacytoid morphology and the ability to 
produce large amounts of IFN-alpha in response to viruses and microbial compounds. It is still controversial to which 
degree PDC are capable of taking up exogenous antigens and play a role in priming of naïve T cells.   
Here we investigated the function of the recently described PDC marker mPDCA-1 as an antigen-uptake receptor. 
Using a monoclonal antibody (mAb) against mPDCA-1 we were able to specifically target PDC both in vivo and in 
vitro. Ligation of mPDCA-1 leads to a rapid internalisation of the antibody-receptor complex, indicating that mPDCA-1 
might serve as a PDC-specific antigen-uptake receptor. Furthermore, targeting PDC with OVA-conjugated anti-
mPDCA-1 mAb, but not with an equivalent amount of soluble OVA, or OVA conjugated to an isotype control mAb 
resulted in efficient proliferation of naive OVA-specific CD4+ T cell receptor transgenic T cells in vitro. However, this 
was clearly dependent on CpG oligonucleotide activation of PDC, since non-activated PDC were not able to prime 
OVA-specific T cells. Our results indicate that efficient processing and presentation of antigen by PDC for stimulation 
of naïve CD4+ T cells requires appropriate PDC stimulation. Currently we investigate, whether PDC may further 
contribute to adaptive immunity by cross-presenting antigens taken up via mPDCA-1 to naïve CD8+ T cell receptor 
transgenic T cells. 
 
International Symposium of Dendritic Cells, 2006 in Edinburgh, UK  
Murine Plasmacytoid Dendritic Cells: Heterogeneous Expression Of Sca-1 Characterises Functional 
Differences 
Fischer, J A A; Janz, M; Schmitz, J; Dzionek, A 
Miltenyi Biotec GmbH, Bergisch Gladbach, Germany 
Murine plasmacytoid dendritic cells (PDC) represent a distinct leukocyte population capable of secreting large 
amounts of type I interferon in response to microbial stimuli. In lymphoid organs all PDC show a homogenous 
expression profile for following markers: B220+, Ly-6C+, CD11cint, mPDCA-1+, CD3-, CD4+/-, CD8a-, CD11b-, CD19-, 
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CD49b-, CD123-, CD40-, CD80low, and CD86-, and MHC-II+. Here we demonstrate differential expression levels of the 
stem cell antigen 1 (Sca-1) on PDC from different organs. In bone marrow (BM) and blood only 15-20% of PDC 
express Sca-1. In contrast, about 35% of liver PDC and about 50% of splenic PDC are positive for Sca-1. In lymph 
nodes (LN) up to 80% of PDC are positive for Sca-1. Phenotyping study of both, Sca-1+ and Sca-1- PDC in BALB/c 
mice revealed no significant differences between the subsets in expression level of any surface marker tested. The 
expression of Sca-1 on Sca-1- PDC from BM and spleen was up-regulated after the culture and could be further 
increased, when stimulated with CpG. Interestingly, when stimulated with the TLR7 ligand Loxoribine the activation-
dependent up-regulation of Sca-1 was decelerated. Furthermore, CpG induced IFNa production correlated inversely 
with the expression level of Sca-1 as we could show by intracellular staining. Analysing the total amount of IFNa in 
culture supernatants, Sca-1- PDC produced strongly elevated IFNa levels compared to Sca-1 positive PDC. These 
results correlate with further data showing higher IFNa production of BM-PDC (mainly Sca-1-) compared to LN-PDC 
(predominantly Sca-1+). Additionally, bromodeoxyuridine labeling in vivo demonstrate that the Sca-1- population 
appeared earlier in the development of PDC. On the basis of the shown association of Sca-1 expression with the 
development stage and Interferon production capacity, we are currently investigating further functional aspects of the 
differential Sca-1 expression on PDC. 
 
ECI, 2006 in Paris, France 
Murine Plasmacytoid Dendritic Cells: Differential expression of Sca-1 (Ly-6A/E) in spleen defines two subsets  
Fischer J. A. A., Janz, M., Schmitz J. and Dzionek A. 
Miltenyi Biotec GmbH, Bergisch Gladbach, Germany 
Murine Plasmacytoid dendritic cells (PDC) represent a distinct leukocyte population capable of secreting large 
amounts of type I interferon in response to viruses and bacteria and are defined by an unique phenotype: B220+, Ly-
6C+, CD11cint. In lymphoid organs the mPDCA-1 antigen is specifically expressed on cells which are CD11cint, B220, 
Ly-6C+, CD3-, CD4+, CD8adim, CD11b-, CD19-, CD49b-, CD90-, CD123-, CD40-, CD80low, and CD86-, and therefore 
phenotypically identical to PDC.   
Here we demonstrate differential expression levels of the stem cell antigen 1 (Sca-1 [Ly-6A/E]) on PDC from different 
organs. In bone marrow (BM) and peripheral blood the Sca-1 expression on PDC is very low: only 15-20% express 
the marker. In contrast, about 35% liver PDC and 45-55% of splenic PDC are positive for Sca-1. In lymph nodes (LN) 
the majority (up to 80%) of PDC are positive for Sca-1. Analysing splenic PDC of several mouse strains, the Sca-1 
expression is not uniform: C57BL/6, Sv129, and CD1 mice show predominantly Sca-1+ PDC, whereas BALB/c and 
FVB mice show heterogeneous Sca-1 expression, and the majority of DBA/1 PDC are Sca-1-. Phenotyping both PDC 
subsets of BALB/c mice, we observe no difference for all cell surface markers tested. After culture of Sca-1+ and Sca-
1- PDC, we detect an upregulation of Sca-1 on primary Sca-1- mPDC. After CpG-stimulation PDC become Sca-1+. In 
vivo activation with CpG ODN also enhances Sca-1 expression on PDC both in BM and spleen, whereas ligation of 
mPDCA-1 has no effect on Sca-1 or co-stimulatory/-inhibitory molecule expression. To show IFNα production 
depending on the Sca-1 change, we performed intracellular IFNα stainings by FACS analysis as well as IFNα ELISA. 
Our results show that the percentage of IFNα producers is much higher in ex vivo Sca-1- PDC compared to Sca-1+ 
PDC. Analysing the total amount of IFNα, Sca-1- PDC also produce strongly elevated IFNα levels. These results 
support previous data when we compared the IFNα production of PDC from both LN and BM. Hypothesising that the 
upregulation of Sca-1 correlates with the maturation or activation status of PDC, we are currently investigating the 
biological function of the differential Sca-1 expression on both PDC subpopulations. 
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AAI, 2006 in Boston, USA 
Differential Expression Of Sca-1 Defines Two Subsets Of  Murine Plasmacytoid Dendritic Cells in Spleen 
Fischer J. A. A., Janz, M., Schmitz J. and Dzionek A. 
Miltenyi Biotec GmbH, Bergisch Gladbach, Germany 
Murine Plasmacytoid dendritic cells (PDC) represent a distinct leukocyte population capable of secreting large 
amounts of type I interferon in response to viruses and bacteria and are defined by a unique phenotype: B220+, Ly-
6C+, CD11cint.  
We have generated a panel of monoclonal antibodies that all identify a single, presumably novel antigen, which we 
have termed Murine Plasmacytoid Dendritic Cell Antigen 1 (mPDCA-1). In lymphoid organs as well as in peripheral 
blood, liver, and lung mPDCA-1 is exclusively expressed on cells, which are CD11cint, B220, Ly-6Chigh, CD3-, CD4+, 
CD8adim, CD11b-, CD19-, CD49b- (DX-5), CD90- (Th-1.2), CD123, CD40-, CD80low, and CD86-, and therefore 
phenotypically identical to PDC.  
In past, PDC were described as a homogenous population. Now we demonstrated differential expression levels of 
the stem cell antigen 1 (Sca-1) in mPDC. In bone marrow (BM) and peripheral blood the Sca-1 expression on PDC is 
very low: only 15% express the marker. In contrast, about 40-50% of splenic PDC are positive for Sca-1. This 
expression can be enhanced following in vivo activation with CpG ODN both in BM and spleen.  
Recently Ly-49Q has been described as a development marker for PDC in BM. It was shown that Ly-49Q and MHC-II 
were heterogeneously expressed on PDC in BM. Nevertheless in spleen only a homogenous Ly-49Q+ MHC-II+ PDC 
fraction could be detected. Therefore Sca-1 is an appropriate marker discriminating PDC subsets in spleen. Gating 
on mPDCA-1+ cells we found MHC-II+ Ly-49Q+ Sca-1+ as well as MHC-II+ Ly-49Q+ Sca-1- mPDC in spleen.  
Functional differences between both splenic mPDC subpopulations are currently under investigation. 
 
Australian Society of Immunology: The 8th HLDA Workshop & Conference, December 12-16, 2004, Adelaide, 
Australia 
mPDCA-1: A Presumably Novel Antigen Exclusively Expressed by Murine Plasmacytoid Dendritic Cells  
Talk presented by Dr. Jürgen Schmitz, Miltenyi Biotec  
 
International Symposium of Dendritic Cells, 2004 in Brugge, Belgium  
mPDCA-1: A presumably novel antigen exclusively expressed by murine plasmacytoid dendritic cells 
(mPDC) 
Fischer J. A. A., Schmitz J. and Dzionek A. 
Miltenyi Biotec GmbH, Bergisch Gladbach, Germany 
PDC represent a unique leukocyte population capable of secreting large amounts of type I interferon (IFN) in 
response to viruses and bacteria. In humans, PDC have been shown to specifically express BDCA-2 and BDCA-4, 
but in mouse, no such specific markers are available to date. Instead, mPDC are typically identified in lymphoid 
organs as CD45R+ (B220+), Ly-6C+, CD11cint, CD8alpha+/-, CD11b- cells.  
We have generated a panel of mAb that all identify a single, presumably novel antigen, which we have termed mPDC 
antigen-1 (mPDCA-1). In lymphoid organs, mPDCA-1 is exclusively present on cells, which are CD11cint, CD45R+ 
(B220), Ly-6Chigh, Gr-1int (Ly-6C/G), CD3-, CD8adim, CD11b-, CD19-, CD49b- (DX-5), CD90- (Th-1.2), MHC-IIint, CD40-, 
CD80dim and CD86-, and therefore phenotypically identical to mPDC. In fact, multi-color-staining reveals, that all 
CD11cint, CD45R+ (B220), Ly-6Chigh mPDC are mPDCA-1+
 
and that there are no other mPDCA-1+ cells present in 
lymphoid organs apart from mPDCA-1+
 
mPDC. mPDCA-1 is also expressed on mPDC generated from bone marrow-
derived hematopoietic progenitors in Flt-3 Ligand/thrombopoietin (TPO) cultures. B cells as well as other types of DC 
may transiently express mPDCA-1 after in vitro stimulation with IFN-alpha. Anti-mPDCA-1 mAb-labeling of mPDC 
results in signal transduction as is evident by an increase in overall protein-tyrosine phosphorylation. Furthermore, 
injection of anti-mPDCA-1 mAb (rat IgG2b/kappa; 200-500 µg/ml intraperitoneally) almost completely depletes mPDC 
in vivo (more than 80% are depleted within 24h in spleen, bone marrow and lymph nodes), indicating that mPDCA-1 
is not only useful for single-color identification of mPDC by flow cytometry, but also of great value for elucidating the 
in vivo role of mPDC. Disclosure of the molecular nature of mPDCA-1 is currently underway. 
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FOCIS/IIC, 2004 in Montreal, Canada 
A panel of new monoclonal antibodies with specificity for mouse plasmacytoid dendritic cell antigen-1 
(mPDCA-1), a presumably novel antigen exclusively expressed by murine plasmacytoid dendritic cells  
Jens Fischer, Jürgen Schmitz, and Andrzej Dzionek  
Miltenyi Biotec, Bergisch Gladbach, Germany 
The immunophenotype of murine PDCs has been reported in several studies. Murine PDC are CD45R+ (B220+), 
Ly6C+, CD11c+, CD8 alpha+/-, CD3-, Thy-1.2-, CD49b- (DX-5-), CD11b-, CD19-. We have generated a panel of 
monoclonal antibodies (mAb) that all identify a single presumably novel antigen, mPDCA-1, which in murine spleen, 
bone marrow and lymph nodes is exclusively present on these cells. Anti PDCA-1 mAb-labeling of PDCs results in 
signal transduction as is evident by an increase in overall protein-tyrosine phosphorylation.  Furthermore, in vivo 
administration of anti PDCA-1 mAb causes depletion of PDC. Disclosure of the molecular nature of PDCA-1 is 
currently underway. 
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 Betreuer: Professor Stefan Kochanek (gegenwärtige Adresse: Universität Ulm) 
Januar 2003 Verleihung des Diplomzeugnisses (Gesamtnote: sehr gut) 
 
Februar 2003 –  Promotionsarbeit am Institut für Genetik, Universität zu Köln; Universitärer Be- 
Oktober 2008  treuer: Professor Manolis Pasparakis. Durchführung der praktischen Arbeiten 
als externer Promotionsstudent in der Firma Miltenyi Biotec GmbH, Bergisch 
Gladbach, unter der Anleitung von  Dr. Andrzej Dzionek und Dr. Jürgen 
Schmitz; Titel der Promotion: “Identification and functional characterization of 
mPDCA-1 as a novel antigen-uptake receptor for murine plasmacytoid dendritic 
cells enabling (cross-) priming of naïve CD4+ and CD8+ T cells.” 
 
August 2006  Praktikum in der Arbeitsgruppe von Dr. Alexander Scheffold, Deutsches 
Rheumaforschungszentrum (DRFZ) Berlin 
 
 
Oktober 2008  Voraussichtlicher Abschluß der Promotion an der Universität zu Köln 
 
 
 
________________ 
Jens A. A. Fischer 
 
Bergisch Gladbach, im August 2008 
